10-K

0001376339-16-000138.txt : 20160229 0001376339-16-000138.hdr.sgml : 20160229 20160229162500 ACCESSION NUMBER: 0001376339-16-000138 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160229 DATE AS OF CHANGE: 20160229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 900300868 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 161468100 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: 678-384-6720 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 10-K 1 mdxg-20151231x10k.htm 10-K 10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K



þ	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2015



o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to __________

Commission file number 001-35887

MIMEDX GROUP, INC.

(Exact name of registrant as specified in its charter)



Florida		26-2792552
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification Number)

1775 West Oak Commons Court, NE Marietta, GA		30062
(Address of principal executive offices)		(Zip Code)

(770) 651-9100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: Common Stock, par value $0.001 per share

Securities registered pursuant to Section 12(g) of the Act: None

(Title of class)

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No þ

Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. þ

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer þ	Accelerated filer o	Non-accelerated filer o	Smaller reporting Company o
	(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

The aggregate market value of Common Stock held by non-affiliates on June 30, 2015, based upon the last sale price of the shares as reported on the NASDAQ on such date, was approximately $1,135,614,000.

There were 107,810,490 shares of Common Stock outstanding as of February 10, 2016.

Documents Incorporated by Reference

Portions of the proxy statement relating to the 2016 Annual Meeting of Shareholders, to be filed within 120 days after the end of the fiscal year to which this report relates, are incorporated by reference in Part III of this Report.

Table of Contents



Part I
Item	Description	Page
Item 1.	Business	2
Item 1A.	Risk Factors	15
Item 1B.	Unresolved Staff comments	26
Item 2.	Properties	27
Item 3.	Legal Proceedings	27
Item 4.	Mine Safety Disclosures	29

Part II
Item 5.	Market for Registrants' Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities	30
Item 6.	Selected Financial Data	33
Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	34
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	41
Item 8.	Financial Statements and Supplementary Data	42
Item 9.	Changes in Disagreements with Accountants on Accounting and Financial Disclosure	70
Item 9A.	Controls and Procedures	70
Item 9B.	Other Information	70

Part III
Item 10.	Directors, Executive Officers and Corporate Governance	71
Item 11.	Executive Compensation	71
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters	71
Item 13.	Certain Relationships and Related Transactions, and Director Independence	71
Item 14.	Principal Accounting Fees and Services	71

Part IV
Item 15.	Exhibits, Financial Statement Schedules	72
Signatures		77

PART I

This Form 10-K and certain information incorporated herein by reference contain forward-looking statements and information within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of our products by the market, and management’s plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission (“SEC”), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “believe,” “expect,” “expectation,” “anticipate,” “estimate,” “intend,” “seeks,” “plan,” “project,” “continue,” “predict,” “will,” “should,” and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference. These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.

Forward-looking statements include, but are not limited to, the following:


•	the advantages of our products;


•	the regulatory pathway for our products;


•	our belief regarding the growth of our direct sales force resulting in increased revenues;


•	expectations regarding Government and other third-party reimbursement for our products;


•	our beliefs regarding our relationships with significant distributors;


•	expectations regarding future revenue growth;


•	our ability to procure sufficient supplies of human tissue to manufacture and process our products;


•	market opportunities for our products and future products;


•	prospects for obtaining additional patents covering our proprietary technology as well as successfully defending our existing patents and prohibiting infringement thereof by third-parties;


•	the outcome of pending litigation and investigations; and


•	our ability to compete effectively.

Actual results and outcomes may differ materially from those expressed or implied in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those discussed in Part I, Item 1A, “Risk Factors,” below. Except as expressly required by the federal securities laws, we undertake no obligation to update any such factors, or to publicly announce the results of, or changes to any of the forward-looking statements contained herein to reflect future events, developments, changed circumstances, or for any other reason.

As used herein, the terms “MiMedx,” “the Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.

Item 1. Business

Overview

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies are AmnioFix®, EpiFix®, OrthoFlo, Physio™, AlloBurn™, and CollaFix™. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane derived from donated placentas. Elected in advance of delivery through our donor program, a mother delivering a healthy baby via scheduled full-term Caesarean section birth may donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 500,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. We recently introduced OrthoFlo, an amniotic fluid derived allograft for homologous use. Amniotic fluid is donated by a consenting mother delivering a full-term healthy baby by scheduled Caesarean section. Through the recent acquisition of Stability Biologics, our newest proprietary platforms include Physio, a unique bone grafting material comprised of 100% bone tissue with no added carrier, a demineralized bone matrix (DBM) to complement our product portfolio offerings within the Orthopedic market and AlloBurn, a skin product for burns. CollaFix, our next technology platform we plan to commercialize, is our collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. CollaFix is the only known biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness.

Our History

Our current business began on February 8, 2008, when Alynx, Co., our predecessor company, acquired MiMedx, Inc., a Florida-based, privately-held, development-stage medical device company, the assets of which included licenses to two development-stage medical device technology platforms- HydroFix® and CollaFix. On March 31, 2008, Alynx, Co. merged

into MiMedx Group, Inc., a Florida corporation and wholly-owned subsidiary that had been formed on February 28, 2008, for purposes of the merger. MiMedx Group, Inc. was the surviving corporation in the merger. In 2010, we commercialized the first medical device product using our HydroFix technology. In 2011 and 2012, we launched additional versions of our HydroFix® product line. In January 2011, the Company acquired all of the outstanding equity interests of Surgical Biologics, LLC (“Surgical Biologics”). The acquisition of Surgical Biologics expanded our business by adding allografts and other products processed from human amniotic membrane to our existing medical device product lines based on our HydroFix technology. In 2013, we changed the name of Surgical Biologics to MiMedx Tissue Services, LLC. Due to the relatively small size of the addressable market for our HydroFix product line, we decided to discontinue that product line in the fourth quarter of 2013. Although we have yet to commercialize any products using our CollaFix technology, we continue to believe that technology presents a significant opportunity in the orthopedic and sports medicine markets.

On January 13, 2016, we acquired all of the outstanding common stock of Stability Inc. d/b/a Stability Biologics. During its five year history, Stability Biologics evolved from its initial focus as a distributor of allografts, to its current position as an integrated provider in the surgical, spine and orthopedics sectors of healthcare specializing in human tissue and bone product design and development, tissue processing and sales and distribution. The acquisition of Stability was effected by the merger of Stability Inc. into a newly created wholly owned subsidiary of the Company. The new subsidiary was the surviving company in the merger and was subsequently renamed Stability Biologics, LLC ("Stability"). The Company is working to integrate Stability's product offerings with the Company's existing surgical, spine and orthopedics portfolio.

For financial information concerning our operating performance, please refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations in Part II, Item 7 of this report and our Consolidated Financial Statements in Part II, Item 8 of this report.

Our Technology and Products

AmnioFix, EpiFix and other Tissue-Based Allografts

The Company is the leading supplier of allografts processed from amniotic tissue, having supplied over 500,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic, and Dental sectors of healthcare. Our amniotic membrane products include our own brands, AmnioFix and EpiFix, as well as products that we supply on a private label or “OEM” basis. We continue to research new opportunities for amniotic tissue, and currently have several additional offerings in various stages of conceptualization and development.

Amniotic membrane is considered immunoprivileged and does not elicit an immune response. Natural human amniotic membrane is composed of multiple layers that contain:


•	Structural proteins; including:


◦	Collagen types I, III, IV, V, and VII


◦	Elastin


•	Specialized extracellular matrix proteins; including:


◦	Fibrillin


◦	Fibronectin


◦	Laminins


•	TIMPs 1,2,4, Tissue Inhibitor of Metalloproteinase 1, 2, 4


•	At least 226 Growth Factors; including but not limited to:


◦	Epidermal Growth Factor (EGF)


◦	Transforming Growth Factor Beta (TGF-B)


◦	Fibroblast Growth Factor (FGF)


◦	Platelet Derived Growth Factors AA & BB (PDGF AA&BB)

We believe our proprietary technique for processing allografts from amniotic tissue preserves more of the natural characteristics of the tissue than the processes used by our competitors. We operate a licensed tissue bank that is registered as a tissue establishment with the United States Food and Drug Administration ("FDA"). We are an accredited member of the American Association of Tissue Banks (“AATB”). We partner with physicians and hospitals to recover donated placental tissue. After consent for donation is obtained, donors are screened for eligibility and the donated tissue is tested for safety in

compliance with federal regulations and AATB standards on communicable disease transmission. All donor records and test results are reviewed by our Medical Director prior to the release of the tissue for processing.

Over several years, we have developed a unique and proprietary technique for processing allografts from the donated placental tissue. The PURION Process produces an allograft that is easy to use and effective. This unique processing technique specifically focuses on preserving the tissue’s bioactive growth factor content, and maintaining the structure and collagen matrix of the tissue. The PURION Process also allows the allograft to be stored at room temperature and have a five-year shelf life. Additionally, each sheet allograft incorporates specialized visual embossments that assist the health care practitioner with proper allograft placement and orientation.

Our management team is dedicated to providing easy to use, effective allografts that exceed customer expectations. To better satisfy the requirements and expectations of our customers, we maintain strict controls on quality at each step of the process beginning at the time of procurement. We have developed and implemented a Quality Management System in compliance with both FDA regulations and AATB standards.

EpiFix

Our EpiFix allograft is configured for external use. It is used to enhance healing as well as to modulate inflammation. The EpiFix platform has been used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds. We offer EpiFix in a sheet form as well as a micronized powder form. The powder can be packed into wounds and is particularly useful for tunneling wounds. Some physicians also choose to mix the powder with saline to inject it into the wound bed and wound margins.

AmnioFix

Our AmnioFix allografts are configured for internal use. Currently, our AmnioFix product line consists of three main configurations, AmnioFix, AmnioFix Wrap and AmnioFix Injectable:


•	AmnioFix is provided in a sheet form. It is used to modulate inflammation, enhance healing and to minimize scar tissue formation. It has been used in spine, urology and general surgeries.


•	AmnioFix Wrap also is supplied in a sheet form and is configured for the same purposes as AmnioFix®, but is optimized for use as a “wrap” for nerves, tendons or ligaments.


•	AmnioFix Injectable is supplied in micronized powder form used to reduce inflammation while enhancing healing. AmnioFix Injectable has been used to treat conditions such as tendonitis, including plantar fasciitis, lateral epicondylitis, and medial epicondylitis, bursitis, strains and sprains.

OEM Products

Currently, allografts for ophthalmic surgery and dental applications are sold on an OEM basis pursuant to agreements whereby we have granted third parties exclusive licenses to some of our technology for use in those fields in specified markets. As further discussed below, the Company also sells products on a non-exclusive OEM basis to Medtronic for spinal procedures and Zimmer Biomet for spine and orthopedic procedures.

OrthoFlo

OrthoFlo is a unique human tissue allograft that is derived from amniotic fluid, donated by mothers delivering healthy babies by scheduled Caesarean section. It is for homologous use to (a) protect and cushion, (b) provide lubrication, and (c) reduce inflammation. Amniotic fluid, in utero, naturally functions to protect, cushion and enhance mobility. Key elements of amniotic fluid include growth factors, carbohydrates, proteins, lipids, electrolytes, and other nutrients, as well as hyaluronic acid (HA), a principal component of viscosity and lubrication in synovial fluid. A multitude of regulatory factors have been identified in amniotic fluid and synovial fluid, including the following which are some of the most notable:

•Interleukin 1 Receptor Antagonist (IL-1ra): Antagonist of IL-1 signaling which is known to be involved in cartilage degeneration

•Tissue Inhibitor of Metalloproteinases (TIMPs): inactivates a number of matrix metalloproteinases responsible for cartilage degradation

Medical Device Technologies

Our CollaFix technology combines an innovative means of creating fibers from soluble collagen and a specialized cross-linking process. Initial laboratory and animal testing shows that the cross-linked collagen fibers produce a very strong, biocompatible, and durable construct that can be transformed into biomechanical constructs intended to treat a number of orthopedic soft-tissue trauma and disease disorders. The technology is licensed from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. pursuant to an exclusive, world-wide license to practice and use the technology and to manufacture, have manufactured, market, offer for sale and sell products incorporating the technology. The license of the technology is perpetual, except that the license terminates on a country-by-country basis as to any patent or portion thereof included in the licensed technology upon the expiration of such patent or portion thereof in the applicable country. We are currently working to develop and commercialize products using our CollaFixtechnology and continue to evaluate how best to exploit this technology. We may license rights to specific aspects of our collagen technology to third parties for use in applications and indications that we choose not to exploit ourselves.

We are required to pay a royalty of 3% on all commercial sales revenue from the sale of products incorporating the licensed technology. We also are obligated to pay a $50,000 minimum annual royalty payment over the life of the license.

Intellectual Property

Our intellectual property includes owned and licensed patents, owned and licensed patent applications and patents pending, proprietary manufacturing processes and trade secrets, and trademarks associated with our technology. Furthermore, we require employees, consultants and advisors to sign Proprietary Information and Inventions Agreements, as well as Nondisclosure Agreements that assign to us and protect the intellectual property existing and generated from their work or that we may otherwise use or own. We believe that our patents, proprietary manufacturing processes, trade secrets, trademarks, and technology licensing rights provide us with important competitive advantages.

Patents and Patent Applications

Because of the substantial expertise and investment of time, effort and financial resources required to bring new regenerative biomaterial products and implants to the market, the importance of obtaining and maintaining patent protection for significant new technologies, products and processes cannot be underestimated. As of the date of this Form 10-K, we own 20 U.S. patents related to our amniotic tissue technology and products. Over 80 additional patent applications covering aspects of this technology are pending at the United States Patent and Trademark Office and with various international patenting agencies.

Worldwide, our CollaFix and HydroFix technologies are protected with 34 and 14 issued patents, respectively. Additionally, in the U.S. and internationally, there are 30 patent applications pending covering our CollaFix technology.

See discussion below- “Risk Factors” under the heading “Risks Related to Our Intellectual Property.”

Market Overview

We currently are focused primarily on the U.S. market, but we are actively working towards international expansion opportunities. In the U.S., the key areas of focus for the products we market currently are (a) Would Care; and (b) Surgical, Sports Medicine and Orthopedics (SSO). We believe Stability's spine and orthopedic related product line is a perfect complement to the Company's existing SSO products, and will serve to expedite the growth of our SSO product offerings.

Wound Care

The number of chronic and acute wounds in the United States is estimated at 8.1 million, with hard to heal wounds (applicable for advanced wound care allografts) estimated at 2.9 million¹. Our placental tissue-based allografts help heal acute and chronic wounds. Chronic wounds are defined as wounds that are delayed in closing compared to healing in an otherwise healthy individual. Some of the most common types of chronic wounds are diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and surgical wounds that become infected. Acute wounds can be caused by surgical intervention, trauma or burns. Our amniotic tissue platforms have the potential to reduce scar tissue formation in a variety of applications, including the chronic wound types listed above and acute wounds such as those occurring in the estimated 1.6 million patients annually undergoing elective aesthetic plastic surgery², as well the estimated 1.3 million patients annually undergoing Cesarean section births³, where scarring can limit flexibility, generate post-operative pain and can be unattractive. In both acute and chronic wounds, the physician’s goal during treatment is to heal the wound while allowing the patient to retain natural function in the area of the wound with minimal scarring and infection. If a wound becomes infected, it can lead to a loss of limb or life,

and physicians want to close the wound as quickly as possible to minimize this risk. Patients with chronic wounds likely have comorbidities, such as diabetes or poor circulation, that complicate or delay the healing cascade. According to BioMedGPS, LLC SmartTRAK Business Intelligence, the 2014 U.S. Wound Biologics segment (comprised of skin/dermal substitutes (which includes the Company's allografts), topical delivery/drugs and collagen/active dressings) of the Advanced Wound Care Market reached approximately $865 million and is expected to increase to approximately $1.38 billion in 2019, a compounded annual growth rate of 9.8%.

Our EpiFix allografts are used for the treatment of chronic and acute, partial and full-thickness wounds. EpiFix contains essential wound healing factors, extracellular matrix proteins and inflammatory mediators to help modulate inflammation, enhance healing, and reduce scar tissue formation. Unlike some competing technologies, the use of EpiFix is not limited to a specific wound type. EpiFix stores at ambient temperature for up to five years. Certain cultured skin substitutes currently on the market require cryogenic freezer storage and expire only six months from time of processing. Another leading skin substitute is delivered on demand and has strict temperature controls between 20° and 23° Celsius with a ten-day shelf-life. We believe the complicated logistics associated with the use of those products highlight the distinct advantages of EpiFix.

In addition, the Company markets multiple sizes of allografts (from 1.5cm² to 49cm²) which minimizes product waste. Two former market leading competitor products come in only one size each, 2 inch x 3 inch (38 cm²) and a 75 mm disc (44 cm²). Since the majority of diabetic foot ulcers areless than 5cm², using either one of these products results in significant waste on average.

Surgical, Sports Medicine and Orthopedics

Our AmnioFix tissue allografts have been used to enhance healing in patients undergoing surgical procedures to help to reduce scar tissue formation in a variety of applications including, but not limited to, plastic surgery, general surgery, gynecological, urology, orthopedics, spine, and sports medicine.

AmnioFix is used as a barrier membrane in procedures where scar tissue formation may be problematic. AmnioFix Wrap is applied by wrapping target tissues (ligaments, tendons, and or nerves) to create a barrier, which performs two functions: it acts as a neo-sheath to protect the target tissue and provides extracellular matrix proteins, cytokines and chemokines to enhance the wound healing process. AmnioFix provides additional benefits, including anti-inflammatory agents and growth factors that may assist with healing.

Spine/Orthopedics

There are approximately 1.47 million spinal surgeries per year⁴ and most of them potentially could use AmnioFix to reduce scarring and modulate inflammation during the primary procedure, which may reduce time during revisions or follow-up surgeries. A reduction of scar tissue is beneficial if the patient needs to have an additional surgical procedure in the future, as it may facilitate the re-access to the surgical site, as well as help with minimizing scar attachment to the spinal dura in spine surgery. In addition to spinal surgeries, the AmnioFix offerings have been used in Arthoplasty (total joint replacement) of the knee, hip, shoulder, ankle, hand and elbow.

Sports Medicine

There are an estimated 90,000⁵ peripheral nerve injuries which require repair each year and an estimated 8.4⁶ million patients who have tendinopathy associated with inflammation that potentially could benefit from our AmnioFix products.AmnioFix Wrap is a surgical implant that has multiple features desired by surgeons to support the repair and replacement of ligaments, tendons grafts and repaired nerves. AmnioFix Injectable and AmnioFix Sports Med address the chronic sports/work soft tissue injury market, including but not limited to tennis elbow, golfers elbow, plantar fasciitis, tendonitis, bursitis and sprains. Soft tissue injuries are often caused by either trauma or overuse of the affected area. Micro-tears in the tissue form and become inflamed. Scar tissue may form and impede a full recovery. Steroids are often used as a first line to help the patient cope with the pain and assist with recovery. There are a number of patients who do not get relief with steroids or do not want to use steroids, and over-use of steroids can cause long-term damage to the tissue. AmnioFix Injectable and AmnioFix Sports Med modulate inflammation and reduce scar tissue formation, while enhancing healing. Additionally, OrthoFlo has recently been launched to address an estimated 26.9 million U.S. adults faced with Osteroarthritis of the joints.⁷

Market overview numbers derived from the following sources:


1.	BioMedGPS SmartTRAK Business Intelligence


2.	American Society of Plastic Surgeons “2012 Plastic Surgery Statistics Report” http://www.plasticsurgery.org/news-and-resources/2012-plastic-surgery-statistics.html


3.	CDC Report - National Hospital Discharge Surgery: 2010 Table, Procedures by Selected patient characteristic - Number by procedure category and age (/nchs/data/nhds/4procedures/2010pro4_numberprocedureage.pdf)


4.	iData 2012, U.S. Market for Spinal Implants


5.	Stabenfeldt, SE, Garcia, AJ, LaPlaca, MC. Thermoreversible laminin-functionalized hydrogel for neural tissue engineering. J of Bio Materials Research. Part A, 2006. 77: p. 718-725


6.	Millenium 2013, clinical articles and management internal estimates


7.	Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.

Marketing and Sales

As of February 2016, our field sales force is comprised of over 230 sales professionals who call on hospitals, wound care clinics, physician offices and federal health care facilities such as Department of Veterans Affairs and Department of Defense Hospitals. Our direct sales force focuses on the Wound Care market and the SSO market, though, on the SSO side, we have continued to maintain a network of independent sales agents and distributors to sell sports medicine and orthopedic spine specialties lines. In addition, Stability's sales distribution organization consists of about 100 independent sales representatives that are focused in specific orthopedic/spine areas.

We continue to pursue private label or “OEM” relationship, to date the most notable of which are Medtronic and Zimmer Biomet. In September 2013, we entered into a non-exclusive distribution agreement with Medtronic, Inc. and its wholly-owned subsidiary, SpinalGraft Technologies, LLC (SGT). Under the agreement, MiMedx provides our PURION Processed grafts to Medtronic to be marketed by SGT under the RDX2® brand name for spinal applications throughout the United States.

In September 2014, we entered into a non-exclusive distribution agreement with Zimmer Biomet to distribute AmnioFix under its private label brand, AmnioRepair®. Under the agreement, Zimmer markets AmnioRepair for reconstructive, sports medicine, trauma, extremities and spine applications in the U.S. These partnerships allow us to leverage the sales and distribution resources of significant industry companies. In the ophthalmic and dental markets, our products are still marketed exclusively through licensee companies in each such field.

Reimbursement

In 2015, approximately 26% of our products were purchased for U.S. Government accounts, which do not depend on reimbursement from third parties. With the exception of Government accounts, most users of our products are doctors, hospitals or ambulatory surgery centers that rely on reimbursement by third-party payers. Accordingly, our growth substantially depends on adequate levels of third-party reimbursement for our products from these payers. In the U.S., such payers include U.S. Governmental programs (e.g., Medicare and Medicaid), private insurance plans, managed care programs and workers’ compensation plans. Governmental payment programs have prescribed coverage criteria and reimbursement rates for medical products, services and procedures. Similarly, private third-party payers have their own coverage criteria and often have negotiated payment levels for medical products, services and procedures. In addition, in the U.S., an increasing percentage of insured individuals are receiving their medical care through managed care programs, which monitor and may require pre-approval of the products and services that a member will receive.

EpiFix Sheet Products

Medicare Coverage

By far, the largest third party payer in the United States is the Medicare program, which is a federally-funded program that provides healthcare coverage for senior citizens and the disabled. The Medicare program is administered by the Centers for Medicare and Medicaid Services (CMS). CMS has appointed eight Medicare Administrative Contractors (MACs), which are private insurance companies that serve as agents of CMS in the administration of the Medicare program, including paying claims and making coverage decisions for the Medicare-assigned jurisdiction for which they are responsible. Each MAC has its own process and standards for determining whether it will cover and reimburse a procedure or particular product. Private payers often follow the lead of Governmental payers in making coverage and reimbursement determinations. Therefore,

achieving favorable Medicare coverage and reimbursement is usually a significant gating factor for successful reimbursement coverage for a new product.

The coverage and reimbursement framework for products under Medicare is determined in accordance with the Social Security Act and pursuant to regulations promulgated by CMS, as well as the agency’s sub regulatory coverage and reimbursement determinations. Ultimately, however, each of the MACs determines whether and on what conditions they will provide coverage for the product. Such decisions are based on their assessments of the efficacy and cost effectiveness of the applicable product. As noted below under the heading “Research and Development,” we have devoted significant resources to clinical studies to be able to provide data to the MACs, as well as other payers, in order to demonstrate the efficacy and clinical effectiveness of our EpiFix sheet products. As of the date of this report, our EpiFix sheet products are eligible for coverage by all eight of the Medicare intermediaries.

For Medicare reimbursement purposes, our EpiFix sheet products are classified as “skin substitutes.” Prior to 2014, providers that administered EpiFix allografts and other skin substitutes were reimbursed for the products based on the size of the graft, computed on a per square centimeter basis. The payment rate was calculated using the manufacturer’s average sales price (“ASP”) information. This payment methodology applied to physician offices, hospital outpatient and ambulatory surgery centers. We and other manufacturers of skin substitutes are required to provide ASP information to CMS on a quarterly basis. The Medicare payment rates are updated quarterly based on this ASP information. The skin substitutes Medicare payment rate, which is established by statute, was ASP plus 6%.

Beginning on April 1, 2013 and continuing through 2016, Medicare payments for all items and services, including EpiFix sheet products, were reduced by 2% under the sequestration required by the Budget Control Act of 2011, Pub. L. No. 112-25, as amended by the American Taxpayer Relief Act of 2012, Pub. L. 112-240.

Our EpiFix sheet allografts come in many sizes that are appropriate to the size of the wounds they are used to treat. Some competitive products come in only one size that is, on average, significantly larger than the wounds they are used to treat. The provider has to cut these products to size and the rest of the product is discarded, and, therefore, wasted. Because reimbursement for these products was based on the size of the graft, the Medicare payment for these grafts was costly. In part to combat this wastage, in November 2013, CMS announced a new reimbursement methodology for skin substitutes in the hospital outpatient and ambulatory surgical center setting effective in 2014. Under the new Hospital Outpatient Prospective Payment System (“OPPS”) Final Rule, skin substitutes are no longer reimbursed based on the size of the graft. Rather the new rule "bundles" or “packages" the reimbursement for skin care substitutes, including EpiFix, with the reimbursement for the related medical procedure under a two-tier payment system. Thus, in the OPPS setting providers receive a single payment that covers the application of the product as well as the product itself. In 2014, skin substitutes with an average sales price above the weighted average mean unit cost of $32 per sq. cm. were classified in the high cost group and were reimbursed at a higher packaged rate; those at or below the weighted average per sq. cm. were classified in the low cost group and are reimbursed at a lower packaged rate. In 2015, the weighted average mean unit cost to determine the high and low cost group was $27 per sq. cm. The national average packaged rate was $1,371 in 2014, $1,407 in 2015 and $1,411 in 2016. All skin substitutes products administered in the OPPS setting are bundled except for those that have been approved by CMS for pass-through status. This "bundled" payment structure only applies to the hospital outpatient and ambulatory surgery settings. Physician office payment structure remains at ASP plus 6%.

Section 1833(t)(6) of the Social Security Act provides for temporary additional payments or “transitional pass-through payments” for certain “new” drugs, devices and biological agents. Under the statute, transitional pass-through payments can be made for at least 2 years but not more than 3 years.

During the pass-through period, biologicals are eligible for separate payment computed as ASP plus 6%, less an offset(reduction) equal to the portion of the packaged payment determined to be attributed to the cost of the product (as opposed to the related procedure). The offset is designed to ensure that the total payment for the grafts does not exceed ASP plus 6%. In 2014, CMS determined that approximately 56% of the packaged payment is associated with the product and that is the amount reduced from the total product payment. The effect of the offset was that only larger size grafts were eligible for additional payments.

Our EpiFix sheet allografts were granted pass-through status through the end of 2014, allowing separate reimbursement for EpiFix sheet allografts administered in hospital outpatient departments and ambulatory surgery centers at ASP plus 6%, subject to the offset. The pass-through status for EpiFix expired in 2014. The Company prepared for this change by offering additional sizes of its grafts at prices below the bundled rate beginning in 2015. The new CMS reimbursement packaged policy does not apply to products applied in physician offices, which will continue to be reimbursed using the ASP plus 6% payment methodology. CMS has not changed the payment methodology as it relates to MiMedx products for calendar year 2016. The methodology under which CMS establishes reimbursement rates is subject to further change.

As discussed below under the heading "Competition," management believes this methodology will provide us with opportunities to increase market share.

Private Payers

We continue to devote considerable resources to clinical trials to support coverage and reimbursement of our products and we are aware of an increasing number of private payers that are reimbursing for EpiFix administered in the physician office or the hospital outpatient and ambulatory surgery center settings. Even when a payer is convinced of the clinical and cost-effectiveness of our product, coverage and reimbursement varies according to the individual or group plan or policy under which the patient has coverage. More than 180 health plans currently provide coverage for EpiFix for the treatment of Diabetic Foot Ulcers (DFU) and Venus Leg Ulcer (VLU) wounds. We have established and continue to grow a reimbursement support group to educate and assist providers and patients with regard to reimbursement for our products.

Hospital Use

EpiFix products administered in the hospital setting generally are bundled as part of the hospital’s bill for a diagnosis-related group (DRG). In these cases, we continue to educate the hospital that the product is both efficacious and cost-effective.

AmnioFix Sheet Products

Our AmnioFix surgical products generally are bundled as part of a hospital’s bill for a DRG. As noted above with respect to EpiFix, the ability to sell products to the hospital market is dependent upon demonstrating to the hospital that the product is both efficacious and cost-effective.

EpiFix and AmnioFix Micronized Products

Currently, our micronized products are available for coverage by only a limited number of commercial and state Medicaid plans.

Other Products

There is currently no third-party reimbursement available for OrthoFlo or any of the products manufactured and processed by Stability, except to the extent such products are bundled as part of a hospital’s bill for a DRG. However, the Company is actively investigating all reimbursement options from third-party payers with respect to these products.

See discussion below- “Risk Factors” under the heading “Our revenues depend on adequate reimbursement from public and private insurers and health systems.”

Customer Concentration

The Company provides products to Government accounts, including the Department of Veteran's Affairs, through a distributor relationship with AvKARE, Inc. ("AvKARE"), which is a veteran-owned General Services Administration Federal Supply Schedule (FSS) Contractor. In addition, in 2014, the Company applied for, and in early 2015 received, its own FSS contract with a term through 2020, which allows the Company to sell directly to Government accounts. The initial term of the distribution agreement with AvKARE was due to expire in April 2015 but it has been extended via amendment through June 30, 2017, with the ability to further extend under certain circumstances. The agreement with AvKARE, as amended, allows the Company to sell its products directly on the FSS. Ultimately, the Company intends to transition all of its Government sales to sales sold directly to Government accounts on the FSS. In 2015, sales to AvKARE represented approximately 24% of total revenue.

See discussion below- “Risk Factors” under the heading “A significant portion of our revenues and accounts receivable come from Government accounts”.

Competition

Competition in the regenerative medicine field is intense and subject to rapid technological change. Companies within the industry compete on the basis of product efficacy, pricing, and ease of handling/logistics. However, the most important factor is third-party reimbursement, which is difficult to obtain as it is a time-consuming and expensive process. We believe our success in obtaining third-party reimbursement for our products is a significant competitive advantage.

The Company competes in multiple areas of clinical treatment where regenerative biomaterials may be employed to modulate inflammation, enhance healing and reduce scar tissue formation: advanced wound care treatment, spine, orthopedic, surgery and sports medicine. The EpiFix product line is promoted primarily for external use such as advanced wound healing, while the AmnioFix products are positioned for healing of surgical wounds and have been used in spine, orthopedics, surgical and sports medicine applications.

Advanced wound care therapies employ technologies to aid in wound healing in cases where the healing has stalled or stopped. The primary competitive products in this space include other amniotic membrane allografts, tissue-engineered living skin equivalents, and porcine- or bovine-derived collagen matrix products, among others. In 2015, our main competitor was Organogenesis, Inc., the manufacturer of Dermagraft® and Apligraf®. These products are tissue-engineered living skin equivalents that require special shipping and/or storage in freezers. The Organogenesis products also come in only one large size, which is significantly larger than the median wound size for the wounds they are used to treat, resulting in a high cost product, much of which is wasted. We have competed effectively against Dermagraft® and Apligraf® based on clinical efficacy, cost effectiveness, ease of use and storage of our products. Other smaller competitors include the Osiris Therapeutics, Inc. product Grafix® and other single-layer amnion products.

Smith & Nephew’s Oasis® is the primary competitive product among the porcine- or bovine- derived collagen matrix products. As a collagen it can help with providing a matrix in the wound; however, it offers limited growth factors to enhance healing and due to the porcine origin may cause an immune response in the patient.

The primary competitive products in the SSO market are other amniotic membrane allografts and injectable solutions.

See discussion below- “Risk Factors” under the heading “We are in a highly competitive and evolving field and face competition from well-established tissue processors and medical device manufacturers, as well as new market entrants.”

Government Regulation

FDA Premarket Clearance and Approval Requirements

Tissue Products

The products manufactured and processed by the Company are derived from human tissue. As discussed below, some tissue-based products are regulated solely under Section 361 of the Public Health Service Act as human cells, tissues and cellular and tissue-based products, or HCT/Ps, which do not require premarket clearance or approval by the FDA. Other tissue products are regulated as biologics and, in order to be lawfully marketed in the United States, require an FDA-approved biologics application (BLA).

Products Regulated as HCT/Ps

The FDA has specific regulations governing human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act (so-called “361 HCT/Ps”) are not subject to any premarket clearance or approval requirements but are subject to post-market regulatory requirements.

To be a 361 HCT/P, a product generally must meet all four of the following criteria:


•	It must be minimally manipulated;


•	It must be intended for homologous use;


•	Its manufacture must not involve combination with another article, except for water, crystalloids or a sterilizing, preserving or storage agent; and


•	It must not have a systemic effect and must not be dependent upon the metabolic activity of living cells for its primary function.

If an HCT/P meets all the above criteria, no FDA review for safety and effectiveness under a drug, device, or biological product marketing application is required. MiMedx believes that its amniotic tissue allografts are 361 HCT/Ps, including the micronized versions of EpiFix and AmnioFix.

However, on August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized amniotic tissue allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has also indicated that it will hold a public hearing on a date in 2016 to be determined to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company has requested and been granted an opportunity to speak at this hearing.

See discussion below- “Risk Factors” under the heading “To the extent our products do not qualify for regulation as human cells, tissues and cellular and tissue-based products under Section 361 of the Public Health Service Act, this could result in removal of the applicable products from the market, would make the introduction of new tissue products more expensive and significantly delay the expansion of our tissue product offerings and subject us to additional post-market regulatory requirements.”

Products Regulated as Biologics- The Biologics License Application (BLA) Pathway

The typical steps for obtaining FDA approval of a BLA to market a biologic product in the U.S. include:


•	Completion of preclinical laboratory tests, animal studies and formulations studies under the FDA’s good laboratory practices regulations;


•	Submission to the FDA of an Investigational New Drug Application (IND) for human clinical testing, which must become effective before human clinical trials may begin and which must include independent Institutional Review Board (IRB) approval at each clinical site before the trials may be initiated;


•	Performance of adequate and well-controlled clinical trials in accordance with Good Clinical Practices to establish the safety and efficacy of the product for each indication;


•	Submission to the FDA of a BLA for marketing the product, which includes, among other things, reports of the outcomes and full data sets of the clinical trials, and proposed labeling and packaging for the product;


•	Satisfactory review of the contents of the BLA by the FDA, including the satisfactory resolution of any questions raised during the review;


•	Satisfactory completion of an FDA Advisory Committee review, if applicable;


•	Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with Current Good Manufacturing Practices (cGMP) regulations, to assure that the facilities, methods and controls are adequate to ensure the product’s identity, strength, quality and purity; and


•	FDA approval of the BLA, including agreement on post-marketing commitments, if applicable.

Generally, clinical trials are conducted in three phases, though the phases may overlap or be combined. Phase I trials typically involve a small number of healthy volunteers and are designed to provide information about the product safety and to evaluate the pattern of drug distribution and metabolism within the body. Phase II trials are conducted in a larger but limited

group of patients afflicted with a particular disease or condition in order to determine preliminary efficacy, dosage tolerance and optimal dosing and to identify possible adverse effects and safety risks. Dosage studies are designated as Phase IIA and efficacy studies are designated as Phase IIB. Phase III clinical trials are generally large-scale, multi-center, comparative trials conducted with patients who have a particular disease or condition in order to provide statistically valid proof of efficacy, as well as safety and potency. In some cases, the FDA will require Phase IV, or post-marketing trials, to collect additional data after a product is on the market. All phases of clinical trials are subject to extensive record keeping, monitoring, auditing, and reporting requirements. As indicated above, the Company is pursuing the Biologics License Application (“BLA”) process for certain of its micronized products. On July 22, 2014, the Company filed its first IND application with the FDA. In response to the IND application, the FDA agreed the Company had sufficient data to begin a Phase IIB clinical trial of its micronized product for a specified indication of use in anticipation of a BLA, which the Company expects to submit at a future date. The clinical trial is expected to enroll approximately 150 patients in 10 - 20 clinical sites in the U.S. The Company initiated the trial in March of 2015.

See discussion below- “Risk Factors” under the heading “Obtaining and maintaining the necessary regulatory approvals for certain products will be expensive and time-consuming and may impede our ability to fully exploit our technologies.”

Medical Devices

Products from our CollaFix product platform are likely to be classified by the FDA as medical devices. Medical Devices are classified as I, II and III in the U.S., with Class II and III requiring either a 510(k) clearance or Premarket Approval (“PMA”) from the FDA prior to marketing. Devices deemed substantially equivalent to legally marketed devices are deemed to pose relatively less risk and are deemed Class I and II. Manufacturers are required to submit a premarket notification requesting clearance for commercial distribution. This is known as 510(k) clearance, which indicates that the device is substantially equivalent to devices already legally on the market. Most Class I devices are considered very low risk and are exempted from this requirement. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or devices deemed not substantially equivalent to a previously 510(k) cleared device or a pre-amendment Class III device for which PMA applications have not been required, are placed in Class III, requiring PMA. Although we may be able to obtain approval for some products through the 510(k) clearance process, in order to fully exploit the CollaFix technology, one or more PMA applications would likely be required.

Like the process of obtaining an approved BLA, the process of obtaining a PMA requires the expenditure of substantial time, effort and financial resources and may take years to complete.

FDA Post Market Regulation

Tissue processors are required to register as an establishment with the FDA. As a registered establishment, we are required to comply with regulations regarding labeling, record keeping, donor eligibility, and screening and testing, process the tissue in accordance with established Good Tissue Practices, and report any adverse reactions attributed to our tissue. Our facilities are also subject to periodic inspections to assess our compliance with the regulations.

Products covered by a BLA, 510(k) clearance, or a PMA are subject to numerous additional regulatory requirements, which include, among others, compliance with cGMP, which imposes certain procedural, substantive and record keeping requirements, labeling regulations, the FDA’s general prohibition against promoting products for unapproved or “off-label” uses, and additional adverse event reporting.

Other Regulation Specific to Tissue Products

We are accredited by the American Association of Tissue Banks (AATB), which has issued operating standards for tissue banking. Compliance with these standards is a requirement in order to become a licensed tissue bank. In addition, some states have their own tissue banking regulations.

processing, preservation, quality control and storage of human tissue and skin. We reimburse tissue banks, hospitals and physicians for their services associated with the recovery, storage and transportation of donated human tissue.

See discussion below- “Risk Factors” under the heading "Our business is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and our failure to comply could result in negative effects on our business".

Fraud, Abuse and False Claims

We are directly and indirectly subject to various federal and state laws governing relationships with healthcare providers and pertaining to healthcare fraud and abuse, including anti-kickback laws. In particular, the federal healthcare program Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending a good or service for which payment may be made in whole or part under federal healthcare programs, such as the Medicare and Medicaid programs. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. In implementing the statute, the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) has issued a series of regulations, known as the “safe harbors.” These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they will not be prosecuted under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy each applicable element of a safe harbor may result in increased scrutiny by Government enforcement authorities, such as the OIG. Many states have laws similar to the federal law.

AdvaMed is one of the primary voluntary U.S. trade associations for medical device manufacturers. This association has established guidelines and protocols for medical device manufacturers in their relationships with healthcare professionals on matters including research and development, product training and education, grants and charitable contributions, support of third-party educational conferences, and consulting arrangements. Adoption of the AdvaMed Code by a medical device manufacturer is voluntary, and while the OIG and other federal and state healthcare regulatory agencies encourage its adoption and may look to the AdvaMed Code, they do not view adoption of the AdvaMed Code as proof of compliance with applicable laws. As part of a Company-wide compliance plan, we have incorporated the principles of the AdvaMed Code in our standard operating procedures, sales force training programs, and relationships with health care professionals. Key to the underlying principles of the AdvaMed Code is the need to focus the relationships between manufacturers and healthcare professionals on matters of training, education and scientific research, and limit payments between manufacturers and healthcare professionals to fair market value for legitimate services provided and payment of modest meal, travel and other expenses for a healthcare professional under limited circumstances. We have incorporated these principles into our relationships with healthcare professionals under our consulting agreements, and our policies regarding payment of travel and lodging expenses, research and educational grant procedures and sponsorship of third-party conferences.

See discussion below- “Risk Factors” under the heading “We and our sales representatives, whether employees or independent contractors, must comply with various federal and state anti-kickback, self-referral, false claims and similar laws, any breach of which could cause a material adverse effect on our business, financial condition and results of operations.”

Manufacturing (Processing)

In early 2014, we expanded our production capacity from one location in Kennesaw, Georgia, by adding a second and significantly larger, manufacturing facility within our headquarters building in Marietta, Georgia. Effective January 2014, our main processing operations were relocated to the Marietta, Georgia facility. The Kennesaw facility serves as a secondary processing site. We also perform research and early stage product and process development activities in our Marietta and Kennesaw, Georgia, locations. Stability maintains a facility in San Antonio, Texas for tissue processing.

We are registered with the FDA as a tissue establishment and are subject to the FDA’s quality system regulations, state regulations, and regulations promulgated by the European Union. Our facilities are subject to periodic unannounced inspections by regulatory authorities, and may undergo compliance inspections conducted by the FDA and corresponding state and foreign agencies.

Placental Donation Program

We have a comprehensive network of hospitals that participate in our placenta donation program. We have a dedicated staff that works at these hospitals, collecting donated placentas from mothers who undergo Cesarean section births and consent to donation. We believe that we will be able to procure an adequate supply of tissue to meet anticipated demand. However, see discussion below- “Risk Factors” under the heading “Our products are dependent on the availability of sufficient quantities of tissue from human donors, and any disruption in supply could adversely affect our business."

Research and Development

Our research and development group has extensive experience in developing products related to our field of interest, and works to design products that are intended to improve patient outcomes, simplify techniques, shorten procedures, reduce hospitalization and rehabilitation times and, as a result, reduce costs. Clinical trials that demonstrate the safety, efficacy and cost effectiveness of our products are key to obtaining broader reimbursement for our products. In addition to our internal staff, we contract with outside labs and physicians who aid us in our research and development process. See Part II, Item 7 below for information regarding expenditures for research and development in each of the last three fiscal years.

Environmental Matters

Our tissue preservation activities generate some chemical and biomedical wastes, consisting primarily of diluted alcohols and acids, and human and animal pathological and biological wastes, including human and animal tissue and body fluids removed during laboratory procedures. The chemical and biomedical wastes generated by our tissue processing operations are placed in appropriately constructed and labeled containers and are segregated from other wastes. We contract with third parties for transport, treatment, and disposal of waste. We strive to remain compliant with applicable laws and regulations promulgated by the Resource Conservation and Recovery Act, the U.S. Environmental Protection Agency and similar state agencies.

Employees

As of December 31, 2015, we had approximately 550 employees. We consider our relationships with our employees to be satisfactory. None of our employees is covered by a collective bargaining agreement.

Available Information

Our website address is www.mimedx.com. We make available on this website under “Investors - SEC Filings,” free of charge, our proxy statements, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports as soon as reasonably practicable after we electronically file or furnish such materials to the SEC. In addition, we post filings of Forms 3, 4, and 5 filed by our directors, executive officers and ten percent or more shareholders. We also make available on this website under the heading “Investors - Corporate Governance” our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee Charters as well as our Code of Business Conduct and Ethics.

The reference to our website does not constitute incorporation by reference of any information contained at that site.

Item 1A. Risk Factors

Risks Related to Our Business and Industry

Our operating results may fluctuate significantly as a result of a variety of factors, many of which are outside of our control.

We are subject to the following factors, among others, that may negatively affect our operating results:


•	The announcement or introduction of new products by our competitors;


•	Failure of Government and private health plans to adequately and timely reimburse the users of our products;


•	Removal of our products from the Federal Supply Schedule or change in the prices that Government accounts will pay for our products;


•	Our ability to upgrade and develop our systems and infrastructure to accommodate growth;


•	Our ability to attract and retain key personnel in a timely and cost effective manner;


•	The amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure;


•	Regulation by Federal, State or Local Governments; and


•	General economic conditions as well as economic conditions specific to the healthcare industry.

We have based our current and future expense levels largely on our investment plans and estimates of future events, although certain of our expense levels are, to a large extent, fixed. We may be unable to adjust spending in a timely manner to compensate for any unexpected revenue shortfall. Accordingly, any significant shortfall in revenue relative to our planned expenditures would have an immediate adverse effect on our business, results of operations and financial condition. Further, as a strategic response to changes in the competitive environment, we may from time to time make certain pricing, service or marketing decisions that could have a material and adverse effect on our business, results of operations and financial condition. Due to the foregoing factors, our revenue and operating results are and will remain difficult to forecast.

We are in a highly competitive and evolving field and face competition from well-established tissue processors and medical device manufacturers, as well as new market entrants.

Our business is in a very competitive and evolving field. Competition from other tissue processors, medical device companies and from research and academic institutions is intense, expected to increase, subject to rapid change, and could be significantly affected by new product introductions. The presence of this competition in our market may lead to pricing pressure, which would make it more difficult to sell our products at a price that will make us profitable or prevent us from selling our products at all. Our success will depend on our ability to perfect and protect our intellectual property rights related to our technologies as well as to develop new technologies and new applications for our technologies. Our failure to compete effectively would have a material and adverse effect on our business, results of operations and financial condition.

Rapid technological change could cause our products to become obsolete.

The technologies underlying our products are subject to rapid and profound technological change. Competition intensifies as technical advances in each field are made and become more widely known. We can give no assurance that others will not develop services, products, or processes with significant advantages over the products, services, and processes that we offer or are seeking to develop. Any such occurrence could have a material and adverse effect on our business, results of operations and financial condition.

Our products are dependent on the availability of sufficient quantities of tissue from human donors, and any disruption in supply could adversely affect our business.

The success of our human tissue products depends upon, among other factors, the availability of sufficient quantities of tissue from human donors. The availability of donated tissue could be adversely impacted by regulatory changes, public opinion of the donor process as well as our own reputation in the industry. Any disruption in the supply of donated human tissue could restrict our growth and could have a material adverse impact on our business and financial condition. We cannot

be sure that the supply of human tissue will continue to be available at current levels or will be sufficient to meet our future needs.

The products we manufacture and process are derived from human tissue and therefore have the potential for disease transmission.

The utilization of human tissue creates the potential for transmission of communicable disease, including, but not limited to, human immunodeficiency virus (“HIV”), viral hepatitis, syphilis and other viral, fungal or bacterial pathogens. We are required to comply with federal and state regulations intended to prevent communicable disease transmission.

Although we maintain strict quality controls over the procurement and processing of our tissue, there is no assurance that these quality controls will be adequate. In addition, negative publicity concerning disease transmission from other companies' improperly processed donated tissue could have a negative impact on the demand for our products.

We depend on key personnel.

Our success will depend, in part, upon our ability to attract and retain skilled personnel, including sales, managerial and technical personnel. There can be no assurance that we will be able to find and attract additional qualified employees to support our expected growth or retain any such personnel. Our inability to hire and retain qualified personnel or the loss of services of our key personnel may have a material and adverse effect on our business and results of operations.

A significant portion of our revenues and accounts receivable come from Government accounts.

We provide products to Government accounts, including the Department of Veterans Affairs, through a distributor that has a Federal Supply Schedule (FSS) Contract. Sales through this distributor, AvKARE, represented approximately 24% of our revenue in 2015, 34% of our revenue in 2014, and 56% of our revenue in 2013. In addition, in 2014, the Company applied for, and in early 2015 received, its own FSS contract with a term through 2020, which allows the Company to sell directly to Government accounts. The initial term of the distribution agreement with AvKARE was due to expire in April 2015 but it has been extended via amendment through June 30, 2017, with the ability to further extend under certain circumstances. The agreement with AvKARE, as amended, allows the Company to sell its products directly on the FSS. Ultimately, the Company intends to transition all of its Government sales to sales sold directly to Government accounts on the FSS. Any disruption of our products on the Federal Supply Schedule (whether we are selling our products directly to Government accounts or through our current or another distributor) or a change in the way the Government purchases products like ours or the price it is willing to pay for our products, could materially and adversely affect our business, revenues and results of operations.

In order to grow revenues from certain of our products, we must expand our relationships with distributors and independent sales representatives.

We derive significant revenues through our relationships with distributors and independent sales representatives, though, other than our distributor for Government accounts as discussed above, no one distributor comprised over 5% of our revenues. If such relationships were terminated for any reason, it could materially and adversely affect our ability to generate revenues and profits. We intend to obtain the assistance of additional distributors and independent sales representatives to continue our sales growth with respect to certain of our products. We may not be able to find additional distributors and independent sales representatives who will agree to market and/or distribute those products on commercially reasonable terms, if at all. If we are unable to establish new distribution and independent sales representative relationships or renew current distribution and sales agency agreements on commercially acceptable terms, our business, financial condition and results of operations could be materially and adversely affected.

We continue to invest significant capital in expanding our internal sales force, and there can be no assurance that these efforts will continue to result in significant increases in sales.

We are engaged in a major initiative to build and further expand our internal sales and marketing capabilities which has contributed to our increased sales. As a result, we continue to invest in a direct sales force for certain of our products to allow us to reach new customers. These expenses impact our operating results, and there can be no assurance that we will continue to be successful in significantly expanding the sales of our products.

Our revenues depend on adequate reimbursement from public and private insurers and health systems.

Our success depends on the extent to which reimbursement for the costs of our products and related treatments will be available from third party payers, such as public and private insurers and health systems. Government and other third-party payers attempt to contain healthcare costs by limiting both coverage and the level of reimbursement of new

products. Therefore, significant uncertainty usually exists as to the reimbursement status of new healthcare products. A significant number of public and private insurers and health systems currently do not provide reimbursement for our products. If we are not successful in obtaining adequate reimbursement for our products from these third party payers, the market's acceptance of our products could be adversely affected. Inadequate reimbursement levels also likely would create downward price pressure on our products. Even if we do succeed in obtaining widespread reimbursement for our products, future changes in reimbursement policies could have a negative impact on our business, financial condition and results of operations.

Disruption of our processing could adversely affect our business, financial condition and results of operations.

Our results of operations are dependent upon the continued operation of our processing facilities. Risks that could impact our ability to use these facilities include the occurrence of natural and other disasters, and the need to comply with the requirements of directives from Government agencies, including the FDA. We have a secondary processing facility in Kennesaw, Georgia that also serves as a disaster recovery center. However, the unavailability of our manufacturing and processing facilities could have a material adverse effect on our business, financial condition, and results of operations during the period of such unavailability.

To be commercially successful, we must convince physicians that our products are safe and effective alternatives to existing treatments and that our products should be used in their procedures.

We believe physicians will only adopt our products if they determine, based on experience, clinical data and published peer reviewed journal articles, that the use of our products in a particular procedure is a favorable alternative to conventional methods. Physicians may be slow to change their medical treatment practices for the following reasons, among others:


·	Their lack of experience with prior procedures in the field using our products;


·	Lack of evidence supporting additional patient benefits and our products over conventional methods;


·	Perceived liability risks generally associated with the use of new products and procedures;


·	Limited availability of reimbursement from third party payers; and


·	The time that must be dedicated to training.

In addition, we believe recommendations for and support of our products by influential physicians are essential for market acceptance and adoption. If we do not receive this support or if we are unable to demonstrate favorable long-term clinical data, physicians and hospitals may not use our products, which would significantly reduce our ability to achieve expected revenue and would prevent us from sustaining profitability.

We will need to expand our organization, and managing growth may be more difficult than expected.

Managing our growth may be more difficult than we expect. We anticipate that a period of significant expansion will be required to penetrate and service the market for our existing and anticipated future products and to continue to develop new products. This expansion will place a significant strain on management, operational and financial resources. To manage the expected growth of our operations and personnel, we must both modify our existing operational and financial systems, procedures and controls and implement new systems, procedures and controls. We must also expand our finance, administrative, and operations staff. Management may be unable to hire, train, retain, motivate and manage necessary personnel or to identify, manage and exploit existing and potential strategic relationships and market opportunities.

We face the risk of product liability claims and may not be able to obtain or maintain adequate product liability insurance.

Our business exposes us to the risk of product liability claims that are inherent in the manufacturing, processing and marketing of medical devices and human tissue products. We may be subject to such claims if our products cause, or appear to have caused, an injury. Claims may be made by patients, healthcare providers or others selling our products. Defending a lawsuit, regardless of merit, could be costly, divert management attention and result in adverse publicity, which could result in the withdrawal of, or reduced acceptance of, our products in the market.

Although we have product liability insurance that we believe is adequate, this insurance is subject to deductibles and coverage limitations and we may not be able to maintain this insurance. Also, it is possible that claims could exceed the limits of our coverage. If we are unable to maintain product liability insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect ourselves against potential product liability claims or we underestimate the amount of

insurance we need, we could be exposed to significant liabilities, which may harm our business. A product liability claim or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could result in significant costs and significant harm to our business.

We may implement a product recall or voluntary market withdrawal, which could significantly increase our costs, damage our reputation and disrupt our business.

The manufacturing, marketing and processing of our tissue products involves an inherent risk that our tissue products or processes do not meet applicable quality standards and requirements. In that event, we may voluntarily implement a recall or market withdrawal or may be required to do so by a regulatory authority. A recall or market withdrawal of one of our products would be costly and would divert management resources. A recall or withdrawal of one of our products, or a similar product processed by another entity, also could impair sales of our products as a result of confusion concerning the scope of the recall or withdrawal, or as a result of the damage to our reputation for quality and safety.

Significant disruptions of information technology systems or breaches of information security could adversely affect our business.

We rely to a large extent upon sophisticated information technology systems to operate our business. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual property). We also have outsourced significant elements of our operations to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our confidential information. The size and complexity of our information technology and information security systems, and those of our third-party vendors with whom we contract (and the large amounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from malicous attacks by third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage and market manipulation) and expertise. While we have invested significantly in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Although we have cyber-insurance coverage that may cover certain events described above, this insurance is subject to deductibles and coverage limitations and we may not be able to maintain this insurance. Also, it is possible that claims could exceed the limits of our coverage. Any interruption or breach in our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us or allow third parties to gain material, inside information that they use to trade in our securities.

We may not be successful in commercializing our CollaFix Technology.

We have invested substantial time and resources in developing various additional products using our CollaFix technology. Further commercialization of this technology will require additional development, clinical evaluation, regulatory clearance or approval, significant marketing efforts and substantial additional investment before they can provide us with any revenue. Despite our efforts, any such products may not become commercially successful products for a number of reasons, including:


·	We may not be able to obtain regulatory clearance or approvals for such products, or the approved indication may be narrower than we seek;


·	Such products may not prove to be safe and effective in preclinical or clinical trials;


·	Physicians or hospitals may not receive any reimbursement from third party payers, or the level of reimbursement may be insufficient to support widespread adoption of such products;


·	We may experience delays in our development programs;


·	Any products that are approved may not be accepted in the marketplace by physicians or patients;


·	We may not be able to manufacture any such products in commercial quantities or at an acceptable cost; and


·	Rapid technological change may make such products obsolete.

We may expand our business through acquisitions, licenses, investments, and other commercial arrangements in other companies or technologies, which contain significant risks.

We periodically evaluate strategic opportunities to acquire companies, divisions, technologies, products, and rights through licenses, distribution agreements, investments, and outright acquisitions to grow our business. In connection with one or more of those transactions, we may:


•	Issue additional equity securities that would dilute our stockholders’ value;


•	Use cash that we may need in the future to operate our business;


•	Incur debt that could have terms unfavorable to us or that we might be unable to repay;


•	Structure the transaction in a manner that has unfavorable tax consequences, such as a stock purchase that does not permit a step-up in the tax basis for the assets acquired;


•	Be unable to realize the anticipated benefits, such as increased revenues, cost savings, or synergies from additional sales;


•	Be unable to secure the services of key employees related to the acquisition; and


•	Be unable to succeed in the marketplace with the acquisition.

Any of these items could materially, and adversely affect our revenues, financial condition, and profitability. Business acquisitions also involve the risk of unknown liabilities associated with the acquired business, which could be material. Incurring unknown liabilities or the failure to realize the anticipated benefits of an acquisition could materially, and adversely affect our business if we are unable to recover our initial investment, which could include the cost of acquiring licenses or distribution rights, acquiring products, purchasing initial inventory, or investments in early stage companies. Inability to recover our investment, or any write off of such investment, associated goodwill, or assets, could have a material and adverse effect on our business, results of operations and financial condition.

Our international expansion and operations in foreign markets expose us to risks associated with international sales and operations.

We are actively seeking to expand into foreign markets. Managing a global organization is difficult, time consuming, and expensive. Conducting international operations subjects us to risks that could be different than those faced by us in the United States. These risks include: lack of familiarity with and unexpected changes in foreign regulatory requirements; longer accounts receivable payment cycles and difficulties in collecting accounts receivable; difficulties in managing and staffing international operations; fluctuations in currency exchange rates; the burdens of complying with a wide variety of foreign laws and legal standards; increased financial reporting burdens and complexities; and political, social, and economic instability abroad. Operating in international markets also requires significant management attention and financial resources. The investment and additional resources required to operate and manage growth in other countries may not produce desired levels of revenue or profitability.

New lines of business or new products and services may subject us to additional risks.

From time to time, we may implement or may acquire new lines of business or offer new products and services within existing lines of business. There are risks and uncertainties associated with these efforts, particularly in instances where the markets are not fully developed or are evolving. In developing and marketing new lines of business and new products and services, we may invest significant time and resources. External factors, such as regulatory compliance obligations, competitive alternatives, and shifting market preferences, may also impact the successful implementation of a new line of business or a new product or service. Failure to successfully manage these risks in the development and implementation of new lines of business or new products or services could have a material adverse effect on our business, results of operations and financial condition.

Risks Related to Our Intellectual Property

Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate, which could have a material and adverse effect on us.

Our success depends significantly on our ability to protect our proprietary rights to the technologies used in our products. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology, including our licensed technology. These legal means afford only limited protection and may not adequately protect our rights or permit us to gain or

keep any competitive advantage. In addition, our pending patent applications include claims to material aspects of our products and procedures that are not currently protected by issued patents. The patent application process can be time consuming and expensive. We cannot ensure that any of our pending patent applications will result in issued patents. Competitors may be able to design around our patents or develop products that provide outcomes that are comparable or even superior to ours. Although we have taken steps to protect our intellectual property and proprietary technology, including entering into confidentiality agreements and intellectual property assignment agreements with some of our officers, employees, consultants and advisors, such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements. Furthermore, the laws of foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States.

The failure to obtain and maintain patents and/or protect our intellectual property rights could have a material and adverse effect on our business, results of operations, and financial condition. Whether a patent is valid is a complex matter of science and law, and therefore we cannot be certain that, if challenged, our patents would be upheld. If one or more of those patents are invalidated, that could reduce or eliminate any competitive advantage we might otherwise have had.

In the event a competitor infringes upon our licensed or pending patent or other intellectual property rights, enforcing those rights may be costly, uncertain, difficult and time consuming. Even if successful, litigation to enforce or defend our intellectual property rights could be expensive and time consuming and could divert our management's attention. Further, bringing litigation to enforce our patents subjects us to the potential for counterclaims. Other companies or entities also have commenced, and may again commence, actions seeking to establish the invalidity of our patents. For example, the defendants in certain of our ongoing patent infringement suits have filed petitions for inter-partes review of certain of our patents with the United States Patent and Trademark Office (USPTO). We intend to defend these actions vigorously, but there is no guarantee of success, and such effort takes financial and time resources from the Company. In the event that one or more of our patents are challenged, a court or the USPTO may invalidate the patent(s) or determine that the patent(s) is not enforceable, which could harm our competitive position. If the USPTO ultimately cancels or narrows the claim in any of our patents through these proceedings, it could prevent or hinder us from being able to enforce them against competitors. Such adverse decisions could negatively impact our future, expected revenue. See Item 3, Legal Proceedings for information regarding our ongoing patent infringement lawsuits and related inter-partes review proceedings.

The prosecution and enforcement of patents licensed to us by third parties are not within our control, and without these technologies, our products may not be successful and our business would be harmed if the patents were infringed or misappropriated.

We have obtained licenses from third parties for patents and patent application rights related to our CollaFix technologies, allowing us to use intellectual property rights owned by or licensed to these third parties. We do not control the maintenance, prosecution, enforcement or strategy for many of these patents or patent application rights and as such are dependent in part on the owners of the intellectual property rights to maintain their viability. Their failure to do so could significantly impair our ability to exploit those technologies.

We may become subject to claims of infringement of the intellectual property rights of others, which could prohibit us from developing our products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages.

Third parties could assert that our products infringe their patents or other intellectual property rights. Whether a product infringes a patent or other intellectual property involves complex legal and factual issues, the determination of which is often uncertain. Therefore, we cannot be certain that we have not infringed the intellectual property rights of others. Because patent applications may take years to issue, there also may be applications now pending of which we are unaware that may later result in issued patents that our products or processes infringe. There also may be existing patents or pending patent applications of which we are unaware that our products or processes may inadvertently infringe.

Any infringement claim could cause us to incur significant costs, place significant strain on our financial resources, divert management's attention from our business and harm our reputation. If the relevant patents in such claim were upheld as valid and enforceable and we were found to infringe, we could be prohibited from selling any product that is found to infringe unless we could obtain licenses to use the technology covered by the patent or other intellectual property or are able to design around the patent or other intellectual property. We may be unable to obtain such a license on terms acceptable to us, if at all, and we may not be able to redesign our products to avoid infringement. A court could also order us to pay compensatory damages for such infringement, plus prejudgment interest and could, in addition, treble the compensatory damages and award attorney fees. These damages could be substantial and could harm our reputation, business, financial condition and operating results. A court also could enter orders that temporarily, preliminarily or permanently enjoin us and our customers from making, using, or selling products, and could enter an order mandating that we undertake certain remedial

activities. Depending on the nature of the relief ordered by the court, we could become liable for additional damages to third parties.

We may be subject to damages resulting from claims that we, our employees, or our independent contractors have wrongfully used or disclosed alleged trade secrets of others.

Some of our employees were previously employed at other medical device or tissue companies. We may also hire additional employees who are currently employed at other medical device or tissue companies, including our competitors. Additionally, consultants or other independent agents with which we may contract may be or have been in a contractual arrangement with one or more of our competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or independent contractors have used or disclosed any party's trade secrets or other proprietary information. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail to defend such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to market existing or new products, which could severely harm our business.

Our License Agreement for our CollaFix technology could be terminated.

Under our license agreement with Shriners' Hospitals for Children and University of South Florida Research Foundation dated January 29, 2007, it is possible for the licensor to terminate the agreement if we breach the license agreement and all of our cure rights are exhausted. If our license agreement were to be terminated, our investment in the CollaFix technology would be lost.

Risks Related to Regulatory Approval of Our Products and Other Government Regulations

To the extent our products do not qualify for regulation as human cells, tissues and cellular and tissue-based products under Section 361 of the Public Health Service Act, this could result in removal of the applicable products from the market, would make the introduction of new tissue products more expensive and significantly delay the expansion of our tissue product offerings and subject us to additional post-market regulatory requirements.

The products we manufacture and process are derived from human tissue. The FDA has specific regulations governing human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act (so-called “361 HCT/Ps”) are not subject to any premarket clearance or approval requirements and are subject to less stringent post-market regulatory requirements.

If a product is deemed not to be a 361 HCT/P, FDA regulations will require premarket clearance or approval requirements that will involve significant time and cost investments by the Company. Further, there can be no assurance that the FDA will not, at some future point, change its position on current or future products' 361 HCT/P status, and any regulatory reclassification could have adverse consequences for us and make it more difficult or expensive for us to conduct our business by requiring premarket clearance or approval and compliance with additional post-market regulatory requirements with respect to those products. Moreover, increased regulatory scrutiny within the industry in which we operate could lead to increased regulation of HCT/Ps, including 361 HCT/Ps. We also cannot assure you that the FDA will not impose more stringent definitions with respect to products that qualify as 361 HCT/Ps.

See "Government Regulation" in Item 1 for a discussion of 361 HCT/Ps and the FDA's position on our products. If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues in 2015.

Obtaining and maintaining the necessary regulatory approvals for certain of our products will be expensive and time-consuming and may impede our ability to fully exploit our technologies.

The process of obtaining regulatory clearances or approvals to market a biologic or medical device from the FDA or similar regulatory authorities outside of the United States is costly and time consuming, and there can be no assurance that such clearances or approvals will be granted on a timely basis, or at all. As discussed above, we intend to pursue approval of a Biologics License Application (BLA) for certain of our micronized products. Additionally, the FDA may take the position that some of the other products that we currently market require a BLA as well. Some of the future products and enhancements to our current products that we expect to develop and market may require marketing clearance or approval from the FDA. There can be no assurance, however, that clearance or approval will be granted with respect to any of our products or enhancements or that FDA review will not involve delays that would adversely affect our ability to market such products or enhancements.

The process of obtaining an approved BLA requires the expenditure of substantial time, effort and financial resources and may take years to complete. The fee for filing a BLA and the annual user fees payable with respect to any establishment that manufactures biologics and with respect to each approved product are substantial. Additionally, there are significant costs associated with clinical trials that cannot be estimated until the IND is approved. Moreover, data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. Additionally, the FDA may limit the indications for use or place other conditions on any approvals that could restrict the commercial application of the products. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Like the process of obtaining an approved BLA, the process of obtaining a PMA requires the expenditure of substantial time, effort and financial resources and may take years to complete. The FDA may not grant approval on a timely basis, or at all. Additionally, the FDA may limit the indications for use or place other conditions on any approvals that could restrict the commercial application of the products. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Our business is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and our failure to comply could result in negative effects on our business.

As discussed above, the FDA has specific regulations governing our tissue-based products, or HCT/Ps. The FDA has broad post-market and regulatory and enforcement powers. The FDA's regulation of HCT/Ps includes requirements for registration and listing of products, donor screening and testing, processing and distribution (“Current Good Tissue Practices”), labeling, record keeping and adverse-reaction reporting, and inspection and enforcement.

Biologics and medical devices are subject to even more stringent regulation by the FDA. Even if pre-market clearance or approval is obtained, the approval or clearance may place substantial restrictions on the indications for which the product may be marketed or to whom it may be marketed, may require warnings to accompany the product or impose additional restrictions on the sale and/or use of the product. In addition, regulatory approval is subject to continuing compliance with regulatory standards, including the FDA's quality system regulations.

If we fail to comply with the FDA regulations regarding our tissue products or medical devices, the FDA could take enforcement action, including, without limitation, any of the following sanctions and the manufacture of our products or processing of our tissue could be delayed or terminated:


•	Untitled letters, warning letters, fines, injunctions, and civil penalties;


•	Recall or seizure of our products;


•	Operating restrictions, partial suspension or total shutdown of production;


•	Refusing our requests for clearance or approval of new products;


•	Withdrawing or suspending current applications for approval or approvals already granted;


•	Refusal to grant export approval for our products; and


•	Criminal prosecution.

It is likely that the FDA's regulation of HCT/Ps will continue to evolve in the future. Complying with any such new regulatory requirements may entail significant time delays and expense, which could have a material adverse effect on our business.

The American Association of Tissue Banks (“AATB”) has issued operating standards for tissue banking. Compliance with these standards is a requirement in order to become an accredited tissue bank. In addition, some states have their own tissue banking regulations.

In addition, procurement of certain human organs and tissue for transplantation is subject to the restrictions of the National Organ Transplant Act (“NOTA”), which prohibits the transfer of certain human organs, including skin and related tissue for valuable consideration, but permits the reasonable payment associated with the removal, transportation, implantation, processing, preservation, quality control and storage of human tissue and skin. We reimburse tissue banks, hospitals and physicians for their services associated with the recovery, storage and transportation of donated human tissue. Although we have independent third party appraisals that confirm that reasonableness of the service fees we pay, if we were to be found to have violated NOTA's prohibition on the sale or transfer of human tissue for valuable consideration, we would potentially be subject to criminal enforcement sanctions, which could materially and adversely affect our results of operations.

Finally, as discussed above, we and other manufacturers of skin substitutes are required to provide ASP information to CMS on a quarterly basis. The Medicare payment rates are updated quarterly based on this ASP information. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, such manufacturer is subject to civil monetary penalties of up to $10,000 for each misrepresentation for each day in which the misrepresentation was applied.

We and our sales representatives, whether employees or independent contractors, must comply with various federal and state anti-kickback, self-referral, false claims and similar laws, any breach of which could cause a material adverse effect on our business, financial condition and results of operations.

Our relationships with physicians, hospitals and other healthcare providers are subject to scrutiny under various federal anti-kickback, self-referral, false claims and similar laws, often referred to collectively as healthcare fraud and abuse laws. Healthcare fraud and abuse laws are complex, and even minor, inadvertent violations can give rise to claims that the relevant law has been violated. Possible sanctions for violation of these fraud and abuse laws include monetary fines, civil and criminal penalties, exclusion from federal and state healthcare programs, including Medicare, Medicaid, Veterans Administration health programs, workers' compensation programs and TRICARE (the healthcare system administered by or on behalf of the U.S. Department of Defense for uniformed services beneficiaries, including active duty and their dependents, retirees and their dependents), and forfeiture of amounts collected in violation of such prohibitions. Certain states have similar fraud and abuse laws, imposing substantial penalties for violations. Any Government investigation or a finding of a violation of these laws would likely result in a material adverse effect on the market price of our common stock, as well as our business, financial condition and results of operations.

Anti-kickback laws and regulations prohibit any knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for the referral of an individual or the ordering or recommending of the use of a product or service for which payment may be made by Medicare, Medicaid or other Government-sponsored healthcare programs. We have entered into consulting agreements, speaker agreements, research agreements and product development agreements with physicians, including some who may order our products or make decisions to use them. In addition, some of these physicians own our stock, which they purchased in arm's length transactions on terms identical to those offered to non-physicians, or received stock awards from us as consideration for services performed by them. While these transactions were structured with the intention of complying with all applicable laws, including state anti-referral laws and other applicable anti-kickback laws, it is possible that regulatory or enforcement agencies or courts may in the future view these transactions as prohibited arrangements that must be restructured or for which we would be subject to other significant civil or criminal penalties. As discussed above, we have incorporated the AdvaMed code principles into our relationships with healthcare professionals under our consulting agreements, and our policies regarding payment of travel and lodging expenses, research and educational grant procedures and sponsorship of third-party conferences. In addition, we have conducted training sessions on these principles. However, there can be no assurance that regulatory or enforcement authorities will view these arrangements as being in compliance with applicable laws or that one or more of our employees or agents will not disregard the rules we have established. Because our strategy relies on the involvement of physicians who consult with us on the design of our products, perform clinical research on our behalf or educate the market about the efficacy and uses of our products, we could be materially impacted if regulatory or enforcement agencies or courts interpret our financial relationships with physicians who refer or order our products to be in violation of applicable laws and determine that we would be unable to achieve compliance with such applicable laws. This could harm our reputation and the reputations of the physicians we engage to provide services on our behalf. In addition, the cost of noncompliance with these laws could be substantial since we could be subject to monetary fines and civil or criminal penalties, and we could also be excluded from federally-funded healthcare programs, including Medicare and Medicaid, for non-compliance.

The Federal False Claims Act (“FCA”) imposes civil liability on any person or entity that submits, or causes the submission of, a false or fraudulent claim to the U.S. Government. Damages under the FCA can be significant and consist of

the imposition of fines and penalties. The FCA also allows a private individual or entity with knowledge of past or present fraud against the Federal Government to sue on behalf of the Government to recover the civil penalties and treble damages. The U.S. Department of Justice (“DOJ”) on behalf of the Government has previously alleged that the marketing and promotional practices of pharmaceutical and medical device manufacturers, including the off-label promotion of products or the payment of prohibited kickbacks to doctors, violated the FCA, resulting in the submission of improper claims to federal and state healthcare entitlement programs such as Medicaid. In certain cases, manufacturers have entered into criminal and civil settlements with the federal government under which they entered into plea agreements, paid substantial monetary amounts and entered into corporate integrity agreements that require, among other things, substantial reporting and remedial actions going forward.

The scope and enforcement of all of these laws is uncertain and subject to rapid change, especially in light of the lack of applicable precedent and regulations. There can be no assurance that federal or state regulatory or enforcement authorities will not investigate or challenge our current or future activities under these laws. Any investigation or challenge could have a material adverse effect on our business, financial condition and results of operations. Any state or federal regulatory or enforcement review of us, regardless of the outcome, would be costly and time consuming. Additionally, we cannot predict the impact of any changes in these laws, whether these changes are retroactive or will have effect on a going-forward basis only.

We face significant uncertainty in the industry due to Government healthcare reform.

There have been and continue to be proposals by the Federal Government, State Governments, regulators and third party payers to control healthcare costs, and generally, to reform the healthcare system in the United States. There are many programs and requirements for which the details have not yet been fully established or the consequences are not fully understood. These proposals may affect aspects of our business. We also cannot predict what further reform proposals, if any, will be adopted, when they will be adopted, or what impact they may have on us.

Risks Related to the Securities Markets and Ownership of Our Common Stock

The price of our common stock has been, and will likely continue to be, volatile.

The market price of our common stock, like that of the securities of many other companies that are in, or are just emerging from, the development stage, has fluctuated over a wide range and it is likely that the price of our common stock will fluctuate in the future. The market price of our common stock could be impacted by a variety of factors, including:


·	Fluctuations in stock market prices and trading volumes of similar companies or of the markets generally;


·	Our ability to successfully launch, market and earn significant revenue from our products;


·	Our ability to obtain additional financing to support our continuing operations;


·	Disclosure of the details and results of regulatory applications and proceedings;


·	Changes in Government regulations or our failure to comply with any such regulations;


·	Additions or departures of key personnel;


·	Our investments in research and development or other corporate resources;


·	Announcements of technological innovations or new commercial products by us or our competitors;


·	Developments in the patents or other proprietary rights owned or licensed by us or our competitors;


·	The timing of new product introductions;


·	Actual or anticipated fluctuations in our operating results, including any restatements of previously reported results;


·	Our ability to effectively and consistently manufacture our products and avoid costs associated with the recall of defective or potentially defective products;


·	Our ability and the ability of our distribution partners to market and sell our products;


·	Changes in reimbursement for our products or the price for our products to our customers;


·	Removal of our products from the Federal Supply Schedule, or changes in how Government accounts purchase products such as ours or in the price for our products to Government accounts; and


.	The other risks detailed in this Item 1A.

Further, due to the relatively fixed nature of most of our costs, which primarily include personnel costs as well as facilities costs, any unanticipated shortfall in revenue in any fiscal quarter would have an adverse effect on our results of operations in that quarter. These fluctuations could cause the trading price of our stock to be negatively affected. Our quarterly operating results have varied substantially in the past and may vary substantially in the future. In addition, the stock market has been very volatile in the recent past. This volatility is often not related to the operating performance of companies listed thereon and will probably continue in the foreseeable future.

Securities analysts may elect not to report on our common stock or may issue negative reports that adversely affect the stock price.

At this time, seven securities analysts provide research coverage of our common stock. However, there is no assurance that these analysts will continue to report on our common stock or that additional analysts will initiate reporting on our common stock. Rules mandated by the Sarbanes-Oxley Act and a global settlement reached in 2003 among the SEC, other regulatory agencies, and a number of investment banks led to a number of fundamental changes in how analysts are reviewed and compensated. In particular, many investment banking firms are required to contract with independent financial analysts for their stock research. If securities analysts discontinue covering our common stock, the lack of research coverage may adversely affect its actual and potential market price. The trading market for our common stock may be affected in part by the research and reports that industry or financial analysts publish about our business. If one or more analysts elect to cover us and then downgrade the stock, the stock price would likely decline rapidly. If one or more of these analysts cease coverage of us, we could lose visibility in the market, which in turn could cause our stock price to decline. This could have a negative effect on the market price of our shares.

Our charges to earnings resulting from acquisition, restructuring and integration costs may materially adversely affect the market value of our common stock.

We account for the completion of our acquisitions using the purchase method of accounting. We allocate the total estimated purchase prices to net tangible assets, amortizable intangible assets and indefinite-lived intangible assets, and based on their fair values as of the date of completion of the acquisitions, record the excess of the purchase price over those fair values as goodwill. Our financial results, including earnings per share, could be adversely affected by a number of financial adjustments required in purchase accounting including the following:


•	We will incur additional amortization expense over the estimated useful lives of certain of the intangible assets acquired in connection with acquisitions during such estimated useful lives.


•	We will incur additional depreciation expense as a result of recording purchased tangible assets.


•	To the extent the value of goodwill or intangible assets becomes impaired, we may be required to incur material charges relating to the impairment of those assets.


•	Cost of sales may increase temporarily following an acquisition as a result of acquired inventory being recorded at its fair market value.


•	Earnings may be affected by changes in estimates of future contingent consideration to be paid when an earn-out is part of the consideration.


•	Earnings may be affected by transaction and implementation costs, which are expensed immediately.

We do not intend to pay cash dividends.

We have never declared or paid cash dividends on our capital stock. We currently expect to use available funds and any future earnings in the development, operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. In addition, the terms of our existing credit facility restrict us from paying dividends. As a result, capital appreciation, if any, of our common stock will be an investor's only source of potential gain from our common stock for the foreseeable future.

We and certain of our executive officers have been named as defendants in a class action lawsuit that could result in substantial costs and divert management’s attention.

As discussed in Item 3, Legal Proceedings, we, and certain of our executive officers, have been named as defendants in purported class action lawsuits that allege violations of federal securities laws related to various statements regarding our belief that our products were 361 HCT/Ps. The Court has preliminarily approved a settlement in this action and has set the final settlement hearing for April 5, 2016. We do not believe the terms of the settlement, if finally approved, will have a material adverse effect on our operating results or financial condition.

In addition, the volatility in our stock price may make us more vulnerable to future class action litigation.

Any adverse judgment in or settlement of the pending or any future litigation could require payments that exceed the limits of our available directors’ and officers’ liability insurance, which could have a material adverse effect on our operating results or financial condition.

Provisions of Florida law and anti-takeover provisions in our organizational documents may discourage or prevent a change of control, even if an acquisition would be beneficial to shareholders, which could affect our share price adversely and prevent attempts by shareholders to remove current management.

We are subject to the Florida affiliated transactions statute, which generally requires approval by the disinterested directors or supermajority approval by shareholders for "affiliated transactions" between a corporation and an "interested stockholder." Additionally our organizational documents contain provisions:


·	Authorizing the issuance of preferred stock that can be created and issued by the Board of Directors without prior common stock shareholder approval, with rights senior to those of the common stock;


·	Restricting persons who may call shareholder meetings;


·	Electing directors on a staggered basis; and


.	Allowing the Board to fill vacancies and to fix the number of directors.

These provisions of Florida law and our articles of incorporation and bylaws could negatively affect our share price, prevent attempts by shareholders to remove current management, prohibit or delay mergers or other takeovers or changes of control of the Company and discourage attempts by other companies to acquire us, even if such a transaction would be beneficial to our shareholders.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Our corporate headquarters are located in Marietta, Georgia, where we lease approximately 80,000 square feet of office, laboratory, tissue processing and warehouse space. We also lease (a) approximately 21,000 square feet for a facility in Kennesaw, Georgia, which primarily consists of laboratory, tissue processing and warehouse space; and (b) approximately 26,000 square feet of additional office space in Marietta, Georgia. In addition, Stability leases approximately 3,000 square feet for its corporate offices in Nashville, Tennessee and approximately 11,000 square feet in San Antonio, Texas which consists of its tissue processing center.

Item 3. Legal Proceedings

Securities Class Action

Following the publication of an Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015. On November 19, 2015, the Court preliminarily approved the settlement and has set the final settlement hearing for April 5, 2016. The Company does not believe the terms of the settlement, if finally approved, will have a material adverse effect on its operating results or financial condition.

OIG Investigation

In the fourth quarter of 2014, the Company received a subpoena from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities. In March 2015, the Company received notice from the Department of Justice that it declined at that time to intervene in the qui tam action that gave rise to the issuance of the subpoena. The qui tam plaintiff had 120 days from the date of the Department of Justice’s notice to proceed with the case. The 120 day period passed without initiation of the lawsuit. The plaintiff, who is an executive at the Company’s competitor Organogenesis, Inc., voluntarily dismissed the lawsuit in July 2015. This dismissal was approved by the Court on October 6, 2015.

Patent Infringement Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are three actions pending, as described below:

The Liventa Action

First, there is an action pending against several entities in the in the United States District Court for the Northern District of Georgia, i.e., “the Liventa Action”. On April 22, 2014, the Company filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. The Liventa Action was filed in the United States District Court for the Northern District of Georgia.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity.

On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery.

required Defendants to supplement their invalidity contentions in view of parallel Inter Partes Review ("IPR")(see further discussion, infra) proceedings. MTF complied on June 26, 2015.

In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the ’437 and ’687 Patents, seeking a partial stay of the litigation as to the ’437, ’687, and ’494 Patents (i.e., the ’437 Patent family). MiMedx opposed the Motion to Stay with respect to the ’494 Patent and once again successfully defeated Defendants’ motion to stay.

Claim Construction proceedings began in October 2014. The parties submitted proposed constructions for key terms for the ’701, ’092, ’437, ’687, ’207, and ’494 Patents. Briefing was completed in March 2015.

On December 22, 2015, a Markman Hearing was held before Special Master Sumner C. Rosenberg. Over thirty disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for one term, the Special Master’s Report essentially adopted MiMedx’s proposed constructions. The parties are awaiting a final Court decision pending their respective objections.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. The Bone Bank Action is in an advanced stage. The parties have (i) substantially completed document production; (ii) taken several fact depositions (both party and non-party); and (iii) completed claim construction briefing. The Markman hearing in this case was held on October 2, 2015. Except for one term, the Court adopted MiMedx’s proposed construction of the disputed terms. The parties have submitted a proposed scheduling order to the Court and are awaiting the Court’s order in this regard. Meanwhile, the parties continue with fact discovery in view of recent depositions.

The NuTech Action

Finally, on March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.

On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On November 24, 2015, the court ruled on NuTech’s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement of the ‘494 and ‘687 patents, as well as violations of the Lanham Act; these claims shall proceed.

On December 30, 2015, the parties submitted a Joint Rule 26(f) Report of Parties’ Planning Meeting and Proposed Case Management Order to the Court. In the Report, the parties requested that the Court stay the proceedings with respect to the ’687 patent pending the completion of the inter partes review on that patent.

On January 8, 2016, MiMedx served its infringement contentions. Discovery has recently begun.

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The

defendants in the Bone Bank Action have challenged the validity of the Company's 8,597,687 and 8,709,494 patents (the "'687" and "'494" patents, respectively); while the defendants in the Liventa Action have challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied defendants' request for institution of an IPR with respect to the '494 patent on all seven challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The PTAB also adopted MiMedx's construction of the claims which will govern the Board's review of the '687 patent. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. Briefing and expert discovery is ongoing.

Following the PTAB decisions, the defendants in the Bone Bank Action moved to stay the district court litigation, despite the Court's previous denial of such a stay, pending the outcome of the '687 patent inter partes review. The parties agreed to stay the case with respect to the '687 patent only and the Court denied Bone Bank's motion to stay the litigation with respect to the '494 patent. The Company has also successfully defeated an attempt by defendants in the Liventa Action to stay that litigation -- also pending the outcome of the IPR of the patents at issue in that case.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities

Our common stock was approved for quotation on the OTC Bulletin Board on July 19, 2007. Only a limited number of shares were traded after the approval of the quotation in July 2007. The common stock was traded with the trading symbol of “AYXC.” Our common stock began trading under the symbol “MDXG” on April 2, 2008. On April 25, 2013, our common stock was approved for trading on the NASDAQ.

The following table sets forth, for the periods indicated, the range of high and low sale prices per share of common stock on NASDAQ for the fiscal years ended December 31, 2014 and 2015.



Year ended December 31, 2015	High		Low
First Quarter	$	11.33	$	7.92
Second Quarter	11.93		8.97
Third Quarter	13.20		8.52
Fourth Quarter	10.14		6.71

Year ended December 31, 2014	High		Low
First Quarter	$	8.68	$	5.56
Second Quarter	7.63		4.88
Third Quarter	7.90		6.10
Fourth Quarter	11.97		6.81

Based upon information supplied from our transfer agent, there were approximately 739 shareholders of record of our common stock as of February 10, 2016.

Stock Performance Graph

The following graph compares the cumulative total stockholder return on our common stock with the cumulative total stockholder return of the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes an investment of $100.00 on December 31, 2010, in each of the common stock, the stocks comprising the Nasdaq Composite Index and the stocks comprising the Nasdaq Biotechnology Index.

ASSUMES $100 INVESTED ON DEC. 31, 2010

ASSUMES NO DIVIDENDS

FISCAL YEAR ENDING DEC. 31, 2015

Unregistered Sales of Equity Securities and Use of Proceeds

In November of 2015, we issued approximately 42,000 unregistered shares of common stock in connection with the exercise of warrants at an exercise price of $1.09 per share. These issuances were exempt under Section 4(a)(2) of the Securities Act of 1933 since the issuance of shares did not involve a public offering.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to a total of $20 million and further increased the authorization in 2015 to a total of $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time. Below is a summary of the Company's stock repurchases, before brokerage commissions of approximately $70,000, for the quarter ended December 31, 2015. All shares were purchased pursuant to the Company's publicly announced repurchase program.



	Total Number of Shares Purchased	Average Price Paid per Share		Total Amount Spent Under the Plan		Remaining Amount to be Spent Under the Plan
Total amount remaining October 1, 2015						$	3,414,850

October 2015 increased spending authorization						$	20,000,000

October 1, 2015 - October 31, 2015	1,282,757	$	8.53	$	10,940,681	$	12,474,169

November 1, 2015 - November 30, 2015	912.456	$	7.65	$	6,980,399	$	5,493,770

December 2015 increased spending authorization						$	10,000,000

December 1, 2015 - December 31, 2015	141,000	$	8.65	$	1,220,131	$	14,273,639

Total for the quarter	2,336,213	$	8.19	$	19,141,211

Item 6. Selected Financial Data

The following selected consolidated financial data was derived from our consolidated financial statements. The data should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 7 and Consolidated Financial Statements and notes in Item 8.




	As of December 31, in thousands
		2015		2014		2013			2012			2011
Statement of Operations Data:

Net sales		$	187,296	$	118,223	$	59,181		$	27,054		$	7,760
Gross margin		167,094		105,558		49,853			21,865			4,403
Operating income (loss)		24,364		7,100		(2,639		)	(5,355		)	(9,761		)
Net income (loss)		$	29,446	$	6,220	$	(4,112	)	$	(7,662	)	$	(10,194	)
Net income (loss) per common share - basic		$	0.28	$	0.06	$	(0.04	)	$	(0.09	)	$	(0.14	)
Net income (loss) per common share - diluted		$	0.26	$	0.05	$	(0.04	)	$	(0.09	)	$	(0.14	)

				As of December 31, in thousands
		2015		2014		2013			2012			2011
Balance Sheet Data:

Total assets		$	135,913	$	109,259	$	84,694		$	35,183		$	27,096
Working capital		69,533		67,272		55,781			13,072			2,149
Long term liabilities		1,148		1,526		1,518			10,158			10,468
Stockholders' equity		107,988		89,329		73,568			20,007			11,897

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and the corresponding notes included in Item 8. Certain percentages presented in this discussion and analysis are calculated from the underlying whole dollar amounts and therefore may not recalculate from the rounded numbers used for disclosure purposes. Some of the information contained in this discussion and analysis or set forth elsewhere in this report includes forward-looking statements that involve risks and uncertainties. You should read the “Risk Factors” section of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires making estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue, and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Overview

Our EpiFix allografts are configured for external use. We offer EpiFix® in a sheet form as well as a micronized powder form. Currently, the EpiFix platform is being used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds (such as wounds following plastic surgery).

Our AmnioFix allografts consist of three configurations, all configured for internal use:


•	AmnioFix is provided in a sheet form. It is used to modulate inflammation, enhance soft tissue healing and to minimize scar tissue formation. It has been used in spine, urology and general surgeries.


•	AmnioFix Wrap also is supplied in a sheet form and is configured for the same purposes as AmnioFix®, but is optimized for use as a “wrap” for nerves, tendons or ligaments.


•	AmnioFix Injectable is supplied in micronized powder form used to reduce inflammation while enhancing healing of soft tissue. AmnioFix Injectable has been used to treat conditions such as tendonitis, including plantar fasciitis, lateral epicondylitis, and medial epicondylitis, bursitis, strains and sprains.

We also process allografts for ophthalmic surgery and dental applications, which are sold on an OEM basis.

Our assets also include licenses to two medical device technology platforms- HydroFix and CollaFix. Although we had commercialized some products based on the HydroFix technology, due to the relatively small size of the addressable market for those products, we decided to discontinue that product line in the fourth quarter of 2013. We are currently working to develop products using our CollaFix technology and continue to assess how best to exploit that technology.

Our distribution model is comprised of direct sales, third party sales agents and stocking distributors that market MiMedx-branded products. We also have several OEM relationships targeting the spine, orthopedic, ophthalmic and dental markets. Our primary focus is in the U.S. market, but we are currently exploring international expansion opportunities. In 2015 approximately 3% of our revenues were from sales outside the U.S. to stocking distributors compared with less than 1% of revenues in 2014.

Recent Events

FDA Guidance

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially, the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to the Company 16 months earlier. The Company submitted comments to the Minimal Manipulation draft guidance asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/ P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has also indicated that it will hold a public hearing on a date in 2016 to be determined to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company has requested, and has been granted an opportunity to speak at this hearing.

Acquisition of Stability

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. The acquisition of Stability was effected by the merger of Stability Inc. into a newly created wholly owned subsidiary of the Company. The new subsidiary was the surviving company in the merger and was subsequently renamed Stability Biologics, LLC ("Stability"). The Company paid $10 million at the closing, comprised of 60% cash and 40% in shares of common stock of MiMedx Group, Inc., assumed approximately $800,000 in debt and eliminated a $2.4 million receivable related to Company products sold to Stability prior to the acquisition. The Company will also pay future contingent consideration through a two-year earn out arrangement based on the 2016 and 2017 performance of Stability's business. The Company expects the earn out will be the larger portion of the overall consideration for the transaction. The earn out will also be paid in the form of 60% cash and 40% in shares of stock of MiMedx Group, Inc.

Critical Accounting Policies

We believe that of our significant accounting policies, which are described in Note 2 to our financial statements appearing elsewhere in this report, the following accounting policies involve a greater degree of judgment and complexity.

Revenue Recognition and Sales Returns, Discounts, and Allowances Accruals

The Company sells its products primarily through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships products directly to the end user, it recognizes revenue according to the shipping terms of the agreement provided all revenue recognition criteria have been met. A portion of the Company’s revenue is generated from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the product has been

used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.

Goodwill and Impairment of Long-Lived Assets

Goodwill is the excess of the purchase price over the fair value of net assets of acquired businesses. Goodwill is tested for impairment annually or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows. Our estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value, including projected future cash flows. No goodwill impairment has been recognized during 2015, 2014 or 2013.

Other intangible assets include patents, trademarks, and purchased technology. Intangible assets with a definite life are amortized on a straight-line or accelerated basis, as appropriate, with estimated useful lives ranging from ten to fourteen years, and are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. Indefinite-lived intangible assets are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. Refer to Note 8 to the consolidated financial statements in Item 8 for additional information. Our impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. We use estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates. In 2012, because our impairment test indicated that the carrying value of the intangible assets related to HydroFix exceeded its fair value, an impairment loss of approximately $1,798,000 was recognized and the intangible asset carrying amount was adjusted to its new basis. During the fourth quarter of 2013 we chose to discontinue the HydroFix product line. This action resulted in an impairment charge of approximately $368,000. This item is included in our Statement of Operations for the year ended December 31, 2013.

Fair Value Measurements

We record certain financial instruments at fair value, including: cash equivalents and contingent consideration. We may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2015 we have not chosen to make any such elections. Fair value financial instruments are recorded in accordance with the fair value measurement framework.

We also measure certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations. We use the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded or written down.

The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows:


•	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;


•	Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and


•	Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.

The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. We may also engage external advisors to assist us in determining fair value, as appropriate.

Although we believe that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.

Share-based Compensation

We follow the provisions of FASB Accounting Standards Codification (“ASC”) 718, “Compensation — Stock Compensation” (ASC 718), previously referred to as Statement of Financial Accounting Standards No. 123R — Share-based Payments which requires the measurement and recognition of compensation expense for all share-based payment awards either modified or granted to employees and directors based upon estimated fair values. The Black-Scholes-Merton option-pricing model, consistent with the provisions of ASC 718, was used to determine the fair value of each option granted. Option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. We use projected volatility rates, which are based upon historical volatility rates, trended into future years. Because our stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of our options.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

Recently Adopted Accounting Pronouncements

See Note 2 to the consolidated financial statements in Item 8 for recently adopted accounting pronouncements.

Results of Operations for the year ended December 31, 2015, compared to the year ended December 31, 2014

Revenue

Total revenue increased $69.1 million, or 58%, from approximately $118.2 million in 2014 to $187.3 million in 2015. This growth in revenue was driven by increases in our direct sales force, taking market share from other suppliers of wound care technologies, as well as market expansion due to the clinical and cost benefits of our EpiFix platform. Growth was also driven by expansion into several new surgical applications with our AmnioFix platform. Wound Care revenue in 2015 grew by $47.5 million, or approximately 51%, compared with 2014. Surgical, Sports Medicine, and Orthopedics (SSO) revenue in 2015 grew by $21.5 million or approximately 87%, compared with 2014.

Tissue Processing Costs and Cost of Products Sold

Cost of sales as a percentage of revenue was 10.8% versus 10.7% when compared to the prior year. The increase is due to the expiration of pass through status of our wound care products for Medicare patients in hospital out-patient clinics and ambulatory surgery centers, product sales mix, mostly offset by an increase in direct sales revenue and higher production rates that absorb a greater percentage of fixed manufacturing costs, and continued improvements in manufacturing efficiencies. SSO sales have lower gross margins than Wound Care sales, so the Company expects cost of sales as a percentage of revenue to increase as SSO sales become a larger percentage of total company sales.

Research and Development Expenses

Our research and development expenses increased approximately $1.4 million, or 19%, to $8.4 million in 2015, compared to approximately $7.0 million in the prior year. The increase is primarily related to increased investments in clinical trials, personnel costs, lab supplies, and consulting fees. The Company expects research and development expenses to remain in line with current spending on a percentage of sales basis moving forward.

Selling, General and Administrative Expenses

Selling, General and Administrative expenses for 2015 increased approximately $42.9 million, or 47%, to $133.4 million compared to $90.5 million for 2014. Selling expense increases were driven primarily by costs associated with building our direct sales organization for both the Wound Care and SSO markets, where headcount grew by 65 during the year, as well as increased commissions due to higher sales volume. General and administrative expense increases were driven primarily by costs associated with adding personnel to support continued growth, as well as increased patent litigation costs.

Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotions and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation. Share-based compensation included in SG&A for the years ended December 31, 2015 and 2014, was approximately $15.8 million and $10.5 million, respectively, an increase of approximately $5.3 million, or 50%.

Amortization expense related to intangible assets remained flat at $0.9 million for the year ended December 31, 2015 as compared to the prior year. We amortize our intangible assets over a period of 10 to 17 years, which we believe represents the remaining useful lives of the patents underlying the licensing rights and intellectual property. We do not amortize goodwill but we test our goodwill at least annually for impairment and periodically evaluate other intangibles for impairment based on events or changes in circumstances as they occur.

Net Interest Expense

We recorded financing and net interest expense of approximately $86,000 during the year ended December 31, 2015, compared with approximately $48,000 of financing and net interest expense during the year ended December 31, 2014. The increase is due to the amortization of deferred financing costs incurred during 2015 related to our $50 million revolving credit facility. See Note 9 in the consolidated financial statements in Item 8 for further details.

Results of Operations for the year ended December 31, 2014, compared to the year ended December 31, 2013

Revenue

Total revenue increased $59 million, or 100%, from approximately $59.2 million in 2013 to $118.2 million in 2014. The increase in revenue as compared to the prior year is due primarily to increased wound care sales of EpiFix in both commercial and Government accounts. Commercial revenue growth was driven by expanded Medicare and private insurance coverage.

Tissue Processing Costs and Cost of Products Sold

Cost of products sold as a percentage of revenue were 10.7% versus 15.8% when compared to the prior year. The improvement was due primarily to the increase in direct sales revenue, favorable product mix and higher production rates that absorb a greater percentage of fixed manufacturing costs.

Research and Development Expenses

Our research and development expenses increased approximately $2.2 million, or 46%, to $7.0 million in 2014, compared to approximately $4.8 million in the prior year. The increase is primarily related to increased investments in clinical trials, personnel costs, lab supplies, and testing costs. Our research and development expenses consist primarily of internal personnel costs, clinical trials, fees paid to external consultants, and supplies and instruments used in our laboratories. Additionally, during 2014, we were granted seven U.S. patents for the amnion technology, one U.S. patent for the collagen technology (under license agreement), and four international patents for the collagen technology (three under license agreements).

Selling, General and Administrative Expenses

Selling, General and Administrative expenses for 2014 increased approximately $44.3 million, or 96%, to $90.5 million compared to $46.2 million for 2013. Selling expense increases were driven by costs associated with building our direct sales organization for Government and commercial accounts, where headcount grew by 94 during the year, as well as increased commissions due to higher sales volume.

Additional increases included spending on support costs related to medical reimbursement, including our reimbursement hotline; our information technology infrastructure to help manage the growth of the business; increased share-based compensation expense, and a provision for anticipated costs associated with the management incentive program.

Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotions and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation. Share-based compensation included in SG&A for the years ended December 31, 2014 and 2013, was approximately $10.5 million and $5.3 million, respectively, an increase of approximately $5.2 million, or 98%.

We recorded approximately $.9 million and $1.1 million in amortization expense related to intangible assets in the years ended December 31, 2014 and 2013, respectively. The decrease of approximately $0.2 million is attributable to the impairment related to our HydroFix product line which we elected to discontinue in the fourth quarter of 2013. We amortize our intangible assets over a period of 10 to 17 years, which we believe represents the remaining useful lives of the patents underlying the licensing rights and intellectual property. We do not amortize goodwill but we test our goodwill at least annually for impairment and periodically evaluate other intangibles for impairment based on events or changes in circumstances as they occur.

Net Interest Expense

We recorded financing and net interest expense of approximately $48,000 during the year ended December 31, 2014, compared with approximately $1.4 million of financing and net interest expense during the year ended December 31, 2013, which represented the amortization of debt discount in connection with convertible senior secured promissory notes issued in 2011.

Contractual Commitments

The table below sets forth our known contractual obligations as of December 31, 2015 (in thousands):



			less than						More than
Contractual Obligations	TOTAL		1 year		1-3 years		3-5 years		5 years
Capital lease obligations	$	133	$	102	$	31	$	—	$	—
Operating lease obligations	7,542		1,804		3,623		2,115		—
Charitable contribution obligations	250		250		—		—		—
Meeting space commitments	1,247		764		483		—		—
	$	9,172	$	2,920	$	4,137	$	2,115	$	—

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Liquidity and Capital Resources

Our net working capital at December 31, 2015, increased $2.2 million to $69.5 million from $67.3 million at December 31, 2014. The increase in working capital was primarily due to our revenue growth resulting in an increase in accounts receivable, mostly offset by cash used for share repurchases. The current ratio (current assets divided by current liabilities) decreased to 3.6 as of December 31, 2015, as compared to 4.6 at December 31, 2014.

outstanding. As of the date hereof, there are no outstanding revolving loans under the Credit Agreement. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The obligations of the Company under the Credit Agreement are guaranteed by the Company's subsidiaries. Borrowings under the Credit Agreement bear interest at a rate equal to, at the Company’s option, the base rate or LIBOR, in each case plus an applicable margin. The base rate under the Credit Agreement equals the highest of (i) the agent’s prime rate, (ii) the Federal Funds rate plus 0.50%, or (iii) LIBOR for a one month interest period plus 1.0%. The initial applicable margin is 0.50% with respect to base rate borrowings and 1.50% with respect to the LIBOR borrowings. The applicable margin is subject to quarterly pricing adjustments based on the Company’s consolidated leverage ratio. In addition to paying interest on outstanding principal under the facility, the Company is required to pay a commitment fee in respect of committed but unutilized commitments equal to 0.25% per annum initially. The commitment fee is subject to quarterly adjustments based on the Company's consolidated leverage ratio. The Company must pay a fee on outstanding letters of credit under the facility at a rate equal to the applicable margin in respect of LIBOR borrowings plus certain fronting and administrative fees. The maturity date of the revolving credit facility is October 12, 2018. The Credit Agreement provides that the maturity date may be extended up to twice for one additional year each, subject to certain customary terms and conditions set forth in the Credit Agreement, if requested by the Company and agreed-upon by the lenders. The Credit Agreement contains customary covenants and events of default for senior secured credit agreements of this type. The covenants include (a) a requirement for the Company to maintain a maximum consolidated leverage ratio of 2.50:1.00; (b) a requirement for the Company to maintain a minimum consolidated fixed charge coverage ratio of 2.00:1.00; and (c) a requirement for the Company to maintain minimum liquidity of $10 million.

As of December 31, 2015, we had approximately $28.5 million of cash and cash equivalents. In addition, we had short term investments in FDIC insured certificates of deposit at various U.S. financial institutions that totaled, approximately $3.0 million. We believe that our anticipated cash from operating activities, existing cash and cash equivalents and availability under the Credit Agreement will enable us to meet our operational liquidity needs and fund our planned investing activities for the next year.

Discussion of cash flows

Net cash from operations during the year ended December 31, 2015, increased approximately $2.0 million to $18.8 million, compared to $16.8 million from operating activities for the year ended December 31, 2014, and was primarily attributable to the increase in Net Income (net of non cash items), partially offset by an increase in accounts receivable.

Net cash used in investing activities during the year ended December 31, 2015, decreased approximately $11.5 million to $0.7 million compared to $12.2 million used in investing activities for the year ended December 31, 2014. The decrease was primarily due to maturing certificates of deposit.

Net cash flows used in financing activities during the year ended December 31, 2015, was approximately $36.2 million compared to $2.1 million during the year ended December 31, 2014. The increase is primarily due to an increase in share repurchases, partially offset by an increase in proceeds received from the exercise of stock options and warrants.

Due to the material amount of non-cash related items included in our results of operations, we have developed an Adjusted EBITDA metric that provides management with a clearer view of operational use of cash (see the table below). Our Adjusted EBITDA for the year ended December 31, 2015, was approximately $44.0 million which is an improvement of approximately $23.3 million as compared to 2014 and an improvement of $38.5 million compared to 2013. These year-over-year improvements were the result of improved operating results.

Adjusted EBITDA is a non-GAAP measure. Non-GAAP financial measures are commonly used in the industry and are presented because management believes they provide relevant and useful information to investors. However, there are limitations to using these non-GAAP financial measures. Adjusted EBITDA is not indicative of cash provided or used by operating activities and may differ from comparable information provided by other companies. Adjusted EBITDA should not be considered in isolation, as an alternative to, or more meaningful than measures of financial performance determined in accordance with U.S. GAAP. The following table presents a reconciliation of Adjusted EBITDA to Net Income (loss), the most comparable financial measure reported under GAAP, for the years ended December 31, 2015, 2014 and 2013.



	Years Ended December 31 (in thousands)
	2015			2014		2013
Net Income (Loss) (Per GAAP)	$	29,446		$	6,220	$	(4,112	)
Add back (deduct):
Income Taxes	(5,168		)	832		100
Financing expense associated with beneficial conversion of Senior Secured Promissory Notes	—			—		1,328
Other interest expense, net	86			48		45
Depreciation Expense	1,799			1,197		637
Loss on fixed asset disposal	—			—		37
Amortization Expense	933			928		1,054
Share-Based Compensation	16,896			11,453		6,010
Impairment of Intangible Assets	—			—		368
Income Before Interest, Taxes, Depreciation, Amortization and Share -Based Compensation (Adjusted EBITDA)	$	43,992		$	20,678	$	5,467

Inflation

We do not believe that the rate of inflation has had a material effect on our operating results. However, inflation could adversely affect our future operating results.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Based on our lack of market risk sensitive instruments outstanding at December 31, 2015, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.

Item 8. Financial Statements and Supplementary Data



Index to Financial Statements

Reports of Independent Registered Public Accounting Firm	43
Consolidated Balance Sheets – As of December 31, 2015 and December 31, 2014	45
Consolidated Statements of Operations – For the years ended December 31, 2015, 2014 and 2013	46
Consolidated Statements of Stockholders’ Equity – For the Years ended December 31, 2015, 2014 and 2013	47
Consolidated Statements of Cash Flows – For the years ended December 31, 2015, 2014 and 2013	48
Notes to Consolidated Financial Statements	49
Schedule II - Valuation and Qualifying Accounts	69

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of MiMedx Group, Inc.

We have audited the accompanying consolidated balance sheets of MiMedx Group, Inc. and subsidiaries ( the "Company") as of December 31, 2015 and 2014, and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the three years ended in the period ended December 31, 2015. We have also audited the accompanying consolidated financial statement schedule for each of the three years in the period ended December 31, 2015 listed in the index at Item 15. These consolidated financial statements and schedules are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of MiMedx Group, Inc. and subsidiaries as of December 31, 2015 and 2014, and the consolidated results of their operations and their cash flows for each of the three years in the period ended December 31, 2015 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the related consolidated financial statement schedule for each of the three years in the period ended December 31, 2015, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), MiMedx Group, Inc.’s internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated February 29, 2016 expressed an unqualified opinion.



/s/ Cherry Bekaert LLP

Atlanta, Georgia

February 29, 2016

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of MiMedx Group, Inc.

We have audited MiMedx Group, Inc.’s internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). MiMedx Group, Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States of America). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, MiMedx Group, Inc maintained, in all material respects, effective internal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of MiMedx Group, Inc. and subsidiaries as of December 31, 2015 and 2014, and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2015 and the related consolidated financial statement schedules as of December 31, 2015, 2014 and 2013, and our report dated February 29, 2016 expressed an unqualified opinion.



/s/ Cherry Bekaert LLP

Atlanta, Georgia

February 29, 2016

MIMEDX GROUP, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except share data)

	December 31,
	2015			2014
ASSETS
Current assets:
Cash and cash equivalents	$	28,486		$	46,582
Short term investments	3,000			5,750
Accounts receivable, net	53,755			26,672
Inventory, net	7,460			5,133
Prepaid expenses and other current assets	3,609			1,540
Total current assets	96,310			85,677
Investments	—			3,250
Property and equipment, net of accumulated depreciation	9,475			5,447
Goodwill	4,040			4,040
Intangible assets, net of accumulated amortization	10,763			10,845
Deferred tax asset, net	14,838			—
Deferred financing costs and other assets	487			—
Total assets	$	135,913		$	109,259
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	6,633		$	3,661
Accrued compensation	15,034			11,523
Accrued expenses	4,644			2,504
Other current liabilities	466			716
Total current liabilities	26,777			18,404

Other liabilities	1,148			1,526
Total liabilities	27,925			19,930
Commitments and contingencies (Note 16)
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	—			—
Common stock; $0.001 par value; 150,000,000 shares authorized; 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 and 108,776,247 issued and 107,789,611 outstanding at December 31, 2014	109			108
Additional paid-in capital	163,133			162,433
Treasury stock at cost: 2,105,945 shares at December 31, 2015 and 986,636 shares at December 31, 2014	(17,125		)	(5,637		)
Accumulated deficit	(38,129		)	(67,575		)
Total stockholders' equity	107,988			89,329
Total liabilities and stockholders' equity	$	135,913		$	109,259

See notes to consolidated financial statements

MIMEDX GROUP, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data)

	Years Ended December 31,
	2015			2014			2013

Net sales	$	187,296		$	118,223		$	59,181
Cost of sales	20,202			12,665			9,328
Gross margin	167,094			105,558			49,853

Operating expenses:
Research and development expenses	8,413			7,050			4,843
Selling, general and administrative expenses	133,384			90,480			46,227
Impairment of intangible assets	—			—			368
Amortization of intangible assets	933			928			1,054

Operating income (loss)	24,364			7,100			(2,639		)

Other income (expense), net
Amortization of debt discount	—			—			(1,328		)
Interest expense, net	(86		)	(48		)	(45		)

Income (loss) before income tax provision	24,278			7,052			(4,012		)
Income tax provision	5,168			(832		)	(100		)

Net income (loss)	$	29,446		$	6,220		$	(4,112	)

Net income (loss) per common share - basic	$	0.28		$	0.06		$	(0.04	)

Net income (loss) per common share - diluted	$	0.26		$	0.05		$	(0.04	)

Weighted average shares outstanding - basic	105,929,205			105,793,008			96,285,504

Weighted average shares outstanding - diluted	113,628,482			113,295,504			96,285,504

See notes to consolidated financial statements

MIMEDX GROUP, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (in thousands, except share data)

	Common Stock				Additional Paid-in			Treasury Stock					Accumulated
	Shares		Amount		Capital			Shares		Amount			Deficit			Total
Balances, December 31, 2012	88,423,169		$	88	$	89,627		50,000		$	(25	)	$	(69,683	)	$	20,007

Share-based compensation expense	—		—		6,010			—		—			—			6,010
Exercise of stock options	1,958,674		2		1,979			—		—			—			1,981
Exercise of warrants	1,844,352		2		2,106			—		—			—			2,108
Common stock issued for 5% convertible note	5,272,004		5		5,267			—		—			—			5,272
Common stock issued for earn - out liability	1,174,915		1		5,791			—		—			—			5,792
Issuance of restricted stock	2,500		—		—			—		—			—			—
Public offering of common stock, net of expenses	5,750,000		6		36,504			—		—			—			36,510
Net income (loss)	—		—		—			—		—			(4,112		)	(4,112		)
Balances, December 31, 2013	104,425,614		$	104	$	147,284		50,000		$	(25	)	$	(73,795	)	$	73,568

Share-based compensation expense	—		—		11,453			—		—			—			11,453
Exercise of stock options	1,653,690		2		2,468			—		—			—			2,470
Exercise of warrants	1,242,416		1		1,112			—		—			—			1,113
Issuance of restricted stock	1,438,569		1		(1		)	—		—			—			—
Shares issued for services performed	15,958		—		117			—		—			—			117
Stock repurchase	—		—		—			936,636		(5,612		)	—			(5,612		)
Net income	—		—		—			—		—			6,220			6,220
Balance December 31, 2014	108,776,247		$	108	$	162,433		986,636		$	(5,637	)	$	(67,575	)	$	89,329

Share-based compensation expense	—		—		16,896			—		—			—			16,896
Tax benefit of share-based compensation expense	—		—		7,757			—		—			—			7,757
Exercise of stock options	647,656		1		(9,792		)	(1,573,225	)	14,420			—			4,629
Exercise of warrants	—		—		(379		)	(42,400	)	425			—			46
Issuance of restricted stock	34,250		—		(14,547		)	(1,940,009	)	14,547			—			—
Restricted stock shares canceled/forfeited	(2,058	)	—		652			69,949		(652		)	—			—
Shares issued for services performed	11,321		—		113			(5,172	)	51			—			164
Stock repurchase	—		—		—			4,610,166		(40,279		)	—			(40,279		)
Net income	—		—		—			—		—			29,446			29,446
Balances, December 31, 2015	109,467,416		$	109	$	163,133		2,105,945		$	(17,125	)	$	(38,129	)	$	107,988

See notes to consolidated financial statements

MIMEDX GROUP, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

	Years Ended December 31,
	2015			2014			2013
Cash flows from operating activities:
Net income (loss)	$	29,446		$	6,220		$	(4,112	)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation	1,799			1,197			637
Loss on fixed asset disposal	—			—			37
Amortization of intangible assets	933			928			1,054
Impairment of intangible assets	—			—			368
Amortization of debt discount and deferred financing costs	42			—			1,328
Share-based compensation	16,896			11,453			6,010
Change in deferred income taxes	(7,081		)	—			—
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(27,083		)	(10,579		)	(8,439		)
Inventory	(2,327		)	(1,252		)	(858		)
Prepaid expenses and other assets	(2,094		)	(203		)	(637		)
Accounts payable	3,136			1,287			1,209
Accrued compensation	3,511			5,935			2,836
Accrued expenses	2,140			1,098			353
Accrued interest	—			—			(42		)
Other liabilities	(511		)	718			(28		)
Net cash flows from operating activities	18,807			16,802			(284		)
Cash flows from investing activities:
Purchases of equipment	(5,827		)	(2,558		)	(2,337		)
Maturity (purchases) of fixed maturity securities	6,000			(9,000		)	—
Patent application costs	(851		)	(594		)	(689		)
Net cash flows from investing activities	(678		)	(12,152		)	(3,026		)

Cash flows from financing activities:
Proceeds from exercise of stock options	4,629			2,470			1,981
Proceeds from exercise of warrants	46			1,113			2,108
Proceeds from public offering, net of expenses	—			—			36,602
Deferred financing costs	(504		)	—			—
Stock repurchase	(40,279		)	(5,612		)	—
Principal payments of equipment leases	(117		)	(117		)	(57		)
Net cash flows from financing activities	(36,225		)	(2,146		)	40,634

Net change in cash	(18,096		)	2,504			37,324
Cash and cash equivalents, beginning of period	46,582			44,078			6,754
Cash and cash equivalents, end of period	$	28,486		$	46,582		$	44,078

See notes to consolidated financial statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE FISCAL YEARS ENDED DECEMBER 31, 2015 AND 2014


1.	Nature of Business

MiMedx Group, Inc. (“MiMedx,” "the Company,” “we,” or “us”) operates in one business segment, Regenerative Biomaterials, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix and EpiFix, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology CollaFix,which the Company has yet to commercialize.

The Company is focused primarily on the United States but is actively exploring international expansion opportunities. The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.


2.	Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation

The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., MiMedx Processing Services, LLC (formerly known as SpineMedica, LLC), and MiMedx Tissue Services, LLC (formerly known as Surgical Biologics, LLC). All significant inter-company balances and transactions have been eliminated.

Segment Reporting

ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment. Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment. Thus, discrete financial information is not available for more than one operating segment.

Market Concentrations and Credit Risk

The Company places its cash and cash equivalents on deposit with financial institutions in the United States. In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts. As of December 31, 2015 and 2014, the Company had cash and cash equivalents of approximately $27,700,000 and $44,600,000, respectively, in excess of the insured amounts.

The Company’s principal market concentration of risk is related to its limited distribution channels. The Company's revenues include the distribution efforts of several independent companies as well as the Company's internal sales force. Significant revenues are derived from the Company's relationship with one of its distributors, AvKare, Inc. which sells our products to the Federal Government. For the years ended December 31, 2015, 2014 and 2013, AvKare revenue was approximately 24%, 34%, and 56%, of total revenue, respectively. Related receivables for the years ended December 31, 2015 and 2014 were approximately 26%, and 33%, of total accounts receivable, respectively.

Cash and Cash Equivalents

Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.

Accounts Receivable

Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.

The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.

Investments

Investments consist of FDIC insured certificates of deposit held at various banks and are classified as either Short term investments or Investments depending on their maturity date and are valued at cost, which approximates market value.

Inventories

Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method. Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes up to when the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.

Goodwill and Purchased Intangible Assets

Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss.

Impairment of Intangible Assets with Finite Lives

The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets.

Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates.

During the fourth quarter of 2013, the Company chose to discontinue the HydroFix product line. This action resulted in an impairment charge of approximately $368,000 related to the Licenses for SaluMedica LLC, Spine Repair and Polyvinyl

Alcohol Cryogel. This item is included in our Statement of Operations for the year ended December 31, 2013. An impairment charge of approximately $1,800,000 had previously been booked in 2012.

Property and Equipment

Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years. Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term. See Notes 7 and 16 for further information regarding capital leases, operating leases and rent expense.

Patent Costs

The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $851,000 of patent costs during 2015, $594,000 of patent costs during 2014 and $689,000 of patent costs during 2013.

Impairment of Long-lived Assets

The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated. If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized. During the fourth quarter of 2013, the Company chose to discontinue the HydroFix product line. This action resulted in a disposal loss of approximately $30,000. This item is included in the Consolidated Statements of Operations for the year ended December 31, 2013, as Selling, General and Administrative expenses.

Grant Income

The Company received a Regional Economic Business Assistance ("REBA") grant in the amount of $250,000 from the State of Georgia to help the Company defray certain expenses and capital expenditures related to the Company's expansion of manufacturing activities in the State. In order to retain the grant monies the Company was required to add a certain number of full time positions and spend a certain amount on capital and operations expenditures by December 31, 2014. As of December 31, 2013, the Company had satisfied the grant requirements. Accordingly, the Company recorded the $250,000 as a reduction of Selling, General and Administrative expenses in the accompanying 2013 Consolidated Statements of Operations.

Revenue Recognition

Research and Development Costs

Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred.

Income Taxes

Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

Share-based Compensation

The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award).

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates their carrying value based upon current rates available to the Company.

Fair Value Measurements

The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments. The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2015, the Company has not chosen to make any such elections. Fair value financial instruments are recorded in accordance with the fair value measurement framework.

The Company also measures certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations. The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.


•	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;


•	Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.


•	Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.

The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method

used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist it in determining fair value, as appropriate.

Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.

Recently Issued Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements.

In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 13. Prior periods were not retrospectively adjusted.

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

All other ASUs issued and not yet effective for the year ended December 31, 2015, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.


3.	Liquidity and Capital Resources

Net Working Capital

As of December 31, 2015, the Company had approximately $28,486,000 of cash and cash equivalents. The Company reported total current assets of approximately $96,310,000 and current liabilities of approximately $26,777,000 and had net working capital of approximately $69,533,000.

Overall Liquidity and Capital Resources

The Company's largest cash requirement for the twelve months ended December 31, 2015 was cash for general working capital needs. In addition, the Company's other cash requirements included capital expenditures, and repurchases of the Company's common stock. The Company funded its cash requirements through its existing cash reserves, and its operating activities which generated approximately $18,807,000 during the period. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents as well as its investments in FDIC insured certificates of deposit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year. In addition, on October 12, 2015, the Company entered into a new three-year $50 million senior secured revolving credit facility, which provides additional liquidity.


4.	Cash Equivalents and Short Term Investments

Included in Cash and cash equivalents as of December 31, 2014, were approximately $1,250,000 of FDIC insured certificates of deposit held with various U.S. financial institutions. Short term investments at December 31, 2015 and 2014 consist of approximately $3,000,000 and $5,750,000, respectively, of FDIC insured certificates of deposits held with various financial institutions. The cost of these instruments approximates their fair market value.


5.	Inventories

Inventories consisted of the following items as of December 31, 2015 and 2014 (in thousands):



	December 31,
	2015			2014
Raw materials	$	602		$	255
Work in process	3,850			3,419
Finished goods	3,405			1,986
Inventory, gross	7,857			5,660
Reserve for obsolescence	(397		)	(527		)
Inventory, net	$	7,460		$	5,133


6.	Investments

Investments consisted of FDIC insured certificates of deposit with various U.S. financial institutions. The balance as of December 31, 2015 was zero and the balance as of December 31, 2014 was approximately $3,250,000 and the cost approximated fair market value. Maturities of these instruments range to May of 2016.


7.	Property and Equipment

Property and equipment consist of the following as of December 31, 2015 and 2014 (in thousands):



	December 31,
	2015			2014
Leasehold improvements	$	2,684		$	2,559
Lab and clean room equipment	4,564			3,040
Furniture and equipment	4,577			2,398
Construction in Progress	2,629			949
Property and equipment, gross	14,454			8,946
Less accumulated depreciation	(4,979		)	(3,499		)
Property and equipment, net	$	9,475		$	5,447

Included in property and equipment is approximately $427,000 of capital leases. The corresponding liability of approximately $133,000 is included in other liabilities in the accompanying condensed consolidated balance sheet. Also included is approximately $1,000,000 in leasehold improvements paid for by the landlord of our main operating facility with a corresponding liability included in long term liabilities, which is amortized over the term of the lease.

Depreciation expense for the years ended December 31, 2015, 2014, and 2013 was approximately $1,799,000, $1,197,000, and $637,000, respectively.


8.	Intangible Assets and Royalty Agreement

Intangible assets are summarized as follows (in thousands):



		December 31,
		2015			2014
	Weighted Average Amortization Lives	Cost			Cost
Licenses (a) (b)	10 years	$	1,009		$	1,009
Patents & Know How (b)	17 years	8,001			7,891
Customer & Supplier Relationships (b)	14 years	3,761			3,761
Tradenames & Trademarks (b)	indefinite	1,008			1,008
In Process Research & Development (b)	n/a	25			25
Patents in Process (c)	n/a	1,823			1,082
Total		15,627			14,776
Less Accumulated amortization		(4,864		)	(3,931		)
Net		$	10,763		$	10,845

(a)

On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000.

(b)

On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.


(c)	Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

Amortization expense for the years ended December 31, 2015, 2014, and 2013, was approximately $933,000, $928,000, and $1,054,000, respectively.

Expected future amortization of intangible assets as of December 31, 2015, is as follows (in thousands):



	Estimated
	Amortization
Year ending December 31,	Expense
2016	$	936
2017	846
2018	836
2019	836
2020	836
Thereafter	5,465
	$	9,755


9.	Long-Term Debt

Senior Secured Promissory Notes

From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000. The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO. In total, the principal of the Notes were convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) plus accrued but unpaid interest at $1.00 per share at any time upon the election of the holder of the note.

In conjunction with the sale of the Notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share. These warrants were exercised in November 2015. The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique. The total direct costs of approximately $47,800 were recorded as deferred financing costs and were amortized over the term of the Notes using the effective interest method. Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP.

During the months of January and February 2013, all holders of the Notes converted their interest in this obligation to shares of MiMedx common stock. The total amount of debt plus accrued interest that was exchanged was approximately $5,272,000. In conjunction with this exchange, approximately 5,272,000 shares of the Company’s common stock were issued in full satisfaction of this obligation. Included in this total are 532,260 shares representing the CEO’s conversion of his Note. This also resulted in the acceleration of amortization of debt discount and total interest expense of approximately $1,328,000 during the year ended December 31, 2013.

Credit Facility

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%. Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary representations, warranties, covenants, and events of default. As of December 31, 2015, there were no outstanding revolving loans under the credit facility.


10.	Net Income (loss) Per Share

Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and restricted stock using the treasury stock method.

The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data):



	Year Ended December 31,
	2015		2014		2013
Net income (loss)	$	29,446	$	6,220	$	(4,112	)
Denominator for basic earnings per share - weighted average shares	105,929,205		105,793,008		96,285,504
Effect of dilutive securities: Stock options, warrants, and restricted stock (a)	7,699,277		7,502,496		—
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	113,628,482		113,295,504		96,285,504
Income (loss) per common share - basic	0.28		0.06		(0.04		)
Income (loss) per common share - diluted	$	0.26	$	0.05	$	(0.04	)

(a)Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2015 and 2014 are as follows:



Effect of dilutive securities:	2015	2014
Stock Options	7,121,774	7,035,728
Warrants	33,676	226,926
Restricted Stock Awards	543,827	239,842
	7,699,277	7,502,496

Securities for the year ended December 31, 2013 were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.


11.	Common Stock Placements

Public Offering of Common Stock

In December of 2013, the Company completed a public offering (the "Offering”) of 5,750,000 shares of its common stock at $6.80 per share. Proceeds from the Offering, net of underwriting expenses were $36,704,000. In addition, the Company incurred approximately $194,000 in various legal fees for services related to the Offering.

Proceeds from the Offering were used for general corporate purposes, including, but not limited to, research, development and further commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures, working capital and future acquisitions of complementary businesses, technology or products.


12.	Equity

Stock Incentive Plans

The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at December 31, 2015, totaled 70,000. The maximum number of shares of common stock that can be issued under the 2006 Plan total 26,500,000 at December 31, 2015.

Activity with respect to the stock options is summarized as follows:



	Number of Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2015	16,474,227		$	3.43
Granted	75,100		$	9.66
Exercised	(2,220,881	)	$	2.08
Unvested options forfeited	(239,322	)	$	6.66
Vested options expired	(69,495	)	$	2.61
Outstanding at December 31, 2015	14,019,629		$	3.62	6.5	$	80,740,577
Vested at December 31, 2015	10,951,694		$	2.80	6.2	$	71,955,234
Vested or expected to vest at December 31, 2015 (a)	13,917,122		$	3.60	6.5	$	80,496,150


(a)	Includes forfeiture adjusted unvested shares.

The intrinsic value of the options exercised during the years ended December 31, 2015, 2014 and 2013 were approximately $17,181,000, $10,566,000, and $8,864,000, respectively.

The intrinsic value of options vested during the years ended December 31, 2015, 2014 and 2013 were approximately $10,044,000, $6,615,000, and $3,351,000, respectively.

Following is a summary of stock options outstanding and exercisable at December 31, 2015:



	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price		Number Exercisable	Weighted- Average Exercise Price
$0.50 - $0.76	441,429	3.4	$	0.72	441,429	$	0.72
$0.87 - $1.35	4,783,304	5.7	1.19		4,783,304	1.19
$1.40 - $2.45	1,641,928	5.1	1.93		1,641,928	1.93
$2.66 - $3.99	957,454	6.8	3.05		907,452	3.00
$4.19 - $6.38	3,552,323	7.4	5.35		2,229,386	5.32
$6.45- $9.78	2,527,525	8.1	7.29		914,703	7.18
$9.90 - $10.99	115,666	8.9	10.43		33,492	10.50
	14,019,629	6.5	$	3.62	10,951,694	$	2.80

A summary of the status of the Company’s unvested stock options as of December 31, 2015 is presented below:



Unvested Stock Options	Number of Shares		Weighted- Average Grant Date Fair Value
Unvested at January 1, 2015	7,193,577		$	3.08
Granted	75,100		$	5.15
Cancelled	(239,322	)	$	3.79
Vested	(3,961,420	)	$	2.53
Unvested at December 31, 2015	3,067,935		$	3.81

Total unrecognized compensation expense at December 31, 2015, was approximately $6,241,000 and will be charged to expense through March 2017.

The fair value of the options granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options. The term of employee options granted is derived using the “simplified method” which computes expected term as the midpoint between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company’s lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded. The term for non-employee options is generally based upon the contractual term of the option. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.

The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:



	Year ended December 31,
	2015	2014	2013
Expected volatility	54.35 - 58.14%	58.14 - 64.50%	61.41 - 64.77%
Expected life (in years)	6	6	6
Expected dividend yield	—	—	—
Risk-free interest rate	1.51 - 1.68%	1.64 - 1.96%	0.85 - 1.88%

The weighted-average grant date fair value for options granted during the years ended December 31, 2015, 2014 and 2013 were approximately $5.15, $4.18 and $3.08, respectively.

Restricted Stock Awards

Following is summary information for restricted stock awards for the year ended December 31, 2015. Shares vest over a one to three year period. As of December 31, 2015, there was approximately $16,606,000 of total unrecognized stock-based compensation related to time-based, non-vested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.1 years.

Additionally, during the twelve months ended December 31, 2015, 5,172 shares of common stock valued at approximately $57,000 were issued under the 2006 Plan to a consultant in return for services performed.



	Number of Shares		Weighted-Average Grant Date Fair Value
Unvested at January 1, 2015	1,228,898		$	7.16
Granted	1,974,259		$	9.80
Vested	(517,883	)	$	6.90
Forfeited	(72,007	)	$	9.77
Unvested at December 31, 2015	2,613,267		$	9.14

For the years ended December 31, 2015, 2014, and 2013 the Company recognized stock-based compensation as follows (in thousands):



	Year Ended December 31,
	2015		2014		2013
Cost of sales	$	352	$	322	$	279
Research and development	790		660		417
Selling, general and administrative	15,754		10,471		5,314
	$	16,896	$	11,453	$	6,010

Warrants

On November 18, 2015, 42,400 common stock warrants representing the balance remaining from those granted in connection with equity share purchases by investors as an additional incentive for providing long - term equity capital to the Company and as additional compensation to consultants and advisors were exercised at an exercise price of $1.09. The warrants were granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances. The warrants were issued for terms of five years.

Treasury Stock

On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.

For the year ended December 31, 2015, the Company purchased approximately 4,610,000 shares of its common stock for an aggregate purchase price of approximately $40,143,000 exclusive of commissions of approximately $136,000. As of December 31, 2015, the Company had approximately $14,274,000 remaining under the repurchase program.


13.	Income Taxes

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):



	December 31,
	2015			2014
Deferred tax assets and liabilities:
Accruals and prepaids	$	4,606		$	3,563
Intangible assets	146			619
Property and equipment	(1,396		)	(770		)
R&D and other tax credits	3,293			2,086
Stock compensation	7,063			4,163
Charitable contributions	—			1
Federal and state basis difference	145			114
Net operating loss	1,763			6,382
Net deferred tax assets	$	15,620		$	16,158

Valuation allowance	(782		)	(16,158		)
	$	14,838		$	—

The reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows:



	December 31,
	2015		2014
Federal statutory rate	34.00	%	34.00	%
State taxes, net of federal benefit	3.33	%	9.58	%
Non deductible compensation	0.63	%	5.59	%
Meals & entertainment	2.27	%	5.55	%
Stock based compensation - ISO	6.39	%	21.73	%
Other	(4.58	)%	(5.92	)%
Valuation allowance	(63.33	)%	(58.73	)%
	(21.29	)%	11.80	%

Current and deferred income tax expense (benefit) is as follows (in thousands):



	December 31, 2015			December 31, 2014
Current:
Federal	$	8,452		$	—
State	1,218			832
Total current	9,670			832

Deferred:
Federal	(13,070		)	—
State	(1,768		)	—
Total deferred	(14,838		)	—

Total expense	$	(5,168	)	$	832

Income taxes are based on estimates of the annual effective tax rate and evaluations of possible future events and transactions and may be subject to subsequent refinement or revision.

Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely.

As of December 31, 2015, our deferred tax assets were primarily the result of accrued liabilities, equity compensation, and tax credit and net operating loss carryforwards. A valuation allowance of approximately $782,000 and $16,158,000 was recorded against our gross deferred tax asset balance as of December 31, 2015, and December 31, 2014, respectively. For the year ended December 31, 2015, we recorded a net valuation allowance release of $15,376,000 on the basis of management's reassessment of the amount of its deferred tax assets that are more likely than not to be realized.

As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2015, in part because in the current year we achieved three years of cumulative pretax income in the U.S. federal tax jurisdiction, management determined that there is sufficient positive evidence to conclude that it is more likely than not that additional deferred taxes are realizable. It therefore reduced the valuation allowance accordingly.

At December 31, 2015, and December 31, 2014, the Company had income tax net operating loss ("NOL") carryforwards for federal and state purposes of $579,000 and $27,552,000, respectively. If not utilized, the federal and state tax loss carryforwards will expire between 2026 and 2031. The Company has recorded a deferred tax asset for both federal and state NOL carryforwards of approximately $197,000 and approximately $1,566,000, respectively. A valuation allowance remains recorded against the deferred tax asset for certain federal net operating loss carryovers in the amount of $197,000 due to limitations provided by Internal Revenue Code Section 382 and certain state net operating loss carryovers in the amount of $585,000 not expected to be utilized prior to expiration.

The Company's net operating losses and tax credits are subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382. The Company has performed an analysis and determined that the limitation exceeds the utilization of NOLs in the current year and does not anticipate much limitation going forward.

As a result of certain realization requirements of ASC 718, Compensation - Stock Compensation, the table of deferred tax assets and liabilities shown above does not include certain deferred tax assets as of December 31, 2015, and December 31, 2014, that arose directly from (or the use of which was postponed by) tax deductions related to equity compensation that are greater than the compensation recognized for financial reporting. During 2015, deferred tax assets in the amount of $7,757,000 were realized resulting in an increase to equity in the same amount. The Company has approximately $1,661,000 of remaining deferred tax assets that will result in an increase to equity, if and when these deferred tax assets are ultimately realized. The Company uses ASC 740 ordering when determining when excess tax benefits have been realized.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):



	December 31, 2015		December 31, 2014
Unrecognized tax benefits - January 1	$	—	$	—

Gross increases - tax positions in current period	170		—

Unrecognized tax benefits - December 31	$	170	$	—

Included in the balance of unrecognized tax benefits as of December 31, 2015 and December 31, 2014, are $170,000 and $0, respectively, of tax benefits that, if recognized, would affect the effective tax rate. Also included in the balance of unrecognized tax benefits as of December 31, 2015 and December 31, 2014, are $170,000 and $0, respectively, of tax benefits that, if recognized, would result in adjustments to other tax accounts, primarily deferred taxes. This amount is recorded in Other Liabilities in the accompanying consolidated balance sheets.

The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, the Company accrued no penalties or interest during 2015, and, in total, as of December 31, 2015 has not recognized any liabilities for penalties or interest. During 2014, we also did not accrue any penalties or interest and, in total, as of December 31, 2014, had not recognized any liability for penalties or interest.

The Company is subject to taxation in the US and various state jurisdictions. As of December 31, 2015, the Company’s tax years for 2012, 2013, 2014 and 2015 are subject to examination by the tax authorities. As of December 31, 2015, the Company is generally no longer subject to US federal, state, or local examinations by tax authorities for years before 2012.

14. Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities

Selected cash payments, receipts, and noncash activities are as follows (in thousands):



	Years Ended December 31,
	2015		2014		2013
Cash paid for interest	$	86	$	48	$	36
Income taxes paid	2,293		384		61
Purchases of equipment financed through capital leases	—		—		355
Retirement of fixed assets	319		—		—
Deferred financing costs	504		—		27
APIC related tax adjustments	7,757		—		—
Stock issuance in connection with Earn-Out Liability of 1,174,915 shares	—		—		5,792
Stock issuance in exchange for convertible debt of 5,272,004 shares	—		—		5,272
Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively	164		117		—
Tenant improvement incentive	—		—		997
Legal fees paid for public offering	—		—		102
Legal fees related to public offering included in accounts payable	—		—		30
Legal fees related to public offering included in accrued expenses	—		—		62


15.	401k Plan

The Company has a 401(k) plan (the “Plan”) covering employees who have attained 21 years of age and have completed three months of service. Under the Plan, participants may defer up to 100% of their eligible wages to a maximum of $18,000 per year (annual limit for 2015). Employees age 50 or over in 2015 may make additional pre-tax contributions up to $6,000 above and beyond normal plan and legal limits. Annually, the Company may elect to match employee contributions up to 6% of the employee’s compensation. Additionally, the Company may elect to make a discretionary contribution to the Plan. The Company did not provide matching contributions for the years ended December 31, 2015, 2014 and 2013.


16.	Commitments and Contingencies

Contractual Arrangements

In addition to the capital leases noted under Property and Equipment above, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next five years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations.

The estimated annual payments are as follows (in thousands):



Year ended December 31,
2016	$	2,818
2017	2,340
2018	1,766
2019	1,763
2020	352
	$	9,039

Rent expense for the years ended December 31, 2015, 2014 and 2013, was approximately $1,317,000, $1,130,000 and $1,000,000, respectively and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit

As a condition of the leases for the Company's facilities we are obligated under standby letters of credit in the amount of approximately $235,000. These obligations are reduced at various times over the lives of the leases.

FDA Untitled Letter, Draft Guidance and Related Litigation

FDA Untitled Letter and Draft Guidance

On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

draft guidance. The FDA has also indicated that it will hold a public hearing on on a date in 2016 to be determined to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company has requested, and has been granted an opportunity to speak at this hearing.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues in 2015.

Related Litigation

Following the publication of the Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015. On November 19, 2015, the Court preliminarily approved the settlement and has set the final settlement hearing for April 5, 2016.

OIG Subpoena

Patent Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are three actions pending, as described below:

The Liventa Action

On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery.

MiMedx served Infringement Contentions on August 29, 2014, and Defendants served Invalidity Contentions and Responses to Infringement Contentions on September 29, 2014. After a protracted series of meet and confers, MiMedx required Defendants to supplement their invalidity contentions in view of parallel Inter Partes Review ("IPR")(see further discussion, infra) proceedings. MTF complied on June 26, 2015.

The Bone Bank Action

The NuTech Action

On January 8, 2016, MiMedx served its infringement contentions. Discovery has recently begun.

Pending IPRs

invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action have challenged the validity of the C ompany's 8,597,687 and 8,709,494 patents (the "'687" and "'494" patents, respectively); while the defendants in the Liventa Action have challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).


17.	Quarterly Financial Data (Unaudited) (in thousands except per share data)



		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
NET SALES	2015	$	40,767		$	45,679		$	49,015		$	51,835
	2014	19,559			25,573			33,518			39,573
	2013	11,556			13,515			16,116			17,994

GROSS MARGIN	2015	$	35,619		$	40,590		$	44,036		$	46,849
	2014	16,582			22,833			30,170			35,973
	2013	9,651			11,316			14,002			14,883

NET INCOME (LOSS)	2015	$	4,087		$	5,430		$	6,551		$	13,378
	2014	(922		)	(390		)	3,700			3,832
	2013	(1,620		)	(757		)	(307		)	(1,427		)

NET INCOME (LOSS) PER COMMON SHARE - BASIC	2015	$	0.04		$	0.05		$	0.06		$	0.13
	2014	(0.01		)	—			0.03			0.04
	2013	(0.02		)	(0.01		)	—			(0.01		)

NET INCOME (LOSS) PER COMMON SHARE - DILUTED	2015	$	0.04		$	0.05		$	0.06		$	0.11
	2014	(0.01		)	—			0.03			0.03
	2013	(0.02		)	(0.01		)	—			(0.01		)

18. Subsequent Events

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. The acquisition of Stability was effected by the merger of Stability Inc. into a newly created wholly owned subsidiary of the Company. The new subsidiary was the surviving company in the merger and was subsequently renamed Stability Biologics, LLC ("Stability"). The Company paid $10 million at the closing, comprised of 60% cash and 40% in shares of common stock of MiMedx Group, Inc., assumed approximately $800,000 in debt, and eliminated a $2.4 million receivable related to Company products sold to Stability prior to the acquisition . The Company will also pay future contingent consideration through a two-year earn out arrangement based on the 2016 and 2017 performance of Stability's business. The Company expects the earn out will be the larger portion of the overall consideration for the transaction. The earn out will also be paid in the form of 60% cash and 40% in shares of stock of MiMedx Group, Inc.

Schedule II Valuation and Qualifying Accounts



MIMEDX GROUP, INC. AND SUBSIDIARIES SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
Years ended December 31, 2015, 2014 and 2013 (in thousands)

	Balance at Beginning of Year		Additions charged to Expense or Revenue		Deductions and write-offs			Balance at End of Year

For the Year ended December 31, 2015
Allowance for doubtful accounts	$	1,750	$	1,698	$	(178	)	$	3,270
Allowance for product returns	841		3,257		(2,836		)	1,262
Allowance for obsolescence	527		540		(670		)	397

For the Year ended December 31, 2014
Allowance for doubtful accounts	$	407	$	1,357	$	(14	)	$	1,750
Allowance for product returns	215		2,215		(1,589		)	841
Allowance for obsolescence	322		405		(200		)	527

For the Year ended December 31, 2013
Allowance for doubtful accounts	$	49	$	391	$	(33	)	$	407
Allowance for product returns	89		917		(791		)	215
Allowance for obsolescence	159		213		(50		)	322

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Disclosure Controls and Procedures

We maintain “disclosure controls and procedures” within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by the Company in the reports filed under the Exchange Act, such as this Annual Report on Form 10-K, is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms. Our disclosure controls and procedures include controls and procedures designed to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and no evaluation of controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, prior to filing this Annual Report on Form 10-K, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2015. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Our management has concluded that, as of December 31, 2015, our internal control over financial reporting is effective based on these criteria.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of the effectiveness of internal controls over financial reporting to future periods are subject to the risk that the controls may become inadequate.

An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any changes in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Cherry Bekaert LLP, an independent registered accounting firm, as auditors of our financial statements have issued an attestation report on the effectiveness of the Company’s and its subsidiaries’ internal control over financial reporting as of December 31, 2015. Cherry Bekaert LLP's report is included in this report.

Item 9B. Other Information

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

Information required by this Item will be contained in our definitive proxy statement relating to our 2016 Annual Meeting of Shareholders under the captions “Executive Officers,” “Election of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance,” or similar captions which are incorporated herein by reference.

We have adopted our “Code of Business Conduct and Ethics” and a copy is posted on our website at www.mimedx.com. In the event that we amend any of the provisions of this Code of Business Conduct and Ethics that require disclosure under applicable law, SEC rules or listing standards, we intend to disclose such amendment on our website.

Any waiver of the Code of Business Conduct and Ethics for any executive officer or director must be approved by the Board and will be disclosed on a Form 8-K filed with the SEC, along with the reasons for the waiver.

Item 11. Executive Compensation

Information required by this Item will be contained in our definitive proxy statement relating to our 2016 Annual Meeting of Shareholders under the caption “Executive Compensation,” or similar caption which is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

Information required by this Item will be contained in our definitive proxy statement relating to our 2016 Annual Meeting of Shareholders under the captions “Stock Ownership",” “Executive Compensation,” and “Equity Compensation Plan Information,” or similar captions which are incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Information required by this Item will be contained in our definitive proxy statement relating to our 2016 Annual Meeting of Shareholders under the captions “Certain Relationships and Related Party Transactions,” and "Election of Directors" or similar captions which are incorporated herein by reference.

Item 14. Principal Accounting Fees and Services

Information required by this Item will be contained in our definitive proxy statement relating to our 2016 Annual Meeting of Shareholders under the captions “Ratification of Appointment of Independent Registered Public Accounting Firm” and “Election of Directors,” or similar captions which are incorporated herein by reference.

PART IV

Item 15. Exhibits, Financial Statement Schedules


(a)	Documents filed as part of this report:


(1)	Financial Statements


(2)	Financial Statement Schedule:

The following Financial Statement Schedule is filed as part of this Report:

Schedule II Valuation and Qualifying Accounts for the years ended December 31, 2015, 2014 and 2013


(3)	Exhibits

See Item 15(b) below. Each management contract or compensation plan has been identified.


(b)	Exhibits



Exhibit Number		Description
2.1##		Agreement and Plan of Merger is entered into as of the 22nd day of December, 2010 by and among MiMedx Group, Inc., MP Holdings Acquisition Sub, LLC, ORCI Acquisition Sub, LLC, Membrane Products Holdings, LLC, Onramp Capital Investments, LLC, each of the OnRamp Members (as defined therein); John R. Daniel, in his capacity as the representative of the Members and Surgical Biologics, LLC (Incorporated by reference to Exhibit 2.2 filed with Registrant's Form 10-K filed on March 31, 2011)
2.2##		Agreement and Plan of Merger dated January 10, 2016, by and among MiMedx Group, Inc., Titan Acquisition Sub I, Inc., Titan Acquisition Sub II, LLC, Stability Inc., certain stockholders of Stability Inc. and Brian Martin as representative of the Stability stockholders (Incorporated by reference to Exhibit 2.1 filed with Registrant's Form 8-K filed on January 13, 2016)
3.1		Articles of Incorporation of MiMedx Group, Inc. as filed with the Secretary of the State of Florida on March 31, 2008 (Incorporated by reference to Exhibit 3.1 filed with Registrant's Form 10-Q on August 8, 2013)
3.2		Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on May 14, 2010 (Incorporated by reference to Exhibit 3.2 filed with Registrant's Form 10-Q on August 8, 2013)
3.3		Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on August 8, 2012 (Incorporated by reference to Exhibit 3.3 filed with Registrant's Form 10-Q on August 8, 2013)
3.4		Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on November 8, 2012 (Incorporated by reference to Exhibit 3.4 filed with Registrant's Form 10-Q on August 8, 2013)
3.5		Articles of Amendment to Articles of Incorporation as filed with the Secretary of the State of Florida on May 15, 2015 (Incorporated by reference to Exhibit 3.5 to the Company's 10-Q filed on August 7, 2015)
3.6		Bylaws of MiMedx Group, Inc. (Incorporated by reference to Exhibit 3.2 filed with Registrant's Form 8-K filed on April 2, 2008)
3.7		Amendment to the Bylaws of MiMedx Group, Inc. adopted by the Board of Directors on May 11, 2010, (Incorporated by reference to Exhibit 3.2 to the Registrant's Form 8-K filed on May 14, 2010)
10.1*		MiMedx Group, Inc. 2006 Assumed Stock Incentive Plan, as amended and restated effective February 25, 2014 (Incorporated by reference to Exhibit 10.1 of the Registrant's Form 8-K filed on March 3, 2014)
10.2*		Form of Restricted Stock Agreement for Non-employee Directors (Incorporated by reference to Exhibit 10.66 to the Registrant's Form 10-Q filed on August 8, 2013)
10.3*		Form of Restricted Stock Agreement under the MiMedx Group, Inc. 2006 Assumed Stock Incentive Plan (Incorporated by reference to Exhibit 10.3 to the Registrant's Form 10-K filed on March 4, 2014)
10.4*		Form of Incentive Award Agreement under the MiMedx Group, Inc. 2006 Assumed Stock Incentive Plan (Incorporated by reference to Exhibit 10.4 to the Registrant's Form 10-K filed on March 4, 2014)



10.5*		Form of Nonqualified Incentive Award Agreement under the MiMedx Group, Inc. 2006 Assumed Stock Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Registrant's Form 10-K filed on March 4, 2014)
10.6*		MiMedx, Inc. 2005 Assumed Stock Plan, formerly the SpineMedica Corp. 2005 Employee, Director and Consultant Stock Plan (Incorporated by reference to Exhibit 10.4 filed with the Registrant's Form 8-K filed February 8, 2008)
10.7*		Declaration of Amendment to MiMedx, Inc. 2005 Assumed Stock Plan (Incorporated by reference to Exhibit 10.6 filed with the Registrant's Form 8-K filed February 8, 2008)
10.8*		Form of Incentive Award Agreement under the MiMedx, Inc. Assumed 2005 Stock Plan (formerly the SpineMedica Corp. 2005 Employee, Director and Consultant Stock Plan), including a list of officers and directors receiving options thereunder (Incorporated by reference to Exhibit 10.7 filed with the Registrant's Form 8-K filed February 8, 2008)
10.9*		Form of Nonqualified Incentive Award Agreement under the MiMedx, Inc. Assumed 2005 Stock Plan (formerly the SpineMedica Corp. 2005 Employee, Director and Consultant Stock Plan) (Incorporated by reference to Exhibit 10.8 filed with the Registrant's Form 8-K filed February 8, 2008)
10.10*		MiMedx, Inc. Assumed 2007 Stock Plan (formerly the SpineMedica Corp. 2007 Stock Incentive Plan) (Incorporated by reference to Exhibit 10.9 filed with the Registrant's Form 8-K filed February 8, 2008)
10.11*		Declaration of Amendment to MiMedx, Inc. Assumed 2007 Stock Plan (formerly the SpineMedica Corp. 2007 Stock Incentive Plan) (Incorporated by reference to Exhibit 10.10 filed with the Registrant's Form 8-K filed February 8, 2008)
10.12*		Form of Incentive Award Agreement under the MiMedx, Inc. Assumed 2007 Stock Plan (formerly the SpineMedica Corp. 2007 Stock Incentive Plan) (Incorporated by reference to Exhibit 10.11 filed with the Registrant's Form 8-K filed February 8, 2008)
10.13*		Form of Nonqualified Incentive Award Agreement under the MiMedx, Inc. Assumed 2007 Stock Plan (formerly the SpineMedica Corp. 2007 Stock Incentive Plan) (Incorporated by reference to Exhibit 10.12 filed with the Registrant's Form 8-K filed February 8, 2008)
10.14*		Form of Indemnification Agreement (Incorporated by reference to Exhibit 10.65 filed with the Registrant's Form 8-K filed July 15, 2008)
10.15*		MiMedx Group, Inc. Amended and Restated Assumed 2005 Stock Plan (Incorporated by reference to Exhibit 10.4 filed with the Registrant's Form S-8 filed August 29, 2008)
10.16*		Form of Incentive Stock Option Award Agreement under MiMedx Group, Inc. Amended and Restated Assumed 2005 Stock Plan (Incorporated by reference to Exhibit 10.68 filed with the Registrant's Form 8 -K filed September 4, 2008)
10.17*		Form of Nonqualified Stock Option Award Agreement under MiMedx Group, Inc. Amended and Restated Assumed 2005 Stock Plan (Incorporated by reference to Exhibit 10.69 filed with the Registrant's Form 8 -K filed September 4, 2008)
10.30		Form of MiMedx, Inc. Employee Proprietary Information and Inventions Assignment Agreement (Incorporated by reference to Exhibit 10.13 filed with the Registrant's Form 8-K filed February 8, 2008)



10.31		Technology License Agreement between MiMedx, Inc., Shriners Hospitals for Children, and University of South Florida Research Foundation dated January 29, 2007 (Incorporated by reference to Exhibit 10.12 filed with the Registrant's Form 8-K filed February 8, 2008)
10.35		Warrant to Purchase Common Stock dated September 22, 2009 (Incorporated by reference to Exhibit 10.3 filed with Registrant's Form 8-K filed September 28, 2009)
10.36		Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 10.4 filed with Registrant's Form 8-K filed January 7, 2010)
10.37		Form of Subscription Agreement 5% Convertible Promissory Note (Incorporated by reference to Exhibit 10.1 filed with Registrant's Form 8-K filed October 25, 2010)
10.38		Form of 5% Convertible Promissory Note (Incorporated by reference to Exhibit 10.2 filed with Registrant's Form 8-K filed October 25, 2010)
10.39		Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 10.3 filed with Registrant's Form 8-K filed October 25, 2010)
10.40		Revolving Secured Line of Credit Agreement dated March 31, 2011 (Incorporated by reference to Exhibit 10.89 filed with Registrant's Form 10-K filed March 31, 2011)
10.41		Amendment dated January 2, 2012, to Revolving Secured Line of Credit Agreement (Incorporated by reference to Exhibit 10.6 filed with Registrant's Form 8-K filed January 3, 2012)
10.42		Form of Subscription Agreement 5% Convertible Senior Secured Promissory Note (Incorporated by reference to Exhibit 10.1 of Registrant's Form 8-K filed January 3, 2012)
10.43		Form of 5% Convertible Senior Secured Promissory Note (Incorporated by reference to Exhibit 10.2 filed with Registrant's Form 8-K filed January 3, 2012)
10.44		Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 10.3 filed with Registrant's Form 8-K filed January 3, 2012)



10.45		Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 10.4 filed with Registrant’s Form 8-K filed January 3, 2012)
10.46		Form of Warrant to Purchase Common (Incorporated by reference to Exhibit 10.5 filed with Registrant’s Form 8-K filed January 3, 2012)
10.47		Form of Amended and Restated Security and Intercreditor Agreement (Incorporated by reference to Exhibit 10.6 filed with Registrant’s Form 8-K filed January 3, 2012)
10.48		Form of Registration Rights Agreement (Incorporated by reference to Exhibit 10.7 filed with Registrant’s Form 8-K filed January 3, 2012)
10.49*		Change of Control Agreement Severance Compensation and Restrictive Covenant Agreement dated November 11, 2011, between MiMedx Group, Inc. and Parker H. Petit (Incorporated by reference to Exhibit 10.91 filed with Registrant’s Form 10-Q filed on November 14, 2011)
10.50*		Change of Control Agreement Severance Compensation and Restrictive Covenant Agreement dated November 11, 2011, between MiMedx Group, Inc. and with William C. Taylor (Incorporated by reference to Exhibit 10.92 filed with Registrant’s Form 10-Q filed on November 14, 2011)
10.51*		First Amendment to Change in Control Severance Compensation and Restrictive Covenant Agreement dated May 9, 2013 by and between MiMedx Group, Inc., and William C. Taylor (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on May 15, 2013)
10.52*		Change of Control Agreement Severance Compensation and Restrictive Covenant Agreement dated November 11, 2011, between MiMedx Group, Inc., and Michael J. Senken(Incorporated by reference to Exhibit 10.93 filed with Registrant’s Form 10-Q filed on November 14, 2011)
10.53*		First Amendment to Change in Control Severance Compensation and Restrictive Covenant Agreement dated May 9, 2013 by and between MiMedx Group, Inc., and Michael J. Senken (Incorporated by reference to Exhibit 10.2 to the Registrant's Form 8-K filed on May 15, 2013)
10.54*		2013 Management Incentive Plan and 2013 Operating Incentive Plan (Incorporated by reference to Exhibit 10.1 filed with Registrant’s Form 8-K filed March 12, 2013)
10.55*		2014 Management Incentive Plan and 2014 Operating Incentive Plan (Incorporated by reference to Exhibit 10.2 filed with Registrant's Form 8-K filed March 3, 2014)
10.56*		2015 Management Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 10-Q filed on May 1, 2015)
10.60**		Product Distribution Agreement by and between AvKARE, Inc. and MiMedx Group, Inc. dated April 19, 2012 (Incorporated by reference to Exhibit 10.56 to the Registrant’s Form 10-K filed March 15, 2013)
10.61		First Amendment to Product Distribution Agreement amending that certain Product Distribution Agreement that was effective April 19, 2012 (Incorporated by reference to Exhibit 10.56 filed with the Registrant’s Form 10-Q filed on November 8, 2013)
10.62**		Second Amendment to Product Distribution between MiMedx Group, Inc. and AvKARE, Inc. (Incorporated by reference to Exhibit 10.58 filed with the Registrant’s Form 10-Q filed on November 8, 2013)
10.63**		Third Amendment to Product Distribution Agreement dated April 17, 2015 between MiMedx Group, Inc. and AvKARE, Inc. (Incorporated by reference to Exhibit 10.2 to the Company's 10-Q filed on August 7, 2015)
10.64		Loan Agreement between MiMedx Group, Inc., and Bank of America N.A. dated May 17, 2013 (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on May 23, 2013)
10.65		Security Agreement dated May 17, 2013, executed by MiMedx Group, Inc. in favor of Bank of America and Bank of America Corporation and its subsidiaries and affiliates (Incorporated by reference to Exhibit 10.4 to the Registrant’s Form 10-Q filed on August 8, 2013)
10.66		Lease by and between Hub Properties of GA, LLC and MiMedx Group, Inc., effective May 1, 2013 (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 10-Q filed May 10, 1013)
10.67		Credit Agreement dated October 12, 2015, among MiMedx Group, Inc., the Guarantors identified therein, Bank of America, N.A., and the other Lenders party thereto (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on October 13, 2015)
10.68		First Amendment to the Credit Agreement dated October 12, 2015, by and among MiMedx Group, Inc., the Guarantors identified therein, Bank of America, N.A. and the other Lenders party thereto (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on January 13, 2016
10.69		Security and Pledge Agreement dated October 12, 2015, among MiMedx Group, Inc., the Guarantors identified therein and Bank of America, N.A., as administrative agent (Incorporated by reference to Exhibit 10.2 to the Registrant's Form 8-K filed on October 13, 2015)



21.1#		Subsidiaries of MiMedx Group, Inc.
23.1#		Consent of Independent Registered Public Accounting Firm
31.1#		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Acts of 2002
31.2#		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Acts of 2002
32.1#		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2#		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS#		XBRL Instance Document
101.SCH#		XBRL Taxonomy Extension Schema Document
101.CAL #		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF#		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB#		XBRL Taxonomy Extension Label Linkbase Document
101.PRE#		XBRL Taxonomy Extension Presentation Linkbase Document

Notes



*	Indicates a management contract or compensatory plan or arrangement
#	Filed herewith
**	Certain confidential material appearing in this document, marked by [*****], has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.
##	Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K, but a copy will be furnished supplementally to the Securities and Exchange Commission upon request)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



February 29, 2016	MIMEDX GROUP, INC.

	By:	/s/ Michael J. Senken
		Michael J. Senken
		Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.



Signature / Name	Title	Date

/s/: Parker H. Petit	Chief Executive Officer and Chairman	February 29, 2016
Parker H. Petit	(principal executive officer)

/s/: Michael J. Senken	Chief Financial Officer	February 29, 2016
Michael J. Senken	(principal financial and accounting officer)

/s/: Joseph G. Bleser	Director	February 29, 2016
Joseph G. Bleser

/s/: J. Terry Dewberry	Director	February 29, 2016
J. Terry Dewberry

/s/: Charles Evans	Director	February 29, 2016
Charles Evans

/s/: Bruce Hack	Director	February 29, 2016
Bruce Hack

/s/: Charles E. Koob	Director	February 29, 2016
Charles E. Koob

/s/: Larry W. Papasan	Director	February 29, 2016
Larry W. Papasan

/s/: William C. Taylor	Director	February 29, 2016
William C. Taylor

/s/: Neil Yeston	Director	February 29, 2016
Neil Yeston

EX-21.1 2 mdxg-20151231x10xkex211.htm EXHIBIT 21.1 Exhibit

EXHIBIT 21.1

MiMedx Group, Inc.
List of Subsidiaries



Company	Jurisdiction of Organization
MiMedx, Inc.	Florida
MiMedx Processing Services, LLC	Florida
MiMedx Tissue Services, LLC	Georgia
Stability Biologics, LLC	Georgia

EX-23.1 3 mdxg-20151231x10xkex231con.htm EXHIBIT 23.1 Exhibit

Consent of Independent Registered Public Accounting Firm

We hereby consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-153255, 333-183991, 333-189784 and 333-199841 and Form S-3 No. 333-189785) of our reports dated February 29, 2016, included in this Annual Report on Form 10-K of MiMedx Group, Inc. and Subsidiaries (the Company) relating to the consolidated balance sheets of the Company as of December 31, 2015 and 2014, and the related consolidated statements of operations, stockholders’ equity, and cash flows and the related consolidated financial statement schedule for each of the three years in the period ended December 31, 2015, and the effectiveness of internal control over financial reporting for the Company as of December 31, 2015.

/s/ Cherry Bekaert LLP

Atlanta, Georgia

February 29, 2016

EX-31.1 4 mdxg-20151231x10xkex311.htm EXHIBIT 31.1 Exhibit

EXHIBIT 31.1

Section 302 Certification

I, Parker H. Petit, certify that:


1.	I have reviewed this annual report on Form 10-K of MiMedx Group, Inc.;


2.	Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;


3.	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared,


(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,


(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation, and


(d)	disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):


(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 29, 2016



	/s/: Parker H. Petit
	Parker H. Petit
	Chief Executive Officer
	(principal executive officer)

EX-31.2 5 mdxg-20151231x10xkex312.htm EXHIBIT 31.2 Exhibit

EXHIBIT 31.2

Section 302 Certification

I, Michael J. Senken, certify that:


1.	I have reviewed this annual report on Form 10-K of MiMedx Group, Inc.;


2.	Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;


3.	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared,


(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,


(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation, and


(d)	disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):


(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 29, 2016



	/s/: Michael J. Senken
	Michael J. Senken
	Chief Financial Officer
	(principal financial officer)

EX-32.1 6 mdxg-20151231x10xkex321.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

Section 906 Certification

The undersigned Parker H. Petit, the Chief Executive Officer of MiMedx Group, Inc. (the “Company”), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company’s Annual Report on Form 10-K for the year ending December 31, 2015 (the “Report”). The undersigned hereby certifies, to the best of his knowledge, that:


(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 29, 2016



	/s/: Parker H. Petit
	Parker H. Petit
	Chief Executive Officer
	(principal executive officer)

EX-32.2 7 mdxg-20151231x10xkex322.htm EXHIBIT 32.2 Exhibit

Exhibit 32.2

Section 906 Certification

The undersigned Michael J. Senken, the Chief Financial Officer of MiMedx Group, Inc. (the “Company”), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company’s Annual Report on Form 10-K for the year ending December 31, 2015 (the “Report”). The undersigned hereby certifies, to the best of his knowledge, that:


(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 29, 2016



	/s/: Michael J. Senken
	Michael J. Senken
	Chief Financial Officer
	(principal financial officer)

EX-101.INS 8 mdxg-20151231.xml XBRL INSTANCE DOCUMENT 0001376339 2015-01-01 2015-12-31 0001376339 2016-02-10 0001376339 2015-06-30 0001376339 2014-12-31 0001376339 2015-12-31 0001376339 2014-01-01 2014-12-31 0001376339 2013-01-01 2013-12-31 0001376339 us-gaap:CommonStockMember 2012-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001376339 us-gaap:TreasuryStockMember 2013-12-31 0001376339 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001376339 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001376339 us-gaap:CommonStockMember 2015-12-31 0001376339 us-gaap:TreasuryStockMember 2015-01-01 2015-12-31 0001376339 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0001376339 us-gaap:TreasuryStockMember 2014-12-31 0001376339 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001376339 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0001376339 us-gaap:TreasuryStockMember 2015-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001376339 us-gaap:CommonStockMember 2013-12-31 0001376339 us-gaap:TreasuryStockMember 2014-01-01 2014-12-31 0001376339 2012-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001376339 us-gaap:TreasuryStockMember 2012-12-31 0001376339 us-gaap:RetainedEarningsMember 2014-12-31 0001376339 us-gaap:CommonStockMember 2014-12-31 0001376339 2013-12-31 0001376339 us-gaap:RetainedEarningsMember 2012-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001376339 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0001376339 us-gaap:RetainedEarningsMember 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2013-12-31 0001376339 mdxg:FivePercentConvertibleSeniorSecuredPromissoryNoteMember 2013-12-31 0001376339 2010-07-31 0001376339 us-gaap:AccountsReceivableMember mdxg:FirstCustomerMember 2014-01-01 2014-12-31 0001376339 2012-01-01 2012-12-31 0001376339 us-gaap:MaximumMember 2015-01-01 2015-12-31 0001376339 us-gaap:SalesRevenueGoodsNetMember mdxg:FirstCustomerMember 2013-01-01 2013-12-31 0001376339 us-gaap:SalesRevenueGoodsNetMember mdxg:FirstCustomerMember 2014-01-01 2014-12-31 0001376339 us-gaap:AccountsReceivableMember mdxg:FirstCustomerMember 2015-01-01 2015-12-31 0001376339 us-gaap:SalesRevenueGoodsNetMember mdxg:FirstCustomerMember 2015-01-01 2015-12-31 0001376339 2013-10-01 2013-12-31 0001376339 us-gaap:PatentsMember 2014-01-01 2014-12-31 0001376339 us-gaap:PatentsMember 2015-01-01 2015-12-31 0001376339 us-gaap:PatentsMember 2013-01-01 2013-12-31 0001376339 us-gaap:MinimumMember 2015-01-01 2015-12-31 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 2015-10-12 0001376339 us-gaap:CertificatesOfDepositMember 2014-12-31 0001376339 us-gaap:CertificatesOfDepositMember 2015-12-31 0001376339 us-gaap:CertificatesOfDepositMember 2015-12-31 0001376339 us-gaap:CertificatesOfDepositMember 2014-12-31 0001376339 us-gaap:ConstructionInProgressMember 2014-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001376339 us-gaap:FurnitureAndFixturesMember 2014-12-31 0001376339 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2014-12-31 0001376339 us-gaap:EquipmentMember 2015-12-31 0001376339 us-gaap:ConstructionInProgressMember 2015-12-31 0001376339 us-gaap:EquipmentMember 2014-12-31 0001376339 us-gaap:AssetsHeldUnderCapitalLeasesMember 2015-12-31 0001376339 mdxg:LeaseholdImprovementsPaidbyOthersMember 2015-12-31 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2014-12-31 0001376339 mdxg:PatentsinProcessMember 2014-12-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2015-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2015-01-01 2015-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2014-12-31 0001376339 us-gaap:LicensingAgreementsMember 2015-12-31 0001376339 mdxg:PatentsinProcessMember 2015-12-31 0001376339 us-gaap:LicensingAgreementsMember 2015-01-01 2015-12-31 0001376339 us-gaap:PatentsMember 2014-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2015-12-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2014-12-31 0001376339 us-gaap:PatentsMember 2015-12-31 0001376339 us-gaap:LicensingAgreementsMember 2014-12-31 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2015-12-31 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2015-01-01 2015-12-31 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-28 2007-01-29 0001376339 mdxg:SurgicalBiologicsMember us-gaap:LicensingAgreementsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:CustomerRelationshipsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:TrademarksAndTradeNamesMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:InProcessResearchAndDevelopmentMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2011-01-05 0001376339 mdxg:FivePercentConvertibleSeniorSecuredPromissoryNoteMember us-gaap:BoardOfDirectorsChairmanMember 2011-12-27 2011-12-31 0001376339 mdxg:FivePercentConvertibleSeniorSecuredPromissoryNoteMember 2011-12-27 2011-12-31 0001376339 mdxg:LoanAgreementMember 2013-01-01 2013-02-28 0001376339 mdxg:FivePercentConvertibleSeniorSecuredPromissoryNoteMember 2011-12-31 0001376339 mdxg:LoanAgreementMember us-gaap:ChiefExecutiveOfficerMember 2013-01-01 2013-02-28 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 mdxg:LoanAgreementMember 2013-01-01 2013-12-31 0001376339 us-gaap:ConvertibleNotesPayableMember 2014-01-01 2014-12-31 0001376339 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0001376339 us-gaap:WarrantMember 2015-01-01 2015-12-31 0001376339 us-gaap:WarrantMember 2014-01-01 2014-12-31 0001376339 us-gaap:ConvertibleNotesPayableMember 2015-01-01 2015-12-31 0001376339 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0001376339 us-gaap:CommonStockMember 2013-12-01 2013-12-31 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-01-01 2014-12-31 0001376339 us-gaap:CostOfSalesMember 2013-01-01 2013-12-31 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-12-31 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2013-01-01 2013-12-31 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-12-31 0001376339 us-gaap:CostOfSalesMember 2014-01-01 2014-12-31 0001376339 us-gaap:CostOfSalesMember 2015-01-01 2015-12-31 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-12-31 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-12-31 0001376339 mdxg:PriceRange2Member 2015-12-31 0001376339 mdxg:PriceRange5Member 2015-12-31 0001376339 mdxg:PriceRange6Member 2015-01-01 2015-12-31 0001376339 mdxg:PriceRange7Member 2015-12-31 0001376339 mdxg:PriceRange6Member 2015-12-31 0001376339 mdxg:PriceRange7Member 2015-01-01 2015-12-31 0001376339 mdxg:PriceRange4Member 2015-01-01 2015-12-31 0001376339 mdxg:PriceRange1Member 2015-01-01 2015-12-31 0001376339 mdxg:PriceRange3Member 2015-12-31 0001376339 mdxg:PriceRange1Member 2015-12-31 0001376339 mdxg:PriceRange4Member 2015-12-31 0001376339 mdxg:PriceRange3Member 2015-01-01 2015-12-31 0001376339 mdxg:PriceRange2Member 2015-01-01 2015-12-31 0001376339 mdxg:PriceRange5Member 2015-01-01 2015-12-31 0001376339 us-gaap:CommonStockMember mdxg:ConsultantMember 2015-01-01 2015-12-31 0001376339 2014-05-12 0001376339 us-gaap:RestrictedStockMember 2015-01-01 2015-12-31 0001376339 us-gaap:WarrantMember 2015-11-18 0001376339 us-gaap:RestrictedStockMember 2015-12-31 0001376339 us-gaap:RestrictedStockMember us-gaap:MaximumMember 2015-01-01 2015-12-31 0001376339 us-gaap:RestrictedStockMember us-gaap:MinimumMember 2015-01-01 2015-12-31 0001376339 us-gaap:RestrictedStockMember 2014-12-31 0001376339 us-gaap:MaximumMember 2014-01-01 2014-12-31 0001376339 us-gaap:MinimumMember 2014-01-01 2014-12-31 0001376339 us-gaap:MaximumMember 2013-01-01 2013-12-31 0001376339 us-gaap:MinimumMember 2013-01-01 2013-12-31 0001376339 us-gaap:DomesticCountryMember 2015-01-01 2015-12-31 0001376339 us-gaap:StateAndLocalJurisdictionMember 2015-12-31 0001376339 us-gaap:DomesticCountryMember 2015-12-31 0001376339 us-gaap:AccruedLiabilitiesMember 2015-01-01 2015-12-31 0001376339 us-gaap:AccountsPayableMember 2013-01-01 2013-12-31 0001376339 us-gaap:AccruedLiabilitiesMember 2013-01-01 2013-12-31 0001376339 us-gaap:AccountsPayableMember 2014-01-01 2014-12-31 0001376339 us-gaap:AccountsPayableMember 2015-01-01 2015-12-31 0001376339 us-gaap:AccruedLiabilitiesMember 2014-01-01 2014-12-31 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-06-29 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-07-10 0001376339 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2015-01-01 2015-12-31 0001376339 mdxg:LiventaAction437PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 mdxg:LiventaActionMember us-gaap:PendingLitigationMember 2015-12-22 0001376339 mdxg:LiventaActionMember us-gaap:PendingLitigationMember 2015-12-30 0001376339 us-gaap:PendingLitigationMember 2015-12-31 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-10-02 0001376339 us-gaap:StandbyLettersOfCreditMember 2015-12-31 0001376339 2015-03-01 2015-03-31 0001376339 mdxg:LiventaAction701PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 2014-04-01 2014-06-30 0001376339 2013-01-01 2013-03-31 0001376339 2015-07-01 2015-09-30 0001376339 2015-10-01 2015-12-31 0001376339 2013-04-01 2013-06-30 0001376339 2014-07-01 2014-09-30 0001376339 2014-10-01 2014-12-31 0001376339 2014-01-01 2014-03-31 0001376339 2013-07-01 2013-09-30 0001376339 2015-04-01 2015-06-30 0001376339 2015-01-01 2015-03-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:SubsequentEventMember 2016-01-13 2016-01-13 0001376339 mdxg:AllowanceforObsolescenceMember 2013-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2013-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2012-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2014-01-01 2014-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2012-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-01-01 2015-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-01-01 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2013-01-01 2013-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2014-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2013-01-01 2013-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2013-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2013-01-01 2013-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2014-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2014-01-01 2014-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2014-01-01 2014-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2012-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 mdxg:Business_Segment iso4217:USD xbrli:shares mdxg:plan xbrli:pure iso4217:USD mdxg:distributor xbrli:shares mdxg:claim mdxg:term false --12-31 FY 2015 2015-12-31 10-K 0001376339 107810490 Yes Accelerated Filer 1135614000 MIMEDX GROUP, INC. No No 0.60 0.40 2400000 P2Y 0.6 0.4 0.03 69533000 5000000 114000 145000 1661000 6000 1 368000 0 0 3931000 4864000 35000000 1 2 30 1 1 P120D 18000 P50Y P21Y P3M 1 3 70000 689000 594000 851000 136000 P30D 32800 0 0 319000 1844352 1242416 -42400 1174915 1174915 2108000 2106000 2000 1113000 1112000 1000 46000 -379000 425000 5792000 5791000 1000 0 0 1.00 0 170000 1.09 P5Y

3661000

6633000

26672000

53755000

2504000

4644000

3499000

4979000

P14Y

P10Y

P17Y

162433000

163133000

7757000

6010000

279000

417000

5314000

11453000

322000

660000

10471000

16896000

352000

790000

15754000

1328000

27000

504000

1328000

42000

1054000

928000

933000

7502496

239842

7035728

226926

7699277

543827

7121774

33676

109259000

135913000

85677000

96310000

10000000

800000

200000

355000

6754000

44078000

46582000

1250000

28486000

37324000

2504000

-18096000

250000

44600000

27700000

1.09

42400

0.001

150000000

108776247

109467416

107789611

107361471

108000

109000

0.56

0.33

0.34

0.26

0.24

0.12

9039000

352000

1763000

2818000

2340000

1766000

9328000

12665000

20202000

8452000

832000

9670000

832000

1218000

5272000

532260

0.0225

0.015

0.05

P3Y

47800

500000

487000

-13070000

-14838000

-7081000

-1768000

1000

619000

146000

16158000

15620000

197000

1566000

14838000

6382000

1763000

2086000

3293000

4163000

7063000

3563000

4606000

16158000

782000

585000

770000

1396000

0.06

637000

1197000

1799000

-0.02

-0.01

0.00

-0.01

-0.04

-0.01

0.00

0.03

0.04

0.06

0.04

0.05

0.06

0.13

0.28

-0.02

-0.01

0.00

-0.01

-0.04

-0.01

0.00

0.03

0.05

0.04

0.05

0.06

0.11

0.26

0.1180

-0.2129

0.34

-0.0592

-0.0458

0.0555

0.0227

0.0559

0.0063

0.2173

0.0639

-0.5873

-0.6333

0.0958

0.0333

11523000

15034000

P2Y1M6D

16606000

6241000

5465000

936000

836000

846000

3761000

1009000

7891000

3761000

1009000

8001000

3761000

13000

7690000

9755000

110000

689000

594000

851000

110000

-37000

4040000

30000

9651000

11316000

14002000

14883000

49853000

16582000

22833000

30170000

35973000

105558000

35619000

40590000

44036000

46849000

167094000

1800000

368000

-4012000

7052000

24278000

7757000

100000

832000

-5168000

61000

384000

2293000

1209000

1287000

3136000

8439000

10579000

27083000

353000

1098000

2140000

2836000

5935000

3511000

-42000

858000

1252000

2327000

-28000

718000

-511000

637000

203000

2094000

1082000

25000

1008000

1823000

25000

1008000

25000

1008000

14776000

15627000

10845000

10763000

45000

48000

86000

36000

48000

86000

1986000

3405000

5660000

7857000

5133000

7460000

255000

602000

527000

397000

3419000

3850000

3250000

1000000

1130000

1317000

194000

P5Y

235000

19930000

27925000

109259000

135913000

18404000

26777000

50000000

40634000

-2146000

-36225000

-3026000

-12152000

-678000

-284000

16802000

18807000

-1620000

-757000

-307000

-1427000

-4112000

-922000

-390000

3700000

3832000

6220000

4087000

5430000

6551000

13378000

29446000

-2639000

7100000

24364000

27552000

579000

716000

466000

1526000

1148000

133000

40143000

997000

504000

102000

30000

62000

57000

117000

996000

2337000

2558000

5827000

9000000

-6000000

0.001

5000000

1540000

3609000

250000

36704000

5000000

500000

36602000

-5612000

-40279000

1981000

2470000

4629000

2108000

1113000

46000

8946000

949000

3040000

2398000

2559000

14454000

2629000

4564000

4577000

2684000

5447000

9475000

1000000

427000

P7Y

P3Y

4843000

7050000

8413000

-67575000

-38129000

50000

11556000

13515000

16116000

17994000

59181000

19559000

25573000

33518000

39573000

118223000

40767000

45679000

49015000

51835000

187296000

46227000

90480000

133384000

6010000

11453000

16896000

P3Y

P1Y

72007

9.77

1974259

9.80

1228898

2613267

7.16

9.14

517883

6.90

0.6477

0.6141

0.6450

0.5814

0.5435

0.0188

0.0196

0.0168

0.0085

0.0164

0.0151

26500000

13917122

2.80

8864000

10566000

17181000

69495

239322

75100

3.08

4.18

5.15

80740577

16474227

14019629

3.43

3.62

80496150

10951694

3.60

71955234

2.08

2.61

6.66

9.66

0.50

0.87

1.40

2.66

4.19

6.45

9.90

10951694

441429

4783304

1641928

907452

2229386

914703

33492

14019629

441429

4783304

1641928

957454

3552323

2527525

115666

0.76

1.35

2.45

3.99

6.38

9.78

10.99

6.80

P6Y

7193577

3067935

239322

3.79

3.08

3.81

P6Y2M12D

P6Y6M

3351000

6615000

10044000

3961420

2.53

2.80

0.72

1.19

1.93

3.00

5.32

7.18

10.50

3.62

0.72

1.19

1.93

3.05

5.35

7.29

10.43

P6Y6M

P3Y4M24D

P5Y8M12D

P5Y1M6D

P6Y9M18D

P7Y4M24D

P8Y1M6D

P8Y10M24D

88423169

50000

104425614

50000

108776247

986636

109467416

2105945

5750000

3000000

5272004

42400

15958

16493

11321

5172

-5172

5750000

-69949

2058

2500

1438569

34250

-1940009

1958674

1653690

2220881

647656

-1573225

5272000

5267000

5000

117000

164000

113000

57000

51000

36510000

36504000

6000

-652000

652000

-1000

1000

-14547000

14547000

6010000

11453000

16896000

1981000

1979000

2000

2470000

2468000

2000

4629000

-9792000

1000

14420000

20000000

60000000

10000000

14274000

20007000

89627000

88000

-69683000

-25000

73568000

147284000

104000

-73795000

-25000

89329000

162433000

108000

-67575000

-5637000

107988000

163133000

109000

-38129000

-17125000

986636

2105945

936636

4610000

4610166

5637000

17125000

5612000

40279000

170000

-15376000

-197000

159000

49000

89000

322000

407000

215000

527000

1750000

841000

397000

3270000

1262000

213000

391000

917000

405000

1357000

2215000

540000

1698000

3257000

50000

33000

791000

200000

14000

1589000

670000

178000

2836000

15000

7502496

7699277

96285504

113295504

113628482

96285504

105793008

105929205

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities</font></div><div style="line-height:120%;padding-bottom:13px;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands)</font><font style="font-family:inherit;font-size:11pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="70%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of equipment financed through capital leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APIC related tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,757</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance in connection with Earn-Out Liability of 1,174,915 shares </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance in exchange for convertible debt of 5,272,004 shares </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,272</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant improvement incentive</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal fees paid for public offering</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal fees related to public offering included in accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal fees related to public offering included in accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated annual payments are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="86%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,340</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,763</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,039</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Incentive Plans</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at December 31, 2015, totaled </font><font style="font-family:inherit;font-size:10pt;">70,000</font><font style="font-family:inherit;font-size:10pt;">.  The maximum number of shares of common stock that can be issued under the 2006 Plan total </font><font style="font-family:inherit;font-size:10pt;">26,500,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,474,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,220,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(239,322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,740,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,951,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,955,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at December 31, 2015 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,917,122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,496,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture adjusted unvested shares.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of the options exercised during the years ended December 31, 2015, 2014 and 2013 were approximately </font><font style="font-family:inherit;font-size:10pt;">$17,181,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$10,566,000</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$8,864,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of options vested during the years ended December 31, 2015, 2014 and 2013 were approximately </font><font style="font-family:inherit;font-size:10pt;">$10,044,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6,615,000</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$3,351,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at December 31, 2015:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,783,304</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,783,304</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,641,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,641,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">907,452</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,552,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,229,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45- $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,527,525</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  $9.90 - $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,951,694</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the status of the Company’s unvested stock options as of December 31, 2015 is presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="66%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested Stock Options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-<br clear="none"/>Average<br clear="none"/>Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,193,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(239,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,961,420</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,067,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized compensation expense at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$6,241,000</font><font style="font-family:inherit;font-size:10pt;"> and will be charged to expense through March 2017.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the options granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method” which computes expected term as the midpoint between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company’s lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54.35 - 58.14%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58.14 - 64.50%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.41 - 64.77%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51 - 1.68%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.64 - 1.96%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.85 - 1.88%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant date fair value for options granted during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, 2014 and 2013 were approximately </font><font style="font-family:inherit;font-size:10pt;">$5.15</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.18</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.08</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Awards</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is summary information for restricted stock awards for the year ended December 31, 2015. Shares vest over a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year period. As of December 31, 2015, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$16,606,000</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized stock-based compensation related to time-based, non-vested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.1 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, during the twelve months ended December 31, 2015, </font><font style="font-family:inherit;font-size:10pt;">5,172</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock valued at approximately </font><font style="font-family:inherit;font-size:10pt;">$57,000</font><font style="font-family:inherit;font-size:10pt;"> were issued under the 2006 Plan to a consultant in return for services performed.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,228,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,974,259</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(517,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,007</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended December 31, 2015, 2014, and 2013 the Company recognized stock-based compensation as follows (in thousands):  </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">660</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">417</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,754</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,471</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,314</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,896</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,010</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 18, 2015, </font><font style="font-family:inherit;font-size:10pt;">42,400</font><font style="font-family:inherit;font-size:10pt;"> common stock warrants representing the balance remaining from those granted in connection with equity share purchases by investors as an additional incentive for providing long - term equity capital to the Company and as additional compensation to consultants and advisors were exercised at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.09</font><font style="font-family:inherit;font-size:10pt;">.  The warrants were granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances.  The warrants were issued for terms of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On May 12, 2014, our Board of Directors authorized the repurchase of up to </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> and further increased the authorization in 2015 to </font><font style="font-family:inherit;font-size:10pt;">$60 million</font><font style="font-family:inherit;font-size:10pt;">. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2015, the Company purchased approximately </font><font style="font-family:inherit;font-size:10pt;">4,610,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$40,143,000</font><font style="font-family:inherit;font-size:10pt;"> exclusive of commissions of approximately </font><font style="font-family:inherit;font-size:10pt;">$136,000</font><font style="font-family:inherit;font-size:10pt;">. As of December 31, 2015, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$14,274,000</font><font style="font-family:inherit;font-size:10pt;"> remaining under the repurchase program.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments.  The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2015, the Company has not chosen to make any such elections.  Fair value financial instruments are recorded in accordance with the fair value measurement framework.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also measures certain non-financial assets at fair value on a non-recurring basis.  These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations.  The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels.  These levels from highest to lowest priority are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity.  Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions.  Management’s assumptions could vary depending on the asset or liability valued and the valuation method used.  Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods.  The Company may also engage external advisors to assist it in determining fair value, as appropriate.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Royalty Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="58%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Licenses (a) (b) </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patents & Know How (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,891</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Customer & Supplier Relationships (b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Tradenames & Trademarks (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">In Process Research & Development (b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,082</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">Less Accumulated amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,931</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.  Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately </font><font style="font-family:inherit;font-size:10pt;">$110,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents & Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Trade Names & Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research & Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. During 2015 approximately </font><font style="font-family:inherit;font-size:10pt;">$110,000</font><font style="font-family:inherit;font-size:10pt;"> of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for the years ended December 31, 2015, 2014, and 2013, was approximately </font><font style="font-family:inherit;font-size:10pt;">$933,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$928,000</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$1,054,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of December 31, 2015, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="86%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">836</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,755</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in Progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">949</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,979</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,499</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,447</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly Financial Data (Unaudited) (in thousands except per share data)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="38%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">First</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Second</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Third</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Fourth</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET SALES</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,767</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,679</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,015</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,835</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,559</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,573</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,518</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,573</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GROSS MARGIN</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,619</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,590</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,036</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,849</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,582</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,833</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,973</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET INCOME (LOSS)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,087</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,430</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,551</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,378</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(922</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,832</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET INCOME (LOSS) <br clear="none"/>PER COMMON SHARE - BASIC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> NET INCOME (LOSS)<br clear="none"/> PER COMMON SHARE - DILUTED</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="padding-bottom:13px;padding-top:8px;padding-left:48px;text-align:justify;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2015 and 2014 are as follows:    </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="76%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,121,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,035,728</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">543,827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,699,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,502,496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands)</font><font style="font-family:inherit;font-size:11pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="70%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of equipment financed through capital leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">355</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APIC related tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,757</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance in connection with Earn-Out Liability of 1,174,915 shares </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance in exchange for convertible debt of 5,272,004 shares </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,272</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tenant improvement incentive</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal fees paid for public offering</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal fees related to public offering included in accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal fees related to public offering included in accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current and deferred income tax expense (benefit) is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="40%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="28%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="28%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,218</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">832</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">      Total current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,070</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,768</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">      Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">832</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals and prepaids</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">619</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&D and other tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charitable contributions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state basis difference</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,763</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,382</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(782</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the Federal statutory income tax rate of </font><font style="font-family:inherit;font-size:10pt;">34%</font><font style="font-family:inherit;font-size:10pt;"> to the effective rate is as follows:</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:68.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non deductible compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Meals & entertainment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock based compensation - ISO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.73</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63.33</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58.73</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21.29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="71%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,419</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,405</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,986</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,660</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(527</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="38%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">First</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Second</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Third</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Fourth</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET SALES</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,767</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,679</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,015</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,835</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,559</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,573</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,518</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,573</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GROSS MARGIN</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,619</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,590</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,036</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,849</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,582</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,833</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,973</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET INCOME (LOSS)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,087</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,430</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,551</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,378</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(922</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,832</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET INCOME (LOSS) <br clear="none"/>PER COMMON SHARE - BASIC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> NET INCOME (LOSS)<br clear="none"/> PER COMMON SHARE - DILUTED</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at December 31, 2015:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,783,304</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,783,304</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,641,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,641,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">957,454</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">907,452</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,552,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,229,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45- $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,527,525</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914,703</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  $9.90 - $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,951,694</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="48%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,474,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,220,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(239,322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(69,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,740,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,951,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,955,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at December 31, 2015 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,917,122</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,496,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture adjusted unvested shares.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54.35 - 58.14%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58.14 - 64.50%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61.41 - 64.77%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51 - 1.68%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.64 - 1.96%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.85 - 1.88%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - January 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross increases - tax positions in current period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - December 31</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Schedule II Valuation and Qualifying Accounts</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MIMEDX GROUP, INC. AND SUBSIDIARIES</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS</font></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Years ended December 31, 2015, 2014 and 2013 (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at <br clear="none"/>Beginning of Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions charged to Expense or Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions <br clear="none"/>and write-offs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at<br clear="none"/> End of Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the Year ended December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,698</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(178</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for product returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(670</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the Year ended December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for product returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,215</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,589</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the Year ended December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for product returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

Includes forfeiture adjusted unvested shares. On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000. Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization. On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.

EX-101.SCH 9 mdxg-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2185100 - Disclosure - 401k Plan link:presentationLink link:calculationLink link:definitionLink 2485401 - Disclosure - 401k Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Cash Equivalents and Short Term Investments link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Cash Equivalents and Short Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2186100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2486402 - Disclosure - Commitments and Contingencies Estimated Annual Lease, Royalty, and Employment Agreement Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2486403 - Disclosure - Commitments and Contingencies Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2386301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2155100 - Disclosure - Common Stock Placements link:presentationLink link:calculationLink link:definitionLink 2455401 - Disclosure - Common Stock Placements (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2160100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2460403 - Disclosure - Equity Activity of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2460406 - Disclosure - Equity Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2460404 - Disclosure - Equity Exercise Price Ranges (Details) link:presentationLink link:calculationLink link:definitionLink 2460402 - Disclosure - Equity Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2460408 - Disclosure - Equity Recognized Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2460407 - Disclosure - Equity Summary of Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 2460405 - Disclosure - Equity Summary of Unvested Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2360301 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2165100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2465402 - Disclosure - Income Taxes Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2465406 - Disclosure - Income Taxes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2465403 - Disclosure - Income Taxes Reconciliation of the Federal Statutory Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 2465405 - Disclosure - Income Taxes Reconciliation of unrecognized tax benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2465404 - Disclosure - Income Taxes Schedule of current and deferred income tax expense (benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 2365301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Intangible Assets and Royalty Agreement link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Intangible Assets and Royalty Agreement Expected Future Amortization of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Intangible Assets and Royalty Agreement Intangible Asssets Activity Summary (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Liquidity and Capital Resources link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Liquidity and Capital Resources (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Net Income (loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Net Income (loss) Per Share Computation of Basic and Dilutive Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Net Income (loss) Per Share Summary of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Net Income (loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2187100 - Disclosure - Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2487402 - Disclosure - Quarterly Financial Data (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 2387301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2189100 - Schedule - Schedule II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2489401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2188100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2488401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2170100 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities link:presentationLink link:calculationLink link:definitionLink 2470402 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 2370301 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 mdxg-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 mdxg-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 mdxg-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Commitments and Contingencies Disclosure [Abstract] 2016 Contractual Obligation, Due in Next Fiscal Year 2017 Contractual Obligation, Due in Second Year 2018 Contractual Obligation, Due in Third Year 2019 Contractual Obligation, Due in Fourth Year 2020 Contractual Obligation, Due after Fifth Year Total Contractual commitments Contractual Obligation Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Unvested options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Vested options expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding, end of period (in shares) Vested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Exercisable options, vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted- Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, weighted average exercise price, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Unvested options forfeited weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Vested options expired weighted-average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, weighted average exercise price, end of period (in dollars per share) Vested at end of period weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and expected to vest, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Stock options, additional disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Outstanding options, weighted average remaining contractual term Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Vested at end of period weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and expected to vest, weighted average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Outstanding intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested at end of period aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Vested and expected to vest, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business Nature of Operations [Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Warrants Warrant [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Consultant Consultant [Member] Consultant [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Class of Stock [Line Items] Class of Stock [Line Items] Number of share-based compensation plans Number of share based compensation plans The number of share-based compensation the company maintains. Outstanding assumed options (in shares) Outstanding assumed options Number of outstanding options assumed by the company. Number of shares available to be issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value of options vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Total unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Weighted-average grant date fair value for options granted during the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Total unrecognized stock-based compensation related to time-based, nonvested restricted stock Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Expenses expected to be recognized over a weighted-average period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Shares issued for services performed (in shares) Stock Issued During Period, Shares, Issued for Services Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively Stock Issued During Period, Value, Issued for Services Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Warrants outstanding (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants, term Warrants term Term of warrants. Authorized share amount for repurchase Stock Repurchase Program, Authorized Amount Stock repurchase (in shares) Treasury Stock, Shares, Acquired Shares repurchased, value Payments for Repurchase of Common Stock Commissions Payments of Stock Repurchase Costs Payments of Stock Repurchase Costs Remaining authorizations under the repurchase program, amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Estimated annual lease, royalty, and employment agreement expenses Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Stockholders' Equity Note [Abstract] Common stock and warrants private placement [Table] Common stock and warrants private placement [Table] Schedule detailing information related to the private placement to sell common stock and warrants. Sale of stocks and warrants [Line Items] Sale of stocks and warrants [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Shares issued (in shares) Stock Issued During Period, Shares, New Issues Share issue price (in dollars per share) Share Price Proceeds from shares issued Proceeds from Issuance of Common Stock Legal fees paid for secondary offering Legal Fees Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Common Stock Placements Stockholders' Equity Note Disclosure [Text Block] Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short term investments Short-term Investments Accounts receivable, net Accounts Receivable, Net, Current Inventory, net Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Investments Investments Property and equipment, net of accumulated depreciation Property, Plant and Equipment, Net Goodwill Goodwill Intangible assets, net of accumulated amortization Intangible Assets, Net (Excluding Goodwill) Deferred tax asset, net Deferred Tax Assets, Net of Valuation Allowance Deferred financing costs and other assets Deferred Costs and Other Assets Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Other liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding Preferred Stock, Value, Issued Common stock; $0.001 par value; 150,000,000 shares authorized; 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 and 108,776,247 issued and 107,789,611 outstanding at December 31, 2014 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury stock at cost: 2,105,945 shares at December 31, 2015 and 986,636 shares at December 31, 2014 Treasury Stock, Value Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Earnings Per Share [Abstract] Computation of basic and diluted net loss per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of antidilutive securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of cash flow and non-cash investing and financing activities Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Accounting Policies [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Market Concentrations and Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Accounts Receivable Receivables, Policy [Policy Text Block] Investments Investment, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Goodwill and Purchased Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Impairment of Intangible Assets with Finite Lives Intangible Assets, Finite-Lived, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Patent Costs Legal Costs, Policy [Policy Text Block] Impairment of Long-lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Grant Income Revenue Recognition, Deferred Revenue [Policy Text Block] Revenue Recognition Revenue Recognition, Sales of Goods [Policy Text Block] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Share-based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Licenses Licensing Agreements [Member] Patents & Know How Patents [Member] Customer & Supplier Relationships Customer Relationships [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Tradenames & Trademarks Trademarks and Trade Names [Member] In Process Research & Development In Process Research and Development [Member] Patents in Process Patents in Process [Member] Patents in Process Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Shriners Hospitals For Children And University Of South Florida Research Foundation, Inc. [Member] Surgical Biologics, LLC Surgical Biologics [Member] Represents Surgical Biologics, LLC ("Surgical Biologics"), a privately held company headquartered in Kennesaw, Georgia. which the Company acquired through an Agreement and Plan of Merger ("the Merger Agreement") with Membrane Products Holdings, LLC and Ramp Capital Investments, LLC on December 21, 2010. Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Weighted Average Amortization Lives Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Gross carrying value Finite-Lived Intangible Assets, Gross Gross carrying value, indefinite lived Indefinite-Lived Intangible Assets (Excluding Goodwill) Intangible assets, gross carrying value Intangible Assets, Gross (Excluding Goodwill) Less Accumulated amortization Intangible Assets, Accumulated Amortization Total of accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance. Intangible Assets, Net Acquisition price Payments to Acquire Intangible Assets Maximum time of approval Period of approval, maximum The maximum amount of time the entity has to obtain approval by the FDA to allow the sale of the product. Contingent payments to licensor Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Contingent royalty to be paid to licensor Contingent royalty to be paid to licensor Royalty payment percentage on all commercial sales revenue from the licensed products. Annual royalty payment Royalty Expense Net book value Finite-Lived Intangible Assets, Net Finite-lived intangible assets, costs Finite-lived Intangible Assets Acquired Amortization of intangible assets Amortization of Intangible Assets Valuation and Qualifying Accounts [Abstract] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Allowance for doubtful accounts Allowance for Doubtful Accounts [Member] Allowance for product returns Allowance for Sales Returns [Member] Allowance for obsolescence Allowance for Obsolescence [Member] Allowance for Obsolescence [Member] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Movement in Valuation Allowances and Reserves [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Year Valuation Allowances and Reserves, Balance Additions charged to Expense or Revenue Valuation Allowances and Reserves, Charged to Cost and Expense Deductions and write-offs Valuation Allowances and Reserves, Deductions Balance at End of Year Intangible Assets and Royalty Agreement Intangible Assets Disclosure [Text Block] EX-101.PRE 13 mdxg-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 mdxg-20141_chartx41044a02.jpg begin 644 mdxg-20141_chartx41044a02.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.3.1.900

Document and Entity Information - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Feb. 10, 2016

Jun. 30, 2015

Document and Entity Information [Abstract]

Entity Registrant Name MIMEDX GROUP, INC.

Entity Central Index Key 0001376339

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Document Type 10-K

Document Period End Date Dec. 31, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus FY

Amendment Flag false

Entity Common Stock, Shares Outstanding 107,810,490

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Public Float $ 1,135,614

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
-- None. No documentation exists for this element. --
+ References
No definition available.
+ Details

Name: mdxg_DocumentAndEntityInformationAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.3.1.900

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 28,486 $ 46,582

Short term investments 3,000 5,750

Accounts receivable, net 53,755 26,672

Inventory, net 7,460 5,133

Prepaid expenses and other current assets 3,609 1,540

Total current assets 96,310 85,677

Investments 0 3,250

Property and equipment, net of accumulated depreciation 9,475 5,447

Goodwill 4,040 4,040

Intangible assets, net of accumulated amortization 10,763 10,845

Deferred tax asset, net 14,838 0

Deferred financing costs and other assets 487 0

Total assets 135,913 109,259

Current liabilities:

Accounts payable 6,633 3,661

Accrued compensation 15,034 11,523

Accrued expenses 4,644 2,504

Other current liabilities 466 716

Total current liabilities 26,777 18,404

Other liabilities 1,148 1,526

Total liabilities $ 27,925 $ 19,930

Commitments and contingencies

Stockholders' equity:

Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding $ 0 $ 0

Common stock; $0.001 par value; 150,000,000 shares authorized; 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 and 108,776,247 issued and 107,789,611 outstanding at December 31, 2014 109 108

Additional paid-in capital 163,133 162,433

Treasury stock at cost: 2,105,945 shares at December 31, 2015 and 986,636 shares at December 31, 2014 (17,125) (5,637)

Accumulated deficit (38,129) (67,575)

Total stockholders' equity 107,988 89,329

Total liabilities and stockholders' equity $ 135,913 $ 109,259

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_AccountsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3-4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Subparagraph a(1)
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 4
-Article 5
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.18)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 12
-Article 7
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount of deferred costs and other assets not separately disclosed.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCostsAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.1(h))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Investments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.32)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 25
-Article 7
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 8
-Article 5
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 8
-Article 7
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Subparagraph g
-Article 7
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 17 R3.htm IDEA: XBRL DOCUMENT v3.3.1.900

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Dec. 31, 2015

Dec. 31, 2014

Stockholders' equity:

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized (in shares) 5,000,000 5,000,000

Preferred stock, shares issued (in shares) 0 0

Preferred stock, shares outstanding (in shares) 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (in shares) 150,000,000 150,000,000

Common stock, shares issued (in shares) 109,467,416 108,776,247

Common stock, shares outstanding (in shares) 107,361,471 107,789,611

Treasury stock, shares (in shares) 2,105,945 986,636

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29
-Article 5
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28,29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 18 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Income Statement [Abstract]

Net sales $ 187,296 $ 118,223 $ 59,181

Cost of sales 20,202 12,665 9,328

Gross margin 167,094 105,558 49,853

Operating expenses:

Research and development expenses 8,413 7,050 4,843

Selling, general and administrative expenses 133,384 90,480 46,227

Impairment of intangible assets 0 0 368

Amortization of intangible assets 933 928 1,054

Operating income (loss) 24,364 7,100 (2,639)

Other income (expense), net

Amortization of debt discount 0 0 (1,328)

Interest expense, net (86) (48) (45)

Income (loss) before income tax provision 24,278 7,052 (4,012)

Income tax provision 5,168 (832) (100)

Net income (loss) $ 29,446 $ 6,220 $ (4,112)

Net income (loss) per common share - basic (in dollars per share) $ 0.28 $ 0.06 $ (0.04)

Net income (loss) per common share - diluted (in dollars per share) $ 0.26 $ 0.05 $ (0.04)

Weighted average shares outstanding - basic (in shares) 105,929,205 105,793,008 96,285,504

Weighted average shares outstanding - diluted (in shares) 113,628,482 113,295,504 96,285,504

X

- Definition
Impairment of Intangible Assets
+ References
No definition available.
+ Details

Name: mdxg_ImpairmentofIntangibleAssets

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=51677171&loc=d3e3636-108311
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 19 R5.htm IDEA: XBRL DOCUMENT v3.3.1.900

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands

Total

Common Stock

Additional Paid-in

Treasury Stock

Accumulated Deficit

Balance, beginning of period at Dec. 31, 2012 $ 20,007 $ 88 $ 89,627 $ (25) $ (69,683)

Balance, beginning of period (in shares) at Dec. 31, 2012 88,423,169 50,000

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 6,010 6,010

Exercise of stock options 1,981 $ 2 1,979

Exercise of stock options (in shares) 1,958,674

Exercise of warrants 2,108 $ 2 2,106

Exercise of warrants (in shares) 1,844,352

Common stock issued for 5% convertible note $ 5,272 $ 5 5,267

Common stock issued for 5% convertible note (in shares) 5,272,004 5,272,004

Common stock issued for earn - out liability $ 5,792 $ 1 5,791

Common stock issued for earn-out liability (in shares) 1,174,915 1,174,915

Issuance of restricted stock $ 0

Issuance of restricted stock (in shares) 2,500

Public offering of common stock, net of expenses 36,510 $ 6 36,504

Public offering of common stock, net of expenses (in shares) 5,750,000

Shares issued for services performed 0

Net income (loss) (4,112) (4,112)

Balance, end of period at Dec. 31, 2013 73,568 $ 104 147,284 $ (25) (73,795)

Balance, end of period (in shares) at Dec. 31, 2013 104,425,614 50,000

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 11,453 11,453

Exercise of stock options 2,470 $ 2 2,468

Exercise of stock options (in shares) 1,653,690

Exercise of warrants 1,113 $ 1 1,112

Exercise of warrants (in shares) 1,242,416

Common stock issued for 5% convertible note 0

Common stock issued for earn - out liability 0

Issuance of restricted stock 0 $ 1 (1)

Issuance of restricted stock (in shares) 1,438,569

Shares issued for services performed $ 117 117

Shares issued for services performed (in shares) 15,958 15,958

Stock repurchase $ (5,612) $ (5,612)

Stock repurchase (in shares) 936,636

Net income (loss) 6,220 6,220

Balance, end of period at Dec. 31, 2014 89,329 $ 108 162,433 $ (5,637) (67,575)

Balance, end of period (in shares) at Dec. 31, 2014 108,776,247 986,636

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 16,896 16,896

Tax benefit of share-based compensation expense 7,757 7,757

Exercise of stock options $ 4,629 $ 1 (9,792) $ 14,420

Exercise of stock options (in shares) 2,220,881 647,656 (1,573,225)

Exercise of warrants $ 46 (379) $ 425

Exercise of warrants (in shares) (42,400)

Common stock issued for 5% convertible note 0

Common stock issued for earn - out liability 0

Issuance of restricted stock 0 (14,547) $ 14,547

Issuance of restricted stock (in shares) 34,250 (1,940,009)

Restricted stock shares canceled/forfeited $ 0 652 $ (652)

Restricted stock shares canceled/forfeited (in shares) 69,949 (2,058)

Shares issued for services performed $ 164 113 $ 51

Shares issued for services performed (in shares) 16,493 11,321 (5,172)

Stock repurchase $ (40,279) $ (40,279)

Stock repurchase (in shares) 4,610,000 4,610,166

Net income (loss) $ 29,446 29,446

Balance, end of period at Dec. 31, 2015 $ 107,988 $ 109 $ 163,133 $ (17,125) $ (38,129)

Balance, end of period (in shares) at Dec. 31, 2015 109,467,416 2,105,945

X

- Definition
The number of shares issued during the period upon the exercise of warrants.
+ References
No definition available.
+ Details

Name: mdxg_StockIssuedDuringPeriodSharesExerciseOfWarrants

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares issued during the period for earn-out liability.
+ References
No definition available.
+ Details

Name: mdxg_StockIssuedDuringPeriodSharesForEarnOutLiability

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued during the period upon the exercise of warrants.
+ References
No definition available.
+ Details

Name: mdxg_StockIssuedDuringPeriodValueExerciseOfWarrants

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares issued during the period for earn-out liability.
+ References
No definition available.
+ Details

Name: mdxg_StockIssuedDuringPeriodValueForEarnOutLiability

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares related to Restricted Stock Award forfeited during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28,29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock related to Restricted Stock Awards forfeited during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate value of stock related to Restricted Stock Awards issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R6.htm IDEA: XBRL DOCUMENT v3.3.1.900

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)

Dec. 31, 2013

Dec. 31, 2011

5% Convertible Senior Secured Promissory Note

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Convertible note 5.00% 5.00%

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdxg_FivePercentConvertibleSeniorSecuredPromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R7.htm IDEA: XBRL DOCUMENT v3.3.1.900

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Cash flows from operating activities:

Net income (loss) $ 29,446 $ 6,220 $ (4,112)

Adjustments to reconcile net income (loss) to net cash from operating activities:

Depreciation 1,799 1,197 637

Loss on fixed asset disposal 0 0 37

Amortization of intangible assets 933 928 1,054

Impairment of intangible assets 0 0 368

Amortization of debt discount and deferred financing costs 42 0 1,328

Share-based compensation 16,896 11,453 6,010

Change in deferred income taxes (7,081) 0 0

Increase (decrease) in cash resulting from changes in:

Accounts receivable (27,083) (10,579) (8,439)

Inventory (2,327) (1,252) (858)

Prepaid expenses and other assets (2,094) (203) (637)

Accounts payable 3,136 1,287 1,209

Accrued compensation 3,511 5,935 2,836

Accrued expenses 2,140 1,098 353

Accrued interest 0 0 (42)

Other liabilities (511) 718 (28)

Net cash flows from operating activities 18,807 16,802 (284)

Cash flows from investing activities:

Purchases of equipment (5,827) (2,558) (2,337)

Maturity (purchases) of fixed maturity securities 6,000 (9,000) 0

Patent application costs (851) (594) (689)

Net cash flows from investing activities (678) (12,152) (3,026)

Cash flows from financing activities:

Proceeds from exercise of stock options 4,629 2,470 1,981

Proceeds from exercise of warrants 46 1,113 2,108

Proceeds from public offering, net of expenses 0 0 36,602

Deferred financing costs (504) 0 0

Stock repurchase (40,279) (5,612) 0

Principal payments of equipment leases (117) (117) (57)

Net cash flows from financing activities (36,225) (2,146) 40,634

Net change in cash (18,096) 2,504 37,324

Cash and cash equivalents, beginning of period 46,582 44,078 6,754

Cash and cash equivalents, end of period $ 28,486 $ 46,582 $ 44,078

X

- Definition
Impairment of Intangible Assets
+ References
No definition available.
+ Details

Name: mdxg_ImpairmentofIntangibleAssets

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Payments for Application Costs, Patent
+ References
No definition available.
+ Details

Name: mdxg_PaymentsforApplicationCostsPatent

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) and income tax credits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11374-113907

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_DeferredIncomeTaxesAndTaxCredits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230
+ Details

Name: us-gaap_GainLossOnDispositionOfAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for payments to acquire rented equipment which is recorded as an asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireEquipmentOnLease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for acquisition of machinery and equipment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireMachineryAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow resulting from the entity's share transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
+ Details

Name: us-gaap_ProceedsFromRepurchaseOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 22 R8.htm IDEA: XBRL DOCUMENT v3.3.1.900

Nature of Business
12 Months Ended

Dec. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business
Nature of Business

MiMedx Group, Inc. (“MiMedx,” "the Company,” “we,” or “us”) operates in one business segment, Regenerative Biomaterials, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.  The Company's biomaterial platform technologies include tissue technologies, AmnioFix and EpiFix, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology CollaFix,which the Company has yet to commercialize.
The Company is focused primarily on the United States but is actively exploring international expansion opportunities.  The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6003-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=51801978&loc=SL51803626-108592
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.3.1.900

Significant Accounting Policies
12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Significant Accounting Policies
Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period.  Actual results could differ from those estimates.
Principles of Consolidation
The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., MiMedx Processing Services, LLC (formerly known as SpineMedica, LLC), and MiMedx Tissue Services, LLC (formerly known as Surgical Biologics, LLC). All significant inter-company balances and transactions have been eliminated.
Segment Reporting
ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting.  The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment.  Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment.  Thus, discrete financial information is not available for more than one operating segment.
Market Concentrations and Credit Risk
The Company places its cash and cash equivalents on deposit with financial institutions in the United States.  In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts. As of December 31, 2015 and 2014, the Company had cash and cash equivalents of approximately $27,700,000 and $44,600,000, respectively, in excess of the insured amounts.
The Company’s principal market concentration of risk is related to its limited distribution channels. The Company's revenues include the distribution efforts of several independent companies as well as the Company's internal sales force. Significant revenues are derived from the Company's relationship with one of its distributors, AvKare, Inc. which sells our products to the Federal Government. For the years ended December 31, 2015, 2014 and 2013, AvKare revenue was approximately 24%, 34%, and 56%, of total revenue, respectively. Related receivables for the years ended December 31, 2015 and 2014 were approximately 26%, and 33%, of total accounts receivable, respectively.
Cash and Cash Equivalents
Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized.  Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.
Investments
Investments consist of FDIC insured certificates of deposit held at various banks and are classified as either Short term investments or Investments depending on their maturity date and are valued at cost, which approximates market value.
Inventories
Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method.  Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes up to when the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates.  Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Goodwill and Purchased Intangible Assets
Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss.

Impairment of Intangible Assets with Finite Lives
The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets.
Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates.
During the fourth quarter of 2013, the Company chose to discontinue the HydroFix product line. This action resulted in an impairment charge of approximately $368,000 related to the Licenses for SaluMedica LLC, Spine Repair and Polyvinyl Alcohol Cryogel. This item is included in our Statement of Operations for the year ended December 31, 2013. An impairment charge of approximately $1,800,000 had previously been booked in 2012.
Property and Equipment
Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years.  Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term. See Notes 7 and 16 for further information regarding capital leases, operating leases and rent expense.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $851,000 of patent costs during 2015, $594,000 of patent costs during 2014 and $689,000 of patent costs during 2013.
Impairment of Long-lived Assets
The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated.  If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized. During the fourth quarter of 2013, the Company chose to discontinue the HydroFix product line. This action resulted in a disposal loss of approximately $30,000. This item is included in the Consolidated Statements of Operations for the year ended December 31, 2013, as Selling, General and Administrative expenses.
Grant Income
The Company received a Regional Economic Business Assistance ("REBA") grant in the amount of $250,000 from the State of Georgia to help the Company defray certain expenses and capital expenditures related to the Company's expansion of manufacturing activities in the State.  In order to retain the grant monies the Company was required to add a certain number of full time positions and spend a certain amount on capital and operations expenditures by December 31, 2014. As of December 31, 2013, the Company had satisfied the grant requirements. Accordingly, the Company recorded the $250,000 as a reduction of Selling, General and Administrative expenses in the accompanying 2013 Consolidated Statements of Operations.
Revenue Recognition
The Company sells its products primarily through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets.  The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance.  In cases where the Company utilizes distributors or ships products directly to the end user, it recognizes revenue according to the shipping terms of the agreement provided all revenue recognition criteria have been met.  A portion of the Company’s revenue is generated from inventory maintained at hospitals or with field representatives.  For these products, revenue is recognized at the time the product has been used or implanted.  The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.
Research and Development Costs
Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies.  These costs are expensed as incurred.
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.
The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.
Share-based Compensation
The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award).
Fair Value of Financial Instruments
The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates their carrying value based upon current rates available to the Company.
Fair Value Measurements
The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments.  The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2015, the Company has not chosen to make any such elections.  Fair value financial instruments are recorded in accordance with the fair value measurement framework.
The Company also measures certain non-financial assets at fair value on a non-recurring basis.  These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations.  The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.
The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels.  These levels from highest to lowest priority are as follows:
•
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;
•
Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
•
Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.
The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity.  Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions.  Management’s assumptions could vary depending on the asset or liability valued and the valuation method used.  Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods.  The Company may also engage external advisors to assist it in determining fair value, as appropriate.
Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.
Recently Issued Accounting Pronouncements
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements.
In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 13. Prior periods were not retrospectively adjusted.
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the year ended December 31, 2015, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.3.1.900

Liquidity and Capital Resources
12 Months Ended

Dec. 31, 2015

Liquidity and Capital Resources [Abstract]

Liquidity and Capital Resources
Liquidity and Capital Resources
Net Working Capital
As of December 31, 2015, the Company had approximately $28,486,000 of cash and cash equivalents.  The Company reported total current assets of approximately $96,310,000 and current liabilities of approximately $26,777,000 and had net working capital of approximately $69,533,000.
Overall Liquidity and Capital Resources
  The Company's largest cash requirement for the twelve months ended December 31, 2015 was cash for general working capital needs. In addition, the Company's other cash requirements included capital expenditures, and repurchases of the Company's common stock. The Company funded its cash requirements through its existing cash reserves, and its operating activities which generated approximately $18,807,000 during the period. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents as well as its investments in FDIC insured certificates of deposit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year. In addition, on October 12, 2015, the Company entered into a new three-year $50 million senior secured revolving credit facility, which provides additional liquidity.

X

- Definition
Liquidity and Capital Resources [Abstract]
+ References
No definition available.
+ Details

Name: mdxg_LiquidityandCapitalResourcesAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Liquidity and Capital Resources [Text Block]
+ References
No definition available.
+ Details

Name: mdxg_LiquidityandCapitalResourcesTextBlock

Namespace Prefix: mdxg_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.3.1.900

Cash Equivalents and Short Term Investments
12 Months Ended

Dec. 31, 2015

Cash and Cash Equivalents [Abstract]

Cash Equivalent and Short Term Investments
Cash Equivalents and Short Term Investments
Included in Cash and cash equivalents as of December 31, 2014, were approximately $1,250,000 of FDIC insured certificates of deposit held with various U.S. financial institutions. Short term investments at December 31, 2015 and 2014 consist of approximately $3,000,000 and $5,750,000, respectively, of FDIC insured certificates of deposits held with various financial institutions. The cost of these instruments approximates their fair market value.

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.
+ References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.3.1.900

Inventories
12 Months Ended

Dec. 31, 2015

Inventory Disclosure [Abstract]

Inventories
Inventories

Inventories consisted of the following items as of December 31, 2015 and 2014 (in thousands):

December 31,

2015

2014
Raw materials
$
602

$
255

Work in process
3,850

3,419

Finished goods
3,405

1,986

Inventory, gross
7,857

5,660

Reserve for obsolescence
(397
)

(527
)
Inventory, net
$
7,460

$
5,133

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a, b, c
-Article 5
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.3.1.900

Investments
12 Months Ended

Dec. 31, 2015

Investments, All Other Investments [Abstract]

Investments
Investments
Investments consisted of FDIC insured certificates of deposit with various U.S. financial institutions. The balance as of December 31, 2015 was zero and the balance as of December 31, 2014 was approximately $3,250,000 and the cost approximated fair market value. Maturities of these instruments range to May of 2016.

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsAllOtherInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments and other noncurrent assets.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.3.1.900

Property and Equipment
12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment
Property and Equipment
Property and equipment consist of the following as of December 31, 2015 and 2014 (in thousands):

December 31,

2015

2014
Leasehold improvements
$
2,684

$
2,559

Lab and clean room equipment
4,564

3,040

Furniture and equipment
4,577

2,398

Construction in Progress
2,629

949

Property and equipment, gross
14,454

8,946

Less accumulated depreciation
(4,979
)

(3,499
)
Property and equipment, net
$
9,475

$
5,447

Included in property and equipment is approximately $427,000 of capital leases. The corresponding liability of approximately $133,000 is included in other liabilities in the accompanying condensed consolidated balance sheet. Also included is approximately $1,000,000 in leasehold improvements paid for by the landlord of our main operating facility with a corresponding liability included in long term liabilities, which is amortized over the term of the lease.
Depreciation expense for the years ended December 31, 2015, 2014, and 2013 was approximately $1,799,000, $1,197,000, and $637,000, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13-14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.3.1.900

Intangible Assets and Royalty Agreement
12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Royalty Agreement
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):

December 31,

2015

2014

Weighted
Average
Amortization
Lives

Cost

Cost
Licenses (a) (b)

10 years

$
1,009

$
1,009

Patents & Know How (b)

17 years

8,001

7,891

Customer & Supplier Relationships (b)

14 years

3,761

3,761

Tradenames & Trademarks (b)

indefinite

1,008

1,008

In Process Research & Development (b)

n/a

25

25

Patents in Process (c)

n/a

1,823

1,082

Total

15,627

14,776

Less Accumulated amortization

(4,864
)

(3,931
)
Net

$
10,763

$
10,845

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.
(c)
Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
Amortization expense for the years ended December 31, 2015, 2014, and 2013, was approximately $933,000, $928,000, and $1,054,000, respectively.
Expected future amortization of intangible assets as of December 31, 2015, is as follows (in thousands):

Estimated

Amortization
Year ending December 31,
Expense
2016
$
936

2017
846

2018
836

2019
836

2020
836

Thereafter
5,465

$
9,755

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.3.1.900

Long-Term Debt
12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Long-Term Debt
Long-Term Debt
Senior Secured Promissory Notes
From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000.  The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO.  In total, the principal of the Notes were convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) plus accrued but unpaid interest at $1.00 per share at any time upon the election of the holder of the note.
In conjunction with the sale of the Notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share.  These warrants were exercised in November 2015.  The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique.  The total direct costs of approximately $47,800 were recorded as deferred financing costs and were amortized over the term of the Notes using the effective interest method.  Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP.
During the months of January and February 2013, all holders of the Notes converted their interest in this obligation to shares of MiMedx common stock.  The total amount of debt plus accrued interest that was exchanged was approximately $5,272,000.  In conjunction with this exchange, approximately 5,272,000 shares of the Company’s common stock were issued in full satisfaction of this obligation.  Included in this total are 532,260 shares representing the CEO’s conversion of his Note.  This also resulted in the acceleration of amortization of debt discount and total interest expense of approximately $1,328,000 during the year ended December 31, 2013.
Credit Facility
On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%. Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary representations, warranties, covenants, and events of default. As of December 31, 2015, there were no outstanding revolving loans under the credit facility.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20,22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.3.1.900

Net Income (loss) Per Share
12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

Net Income (loss) Per Share
Net Income (loss) Per Share
Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and restricted stock using the treasury stock method.
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data):

Year Ended December 31,

2015

2014

2013
Net income (loss)
$
29,446

$
6,220

$
(4,112
)
Denominator for basic earnings per share - weighted average shares
105,929,205

105,793,008

96,285,504

Effect of dilutive securities: Stock options, warrants, and restricted stock (a)
7,699,277

7,502,496

—

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
113,628,482

113,295,504

96,285,504

Income (loss) per common share - basic
0.28

0.06

(0.04
)
Income (loss) per common share - diluted
$
0.26

$
0.05

$
(0.04
)
(a)Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2015 and 2014 are as follows:
Effect of dilutive securities:
2015

2014

    Stock Options
7,121,774

7,035,728

    Warrants
33,676

226,926

    Restricted Stock Awards
543,827

239,842

7,699,277

7,502,496

Securities for the year ended December 31, 2013 were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R18.htm IDEA: XBRL DOCUMENT v3.3.1.900

Common Stock Placements
12 Months Ended

Dec. 31, 2015

Stockholders' Equity Note [Abstract]

Common Stock Placements
Common Stock Placements
Public Offering of Common Stock
In December of 2013, the Company completed a public offering (the "Offering”) of 5,750,000 shares of its common stock at $6.80 per share. Proceeds from the Offering, net of underwriting expenses were $36,704,000. In addition, the Company incurred approximately $194,000 in various legal fees for services related to the Offering.
Proceeds from the Offering were used for general corporate purposes, including, but not limited to, research, development and further commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures, working capital and future acquisitions of complementary businesses, technology or products.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R19.htm IDEA: XBRL DOCUMENT v3.3.1.900

Equity
12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity
Equity
Stock Incentive Plans
The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at December 31, 2015, totaled 70,000.  The maximum number of shares of common stock that can be issued under the 2006 Plan total 26,500,000 at December 31, 2015.
Activity with respect to the stock options is summarized as follows:

Number of
Shares

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term
(in years)

Aggregate
Intrinsic
Value
Outstanding at January 1, 2015
16,474,227

$
3.43

Granted
75,100

$
9.66

Exercised
(2,220,881
)

$
2.08

Unvested options forfeited
(239,322
)

$
6.66

Vested options expired
(69,495
)

$
2.61

Outstanding at December 31, 2015
14,019,629

$
3.62

6.5

$
80,740,577

Vested at December 31, 2015
10,951,694

$
2.80

6.2

$
71,955,234

Vested or expected to vest at December 31, 2015 (a)
13,917,122

$
3.60

6.5

$
80,496,150

(a)
Includes forfeiture adjusted unvested shares.
The intrinsic value of the options exercised during the years ended December 31, 2015, 2014 and 2013 were approximately $17,181,000, $10,566,000, and $8,864,000, respectively.
The intrinsic value of options vested during the years ended December 31, 2015, 2014 and 2013 were approximately $10,044,000, $6,615,000, and $3,351,000, respectively.

Following is a summary of stock options outstanding and exercisable at December 31, 2015:

Options Outstanding

Options Exercisable
Range of Exercise Prices
Number outstanding

Weighted-
Average
Remaining
Contractual
Term
(in years)

Weighted-
Average
Exercise
Price

Number Exercisable

Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

3.4

$
0.72

441,429

$
0.72

$0.87 - $1.35
4,783,304

5.7

1.19

4,783,304

1.19

$1.40 - $2.45
1,641,928

5.1

1.93

1,641,928

1.93

$2.66 - $3.99
957,454

6.8

3.05

907,452

3.00

$4.19 - $6.38
3,552,323

7.4

5.35

2,229,386

5.32

$6.45- $9.78
2,527,525

8.1

7.29

914,703

7.18

  $9.90 - $10.99
115,666

8.9

10.43

33,492

10.50

14,019,629

6.5

$
3.62

10,951,694

$
2.80

A summary of the status of the Company’s unvested stock options as of December 31, 2015 is presented below:
Unvested Stock Options
Number of
Shares

Weighted-
Average
Grant Date Fair Value
Unvested at January 1, 2015
7,193,577

$
3.08

Granted
75,100

$
5.15

Cancelled
(239,322
)

$
3.79

Vested
(3,961,420
)

$
2.53

Unvested at December 31, 2015
3,067,935

$
3.81

Total unrecognized compensation expense at December 31, 2015, was approximately $6,241,000 and will be charged to expense through March 2017.
The fair value of the options granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method” which computes expected term as the midpoint between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company’s lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:

Year ended December 31,

2015

2014

2013
Expected volatility
54.35 - 58.14%

58.14 - 64.50%

61.41 - 64.77%

Expected life (in years)
6

6

6

Expected dividend yield
—

—

—

Risk-free interest rate
1.51 - 1.68%

1.64 - 1.96%

0.85 - 1.88%

The weighted-average grant date fair value for options granted during the years ended December 31, 2015, 2014 and 2013 were approximately $5.15, $4.18 and $3.08, respectively.
Restricted Stock Awards
Following is summary information for restricted stock awards for the year ended December 31, 2015. Shares vest over a one to three year period. As of December 31, 2015, there was approximately $16,606,000 of total unrecognized stock-based compensation related to time-based, non-vested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.1 years.
Additionally, during the twelve months ended December 31, 2015, 5,172 shares of common stock valued at approximately $57,000 were issued under the 2006 Plan to a consultant in return for services performed.

Number of
Shares

Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2015

1,228,898

$
7.16

Granted

1,974,259

$
9.80

Vested

(517,883
)

$
6.90

Forfeited

(72,007
)

$
9.77

Unvested at December 31, 2015

2,613,267

$
9.14

For the years ended December 31, 2015, 2014, and 2013 the Company recognized stock-based compensation as follows (in thousands):

Year Ended December 31,

2015

2014

2013
Cost of sales
$
352

$
322

$
279

Research and development
790

660

417

Selling, general and administrative
15,754

10,471

5,314

$
16,896

$
11,453

$
6,010

Warrants
On November 18, 2015, 42,400 common stock warrants representing the balance remaining from those granted in connection with equity share purchases by investors as an additional incentive for providing long - term equity capital to the Company and as additional compensation to consultants and advisors were exercised at an exercise price of $1.09.  The warrants were granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances.  The warrants were issued for terms of five years.
Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the year ended December 31, 2015, the Company purchased approximately 4,610,000 shares of its common stock for an aggregate purchase price of approximately $40,143,000 exclusive of commissions of approximately $136,000. As of December 31, 2015, the Company had approximately $14,274,000 remaining under the repurchase program.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R20.htm IDEA: XBRL DOCUMENT v3.3.1.900

Income Taxes
12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes
Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):

December 31,

2015

2014
Deferred tax assets and liabilities:

Accruals and prepaids
$
4,606

$
3,563

Intangible assets
146

619

Property and equipment
(1,396
)

(770
)
R&D and other tax credits
3,293

2,086

Stock compensation
7,063

4,163

Charitable contributions
—

1

Federal and state basis difference
145

114

Net operating loss
1,763

6,382

Net deferred tax assets
$
15,620

$
16,158

Valuation allowance
(782
)

(16,158
)

$
14,838

$
—

The reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows:

December 31,

2015

2014
Federal statutory rate
34.00
%

34.00
%
State taxes, net of federal benefit
3.33
%

9.58
%
Non deductible compensation
0.63
%

5.59
%
Meals & entertainment
2.27
%

5.55
%
Stock based compensation - ISO
6.39
%

21.73
%
Other
(4.58
)%

(5.92
)%
Valuation allowance
(63.33
)%

(58.73
)%

(21.29
)%

11.80
%

Current and deferred income tax expense (benefit) is as follows (in thousands):

December 31, 2015

December 31, 2014

Current:

   Federal
$
8,452

$
—

   State
1,218

832

      Total current
9,670

832

Deferred:

   Federal
(13,070
)
—

   State
(1,768
)
—

      Total deferred
(14,838
)
—

Total expense
$
(5,168
)
$
832

Income taxes are based on estimates of the annual effective tax rate and evaluations of possible future events and transactions and may be subject to subsequent refinement or revision.
Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely.
As of December 31, 2015, our deferred tax assets were primarily the result of accrued liabilities, equity compensation, and tax credit and net operating loss carryforwards. A valuation allowance of approximately $782,000 and $16,158,000 was recorded against our gross deferred tax asset balance as of December 31, 2015, and December 31, 2014, respectively. For the year ended December 31, 2015, we recorded a net valuation allowance release of $15,376,000 on the basis of management's reassessment of the amount of its deferred tax assets that are more likely than not to be realized.
As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2015, in part because in the current year we achieved three years of cumulative pretax income in the U.S. federal tax jurisdiction, management determined that there is sufficient positive evidence to conclude that it is more likely than not that additional deferred taxes are realizable. It therefore reduced the valuation allowance accordingly.

At December 31, 2015, and December 31, 2014, the Company had income tax net operating loss ("NOL") carryforwards for federal and state purposes of $579,000 and $27,552,000, respectively. If not utilized, the federal and state tax loss carryforwards will expire between 2026 and 2031. The Company has recorded a deferred tax asset for both federal and state NOL carryforwards of approximately $197,000 and approximately $1,566,000, respectively. A valuation allowance remains recorded against the deferred tax asset for certain federal net operating loss carryovers in the amount of $197,000 due to limitations provided by Internal Revenue Code Section 382 and certain state net operating loss carryovers in the amount of $585,000 not expected to be utilized prior to expiration.

The Company's net operating losses and tax credits are subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382. The Company has performed an analysis and determined that the limitation exceeds the utilization of NOLs in the current year and does not anticipate much limitation going forward.

As a result of certain realization requirements of ASC 718, Compensation - Stock Compensation, the table of deferred tax assets and liabilities shown above does not include certain deferred tax assets as of December 31, 2015, and December 31, 2014, that arose directly from (or the use of which was postponed by) tax deductions related to equity compensation that are greater than the compensation recognized for financial reporting. During 2015, deferred tax assets in the amount of $7,757,000 were realized resulting in an increase to equity in the same amount. The Company has approximately $1,661,000 of remaining deferred tax assets that will result in an increase to equity, if and when these deferred tax assets are ultimately realized. The Company uses ASC 740 ordering when determining when excess tax benefits have been realized.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):

December 31, 2015

December 31, 2014

Unrecognized tax benefits - January 1
$
—

$
—

Gross increases - tax positions in current period
170

—

Unrecognized tax benefits - December 31
$
170

$
—

Included in the balance of unrecognized tax benefits as of December 31, 2015 and December 31, 2014, are $170,000 and $0, respectively, of tax benefits that, if recognized, would affect the effective tax rate. Also included in the balance of unrecognized tax benefits as of December 31, 2015 and December 31, 2014, are $170,000 and $0, respectively, of tax benefits that, if recognized, would result in adjustments to other tax accounts, primarily deferred taxes. This amount is recorded in Other Liabilities in the accompanying consolidated balance sheets.
The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, the Company accrued no penalties or interest during 2015, and, in total, as of December 31, 2015 has not recognized any liabilities for penalties or interest. During 2014, we also did not accrue any penalties or interest and, in total, as of December 31, 2014, had not recognized any liability for penalties or interest.

The Company is subject to taxation in the US and various state jurisdictions. As of December 31, 2015, the Company’s tax years for 2012, 2013, 2014 and 2015 are subject to examination by the tax authorities. As of December 31, 2015, the Company is generally no longer subject to US federal, state, or local examinations by tax authorities for years before 2012.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.3.1.900

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities
12 Months Ended

Dec. 31, 2015

Supplemental Cash Flow Elements [Abstract]

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities
Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):

Years Ended December 31,

2015

2014

2013
Cash paid for interest
$
86

$
48

$
36

Income taxes paid
2,293

384

61

Purchases of equipment financed through capital leases
—

—

355

Retirement of fixed assets
319

—

—

Deferred financing costs
504

—

27

APIC related tax adjustments
7,757

—

—

Stock issuance in connection with Earn-Out Liability of 1,174,915 shares
—

—

5,792

Stock issuance in exchange for convertible debt of 5,272,004 shares
—

—

5,272

Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively
164

117

—

Tenant improvement incentive
—

—

997

Legal fees paid for public offering
—

—

102

Legal fees related to public offering included in accounts payable
—

—

30

Legal fees related to public offering included in accrued expenses
—

—

62

X

- Definition
The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
+ Details

Name: us-gaap_CashFlowSupplementalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R22.htm IDEA: XBRL DOCUMENT v3.3.1.900

401k Plan
12 Months Ended

Dec. 31, 2015

Compensation and Retirement Disclosure [Abstract]

401k Plan
401k Plan
The Company has a 401(k) plan (the “Plan”) covering employees who have attained 21 years of age and have completed three months of service. Under the Plan, participants may defer up to 100% of their eligible wages to a maximum of $18,000 per year (annual limit for 2015). Employees age 50 or over in 2015 may make additional pre-tax contributions up to $6,000 above and beyond normal plan and legal limits.  Annually, the Company may elect to match employee contributions up to 6% of the employee’s compensation.  Additionally, the Company may elect to make a discretionary contribution to the Plan. The Company did not provide matching contributions for the years ended December 31, 2015, 2014 and 2013.

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for pension and other postretirement benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 80
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=49170332&loc=SL14450702-114947

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=58740216&loc=d3e2410-114920

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39675-114964

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6414199&loc=d3e39622-114963
+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R23.htm IDEA: XBRL DOCUMENT v3.3.1.900

Commitments and Contingencies
12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies
Contractual Arrangements
In addition to the capital leases noted under Property and Equipment above, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next five years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations.
The estimated annual payments are as follows (in thousands):
Year ended December 31,

2016
$
2,818

2017
2,340

2018
1,766

2019
1,763

2020
352

$
9,039

Rent expense for the years ended December 31, 2015, 2014 and 2013, was approximately $1,317,000, $1,130,000 and $1,000,000, respectively and is allocated among cost of sales, research and development, and selling, general and administrative expenses.
Letters of Credit
As a condition of the leases for the Company's facilities we are obligated under standby letters of credit in the amount of approximately $235,000. These obligations are reduced at various times over the lives of the leases.
FDA Untitled Letter, Draft Guidance and Related Litigation

FDA Untitled Letter and Draft Guidance

On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound.

On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has also indicated that it will hold a public hearing on on a date in 2016 to be determined to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company has requested, and has been granted an opportunity to speak at this hearing.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues in 2015.

Related Litigation

Following the publication of the Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015. On November 19, 2015, the Court preliminarily approved the settlement and has set the final settlement hearing for April 5, 2016.

OIG Subpoena

In the fourth quarter of 2014, the Company received a subpoena from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities. In March 2015, the Company received notice from the Department of Justice that it declined at that time to intervene in the qui tam action that gave rise to the issuance of the subpoena. The qui tam plaintiff had 120 days from the date of the Department of Justice’s notice to proceed with the case. The 120 day period passed without initiation of the lawsuit. The plaintiff, who is an executive at the Company’s competitor Organogenesis, Inc., voluntarily dismissed the lawsuit in July 2015. This dismissal was approved by the Court on October 6, 2015.

Patent Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are three actions pending, as described below:

The Liventa Action

First, there is an action pending against several entities in the in the United States District Court for the Northern District of Georgia, i.e., “the Liventa Action”. On April 22, 2014, the Company filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. The Liventa Action was filed in the United States District Court for the Northern District of Georgia.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity.

On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery.

MiMedx served Infringement Contentions on August 29, 2014, and Defendants served Invalidity Contentions and Responses to Infringement Contentions on September 29, 2014. After a protracted series of meet and confers, MiMedx required Defendants to supplement their invalidity contentions in view of parallel Inter Partes Review ("IPR")(see further discussion, infra) proceedings. MTF complied on June 26, 2015.

In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the ’437 and ’687 Patents, seeking a partial stay of the litigation as to the ’437, ’687, and ’494 Patents (i.e., the ’437 Patent family). MiMedx opposed the Motion to Stay with respect to the ’494 Patent and once again successfully defeated Defendants’ motion to stay.

Claim Construction proceedings began in October 2014. The parties submitted proposed constructions for key terms for the ’701, ’092, ’437, ’687, ’207, and ’494 Patents. Briefing was completed in March 2015.

On December 22, 2015, a Markman Hearing was held before Special Master Sumner C. Rosenberg. Over thirty disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for one term, the Special Master’s Report essentially adopted MiMedx’s proposed constructions. The parties are awaiting a final Court decision pending their respective objections.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. The Bone Bank Action is in an advanced stage. The parties have (i) substantially completed document production; (ii) taken several fact depositions (both party and non-party); and (iii) completed claim construction briefing. The Markman hearing in this case was held on October 2, 2015. Except for one term, the Court adopted MiMedx’s proposed construction of the disputed terms. The parties have submitted a proposed scheduling order to the Court and are awaiting the Court’s order in this regard. Meanwhile, the parties continue with fact discovery in view of recent depositions.

The NuTech Action

Finally, on March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.

On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On November 24, 2015, the court ruled on NuTech’s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement of the ‘494 and ‘687 patents, as well as violations of the Lanham Act; these claims shall proceed.

On December 30, 2015, the parties submitted a Joint Rule 26(f) Report of Parties’ Planning Meeting and Proposed Case Management Order to the Court. In the Report, the parties requested that the Court stay the proceedings with respect to the ’687 patent pending the completion of the inter partes review on that patent.

On January 8, 2016, MiMedx served its infringement contentions. Discovery has recently begun.

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action have challenged the validity of the C ompany's 8,597,687 and 8,709,494 patents (the "'687" and "'494" patents, respectively); while the defendants in the Liventa Action have challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied defendants' request for institution of an IPR with respect to the '494 patent on all seven challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The PTAB also adopted MiMedx's construction of the claims which will govern the Board's review of the '687 patent. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. Briefing and expert discovery is ongoing.

Following the PTAB decisions, the defendants in the Bone Bank Action moved to stay the district court litigation, despite the Court's previous denial of such a stay, pending the outcome of the '687 patent inter partes review. The parties agreed to stay the case with respect to the '687 patent only and the Court denied Bone Bank's motion to stay the litigation with respect to the '494 patent. The Company has also successfully defeated an attempt by defendants in the Liventa Action to stay that litigation -- also pending the outcome of the IPR of the patents at issue in that case.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.3.1.900

Quarterly Financial Data (Unaudited)
12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited) (in thousands except per share data)

First
Quarter

Second
Quarter

Third
Quarter

Fourth
Quarter
NET SALES

2015

$
40,767

$
45,679

$
49,015

$
51,835

2014

19,559

25,573

33,518

39,573

2013

11,556

13,515

16,116

17,994

GROSS MARGIN

2015

$
35,619

$
40,590

$
44,036

$
46,849

2014

16,582

22,833

30,170

35,973

2013

9,651

11,316

14,002

14,883

NET INCOME (LOSS)

2015

$
4,087

$
5,430

$
6,551

$
13,378

2014

(922
)

(390
)

3,700

3,832

2013

(1,620
)

(757
)

(307
)

(1,427
)

NET INCOME (LOSS)
PER COMMON SHARE - BASIC

2015

$
0.04

$
0.05

$
0.06

$
0.13

2014

(0.01
)

—

0.03

0.04

2013

(0.02
)

(0.01
)

—

(0.01
)

NET INCOME (LOSS)
PER COMMON SHARE - DILUTED

2015

$
0.04

$
0.05

$
0.06

$
0.11

2014

(0.01
)

—

0.03

0.03

2013

(0.02
)

(0.01
)

—

(0.01
)

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)-(j)
-URI http://asc.fasb.org/extlink&oid=51825399&loc=d3e1280-108306

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section G
-Subsection 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K (SK)
-Number 229
-Section 302
-Paragraph a
+ Details

Name: us-gaap_QuarterlyFinancialInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.3.1.900

Subsequent Events
12 Months Ended

Dec. 31, 2015

Subsequent Events [Abstract]

Subsequent Events
Subsequent Events

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. The acquisition of Stability was effected by the merger of Stability Inc. into a newly created wholly owned subsidiary of the Company. The new subsidiary was the surviving company in the merger and was subsequently renamed Stability Biologics, LLC ("Stability"). The Company paid $10 million at the closing, comprised of 60% cash and 40% in shares of common stock of MiMedx Group, Inc., assumed approximately $800,000 in debt, and eliminated a $2.4 million receivable related to Company products sold to Stability prior to the acquisition . The Company will also pay future contingent consideration through a two-year earn out arrangement based on the 2016 and 2017 performance of Stability's business. The Company expects the earn out will be the larger portion of the overall consideration for the transaction. The earn out will also be paid in the form of 60% cash and 40% in shares of stock of MiMedx Group, Inc.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.3.1.900

Schedule II - Valuation and Qualifying Accounts
12 Months Ended

Dec. 31, 2015

Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts
Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
Years ended December 31, 2015, 2014 and 2013 (in thousands)

Balance at
Beginning of Year

Additions charged to Expense or Revenue

Deductions
and write-offs

Balance at
End of Year

For the Year ended December 31, 2015

Allowance for doubtful accounts

$
1,750

$
1,698

$
(178
)

$
3,270

Allowance for product returns

841

3,257

(2,836
)

1,262

Allowance for obsolescence

527

540

(670
)

397

For the Year ended December 31, 2014

Allowance for doubtful accounts

$
407

$
1,357

$
(14
)

$
1,750

Allowance for product returns

215

2,215

(1,589
)

841

Allowance for obsolescence

322

405

(200
)

527

For the Year ended December 31, 2013

Allowance for doubtful accounts

$
49

$
391

$
(33
)

$
407

Allowance for product returns

89

917

(791
)

215

Allowance for obsolescence

159

213

(50
)

322

X

- Definition
The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
+ Details

Name: us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ValuationAndQualifyingAccountsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 41 R27.htm IDEA: XBRL DOCUMENT v3.3.1.900

Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period.  Actual results could differ from those estimates.

Principles of Consolidation
Principles of Consolidation
The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., MiMedx Processing Services, LLC (formerly known as SpineMedica, LLC), and MiMedx Tissue Services, LLC (formerly known as Surgical Biologics, LLC). All significant inter-company balances and transactions have been eliminated.

Segment Reporting
Segment Reporting
ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting.  The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment.  Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment.  Thus, discrete financial information is not available for more than one operating segment.

Market Concentrations and Credit Risk
Market Concentrations and Credit Risk
The Company places its cash and cash equivalents on deposit with financial institutions in the United States.  In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts. As of December 31, 2015 and 2014, the Company had cash and cash equivalents of approximately $27,700,000 and $44,600,000, respectively, in excess of the insured amounts.
The Company’s principal market concentration of risk is related to its limited distribution channels. The Company's revenues include the distribution efforts of several independent companies as well as the Company's internal sales force. Significant revenues are derived from the Company's relationship with one of its distributors, AvKare, Inc. which sells our products to the Federal Government.

Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.

Accounts Receivable
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized.  Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.

Investments
Investments
Investments consist of FDIC insured certificates of deposit held at various banks and are classified as either Short term investments or Investments depending on their maturity date and are valued at cost, which approximates market value.

Inventories
Inventories
Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method.  Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes up to when the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates.  Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.

Goodwill and Purchased Intangible Assets
Goodwill and Purchased Intangible Assets
Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss.

Impairment of Intangible Assets with Finite Lives
Impairment of Intangible Assets with Finite Lives
The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets.
Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates.

Property and Equipment
Property and Equipment
Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years.  Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term.

Patent Costs
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company.

Impairment of Long-lived Assets
Impairment of Long-lived Assets
The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated.  If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized.

Grant Income
Grant Income
The Company received a Regional Economic Business Assistance ("REBA") grant in the amount of $250,000 from the State of Georgia to help the Company defray certain expenses and capital expenditures related to the Company's expansion of manufacturing activities in the State.  In order to retain the grant monies the Company was required to add a certain number of full time positions and spend a certain amount on capital and operations expenditures by December 31, 2014. As of December 31, 2013, the Company had satisfied the grant requirements.

Revenue Recognition
Revenue Recognition
The Company sells its products primarily through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets.  The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance.  In cases where the Company utilizes distributors or ships products directly to the end user, it recognizes revenue according to the shipping terms of the agreement provided all revenue recognition criteria have been met.  A portion of the Company’s revenue is generated from inventory maintained at hospitals or with field representatives.  For these products, revenue is recognized at the time the product has been used or implanted.  The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.

Research and Development Costs
Research and Development Costs
Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies.  These costs are expensed as incurred.

Income Taxes
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.
The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

Share-based Compensation
Share-based Compensation
The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award).

Fair Value of Financial Instruments
Fair Value of Financial Instruments
The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates their carrying value based upon current rates available to the Company.

Fair Value Measurements
Fair Value Measurements
The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments.  The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2015, the Company has not chosen to make any such elections.  Fair value financial instruments are recorded in accordance with the fair value measurement framework.
The Company also measures certain non-financial assets at fair value on a non-recurring basis.  These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations.  The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.
The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels.  These levels from highest to lowest priority are as follows:
•
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;
•
Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
•
Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.
The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity.  Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions.  Management’s assumptions could vary depending on the asset or liability valued and the valuation method used.  Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods.  The Company may also engage external advisors to assist it in determining fair value, as appropriate.
Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.

Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements.
In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 13. Prior periods were not retrospectively adjusted.
In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the year ended December 31, 2015, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 203
-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph k
-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02, 03
-Article 3A
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=51717228&loc=d3e202-110218

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section CC
-Subsection 3
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 206
-Paragraph b
-Subparagraph i, ii
-Chapter 2

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a
-Article 5
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2,12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 325
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6872867&loc=d3e40691-111596

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section M
+ Details

Name: us-gaap_InvestmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751
+ Details

Name: us-gaap_LegalCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e4975-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3-5
-Article 5
+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.B.Q1)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section B
-Paragraph Question 1
+ Details

Name: us-gaap_RevenueRecognitionDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition for the sale of goods, which is a transaction between an entity delivering a tangible good to a purchaser. The entity also may disclose its treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.B.Q1)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2197222

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 15
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51677986&loc=d3e47119-111625

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section B
-Paragraph Question 1
+ Details

Name: us-gaap_RevenueRecognitionSalesOfGoods

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R28.htm IDEA: XBRL DOCUMENT v3.3.1.900

Inventories (Tables)
12 Months Ended

Dec. 31, 2015

Inventory Disclosure [Abstract]

Inventory
Inventories consisted of the following items as of December 31, 2015 and 2014 (in thousands):

December 31,

2015

2014
Raw materials
$
602

$
255

Work in process
3,850

3,419

Finished goods
3,405

1,986

Inventory, gross
7,857

5,660

Reserve for obsolescence
(397
)

(527
)
Inventory, net
$
7,460

$
5,133

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 2
-Paragraph 6
-Subparagraph a,b,c
-Article 5
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R29.htm IDEA: XBRL DOCUMENT v3.3.1.900

Property and Equipment (Tables)
12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property and equipment
Property and equipment consist of the following as of December 31, 2015 and 2014 (in thousands):

December 31,

2015

2014
Leasehold improvements
$
2,684

$
2,559

Lab and clean room equipment
4,564

3,040

Furniture and equipment
4,577

2,398

Construction in Progress
2,629

949

Property and equipment, gross
14,454

8,946

Less accumulated depreciation
(4,979
)

(3,499
)
Property and equipment, net
$
9,475

$
5,447

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph b
-Article 5
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R30.htm IDEA: XBRL DOCUMENT v3.3.1.900

Intangible Assets and Royalty Agreement (Tables)
12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible assets activity summary
Intangible assets are summarized as follows (in thousands):

December 31,

2015

2014

Weighted
Average
Amortization
Lives

Cost

Cost
Licenses (a) (b)

10 years

$
1,009

$
1,009

Patents & Know How (b)

17 years

8,001

7,891

Customer & Supplier Relationships (b)

14 years

3,761

3,761

Tradenames & Trademarks (b)

indefinite

1,008

1,008

In Process Research & Development (b)

n/a

25

25

Patents in Process (c)

n/a

1,823

1,082

Total

15,627

14,776

Less Accumulated amortization

(4,864
)

(3,931
)
Net

$
10,763

$
10,845

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.
(c)
Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

Estimated future amortization expense of intangible assets
Expected future amortization of intangible assets as of December 31, 2015, is as follows (in thousands):

Estimated

Amortization
Year ending December 31,
Expense
2016
$
936

2017
846

2018
836

2019
836

2020
836

Thereafter
5,465

$
9,755

X

- Definition
Tabular disclosure of intangible assets activity, which may be broken down by segment or major class.
+ References
No definition available.
+ Details

Name: mdxg_ScheduleOfIntangibleAssetsActivityTableTextBlock

Namespace Prefix: mdxg_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R31.htm IDEA: XBRL DOCUMENT v3.3.1.900

Net Income (loss) Per Share (Tables)
12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

Computation of basic and diluted net loss per share
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data):

Year Ended December 31,

2015

2014

2013
Net income (loss)
$
29,446

$
6,220

$
(4,112
)
Denominator for basic earnings per share - weighted average shares
105,929,205

105,793,008

96,285,504

Effect of dilutive securities: Stock options, warrants, and restricted stock (a)
7,699,277

7,502,496

—

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
113,628,482

113,295,504

96,285,504

Income (loss) per common share - basic
0.28

0.06

(0.04
)
Income (loss) per common share - diluted
$
0.26

$
0.05

$
(0.04
)
(a)Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2015 and 2014 are as follows:

Summary of antidilutive securities
Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2015 and 2014 are as follows:
Effect of dilutive securities:
2015

2014

    Stock Options
7,121,774

7,035,728

    Warrants
33,676

226,926

    Restricted Stock Awards
543,827

239,842

7,699,277

7,502,496

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R32.htm IDEA: XBRL DOCUMENT v3.3.1.900

Equity (Tables)
12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock options activity
Activity with respect to the stock options is summarized as follows:

Number of
Shares

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term
(in years)

Aggregate
Intrinsic
Value
Outstanding at January 1, 2015
16,474,227

$
3.43

Granted
75,100

$
9.66

Exercised
(2,220,881
)

$
2.08

Unvested options forfeited
(239,322
)

$
6.66

Vested options expired
(69,495
)

$
2.61

Outstanding at December 31, 2015
14,019,629

$
3.62

6.5

$
80,740,577

Vested at December 31, 2015
10,951,694

$
2.80

6.2

$
71,955,234

Vested or expected to vest at December 31, 2015 (a)
13,917,122

$
3.60

6.5

$
80,496,150

(a)
Includes forfeiture adjusted unvested shares.

Summary of stock options outstanding and exercisable
Following is a summary of stock options outstanding and exercisable at December 31, 2015:

Options Outstanding

Options Exercisable
Range of Exercise Prices
Number outstanding

Weighted-
Average
Remaining
Contractual
Term
(in years)

Weighted-
Average
Exercise
Price

Number Exercisable

Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

3.4

$
0.72

441,429

$
0.72

$0.87 - $1.35
4,783,304

5.7

1.19

4,783,304

1.19

$1.40 - $2.45
1,641,928

5.1

1.93

1,641,928

1.93

$2.66 - $3.99
957,454

6.8

3.05

907,452

3.00

$4.19 - $6.38
3,552,323

7.4

5.35

2,229,386

5.32

$6.45- $9.78
2,527,525

8.1

7.29

914,703

7.18

  $9.90 - $10.99
115,666

8.9

10.43

33,492

10.50

14,019,629

6.5

$
3.62

10,951,694

$
2.80

Unvested stock options roll forward
A summary of the status of the Company’s unvested stock options as of December 31, 2015 is presented below:
Unvested Stock Options
Number of
Shares

Weighted-
Average
Grant Date Fair Value
Unvested at January 1, 2015
7,193,577

$
3.08

Granted
75,100

$
5.15

Cancelled
(239,322
)

$
3.79

Vested
(3,961,420
)

$
2.53

Unvested at December 31, 2015
3,067,935

$
3.81

Fair value of options valuation assumptions
The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:

Year ended December 31,

2015

2014

2013
Expected volatility
54.35 - 58.14%

58.14 - 64.50%

61.41 - 64.77%

Expected life (in years)
6

6

6

Expected dividend yield
—

—

—

Risk-free interest rate
1.51 - 1.68%

1.64 - 1.96%

0.85 - 1.88%

Restricted stock awards roll forward
Following is summary information for restricted stock awards for the year ended December 31, 2015. Shares vest over a one to three year period. As of December 31, 2015, there was approximately $16,606,000 of total unrecognized stock-based compensation related to time-based, non-vested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.1 years.
Additionally, during the twelve months ended December 31, 2015, 5,172 shares of common stock valued at approximately $57,000 were issued under the 2006 Plan to a consultant in return for services performed.

Number of
Shares

Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2015

1,228,898

$
7.16

Granted

1,974,259

$
9.80

Vested

(517,883
)

$
6.90

Forfeited

(72,007
)

$
9.77

Unvested at December 31, 2015

2,613,267

$
9.14

Allocation of share-based compensation
For the years ended December 31, 2015, 2014, and 2013 the Company recognized stock-based compensation as follows (in thousands):

Year Ended December 31,

2015

2014

2013
Cost of sales
$
352

$
322

$
279

Research and development
790

660

417

Selling, general and administrative
15,754

10,471

5,314

$
16,896

$
11,453

$
6,010

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14
-Section F
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in stock options.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R33.htm IDEA: XBRL DOCUMENT v3.3.1.900

Income Taxes (Tables)
12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Deferred tax assets and liabilities
Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):

December 31,

2015

2014
Deferred tax assets and liabilities:

Accruals and prepaids
$
4,606

$
3,563

Intangible assets
146

619

Property and equipment
(1,396
)

(770
)
R&D and other tax credits
3,293

2,086

Stock compensation
7,063

4,163

Charitable contributions
—

1

Federal and state basis difference
145

114

Net operating loss
1,763

6,382

Net deferred tax assets
$
15,620

$
16,158

Valuation allowance
(782
)

(16,158
)

$
14,838

$
—

Reconciliation of the Federal statutory income tax
The reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows:

December 31,

2015

2014
Federal statutory rate
34.00
%

34.00
%
State taxes, net of federal benefit
3.33
%

9.58
%
Non deductible compensation
0.63
%

5.59
%
Meals & entertainment
2.27
%

5.55
%
Stock based compensation - ISO
6.39
%

21.73
%
Other
(4.58
)%

(5.92
)%
Valuation allowance
(63.33
)%

(58.73
)%

(21.29
)%

11.80
%

Schedule of current and deferred income tax expense (benefit)
Current and deferred income tax expense (benefit) is as follows (in thousands):

December 31, 2015

December 31, 2014

Current:

   Federal
$
8,452

$
—

   State
1,218

832

      Total current
9,670

832

Deferred:

   Federal
(13,070
)
—

   State
(1,768
)
—

      Total deferred
(14,838
)
—

Total expense
$
(5,168
)
$
832

Reconciliation of unrecognized tax benefits
The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):

December 31, 2015

December 31, 2014

Unrecognized tax benefits - January 1
$
—

$
—

Gross increases - tax positions in current period
170

—

Unrecognized tax benefits - December 31
$
170

$
—

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
+ Details

Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 55
-Paragraph 217
-URI http://asc.fasb.org/extlink&oid=51663037&loc=d3e36027-109320

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319
+ Details

Name: us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R34.htm IDEA: XBRL DOCUMENT v3.3.1.900

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables)
12 Months Ended

Dec. 31, 2015

Supplemental Cash Flow Elements [Abstract]

Supplemental disclosure of cash flow and non-cash investing and financing activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):

Years Ended December 31,

2015

2014

2013
Cash paid for interest
$
86

$
48

$
36

Income taxes paid
2,293

384

61

Purchases of equipment financed through capital leases
—

—

355

Retirement of fixed assets
319

—

—

Deferred financing costs
504

—

27

APIC related tax adjustments
7,757

—

—

Stock issuance in connection with Earn-Out Liability of 1,174,915 shares
—

—

5,792

Stock issuance in exchange for convertible debt of 5,272,004 shares
—

—

5,272

Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively
164

117

—

Tenant improvement incentive
—

—

997

Legal fees paid for public offering
—

—

102

Legal fees related to public offering included in accounts payable
—

—

30

Legal fees related to public offering included in accrued expenses
—

—

62

X

- Definition
Tabular disclosure of supplemental cash flow information for the periods presented.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R35.htm IDEA: XBRL DOCUMENT v3.3.1.900

Commitments and Contingencies (Tables)
12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Estimated annual lease, royalty, and employment agreement expenses
The estimated annual payments are as follows (in thousands):
Year ended December 31,

2016
$
2,818

2017
2,340

2018
1,766

2019
1,763

2020
352

$
9,039

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K (SK)
-Number 229
-Section 303
-Paragraph a
-Subparagraph 5
+ Details

Name: us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R36.htm IDEA: XBRL DOCUMENT v3.3.1.900

Quarterly Financial Data (Unaudited) (Tables)
12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Schedule of quarterly financial information

First
Quarter

Second
Quarter

Third
Quarter

Fourth
Quarter
NET SALES

2015

$
40,767

$
45,679

$
49,015

$
51,835

2014

19,559

25,573

33,518

39,573

2013

11,556

13,515

16,116

17,994

GROSS MARGIN

2015

$
35,619

$
40,590

$
44,036

$
46,849

2014

16,582

22,833

30,170

35,973

2013

9,651

11,316

14,002

14,883

NET INCOME (LOSS)

2015

$
4,087

$
5,430

$
6,551

$
13,378

2014

(922
)

(390
)

3,700

3,832

2013

(1,620
)

(757
)

(307
)

(1,427
)

NET INCOME (LOSS)
PER COMMON SHARE - BASIC

2015

$
0.04

$
0.05

$
0.06

$
0.13

2014

(0.01
)

—

0.03

0.04

2013

(0.02
)

(0.01
)

—

(0.01
)

NET INCOME (LOSS)
PER COMMON SHARE - DILUTED

2015

$
0.04

$
0.05

$
0.06

$
0.11

2014

(0.01
)

—

0.03

0.03

2013

(0.02
)

(0.01
)

—

(0.01
)

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)-(j)
-URI http://asc.fasb.org/extlink&oid=51825399&loc=d3e1280-108306
+ Details

Name: us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R37.htm IDEA: XBRL DOCUMENT v3.3.1.900

Nature of Business (Details)
12 Months Ended

Dec. 31, 2015

Business_Segment

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Number of business segments 1

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R38.htm IDEA: XBRL DOCUMENT v3.3.1.900

Significant Accounting Policies (Details)
3 Months Ended 12 Months Ended

Dec. 31, 2013

USD ($)

Dec. 31, 2015

USD ($)

Business_Segment

distributor

Dec. 31, 2014

USD ($)

Dec. 31, 2013

USD ($)

Dec. 31, 2012

USD ($)

Jul. 31, 2010

USD ($)

Market Concentrations and Credit Risk [Line Items]

Number of business segments | Business_Segment 1

FDIC insured amount $ 250,000

Cash and cash equivalents uninsured amount $ 27,700,000 $ 44,600,000

Number of major customers | distributor 1

Impairment of intangible assets $ 368,000 $ 1,800,000

Impairment of Long-lived Assets [Abstract]

Impairment loss $ 30,000

Grant Income [Abstract]

Proceeds from grant 250,000

Patents

Impairment of Long-lived Assets [Abstract]

Intangible assets, net of accumulated amortization $ 851,000 $ 594,000 $ 689,000

Minimum

Property and Equipment [Abstract]

Property and equipment estimated useful life 3 years

Maximum

Property and Equipment [Abstract]

Property and equipment estimated useful life 7 years

Revenue | AvKare

Market Concentrations and Credit Risk [Line Items]

Concentration of risk (percent) 24.00% 34.00% 56.00%

Accounts Receivable | AvKare

Market Concentrations and Credit Risk [Line Items]

Concentration of risk (percent) 26.00% 33.00%

X

- Definition
Refers to the total number of major customers or single external customer that accounts for 10 percent or more of an entity's revenues.
+ References
No definition available.
+ Details

Name: mdxg_NumberOfMajorCustomers

Namespace Prefix: mdxg_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetImpairmentChargesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashFDICInsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashUninsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash received from grantors during the current period related to operating activities. This element represents receipts from a guarantor for the amount of guarantee provided.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromGrantors

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=mdxg_FirstCustomerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R39.htm IDEA: XBRL DOCUMENT v3.3.1.900

Liquidity and Capital Resources (Details) - USD ($)
12 Months Ended

Oct. 12, 2015

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Debt Instrument [Line Items]

Cash and cash equivalents $ 28,486,000 $ 46,582,000 $ 44,078,000 $ 6,754,000

Total current assets 96,310,000 85,677,000

Total current liabilities 26,777,000 18,404,000

Net working capital 69,533,000

Net cash flows from operating activities $ 18,807,000 $ 16,802,000 $ (284,000)

Credit Agreement | Revolving Credit Facility

Debt Instrument [Line Items]

Debt term 3 years

Senior secured revolving credit facility $ 50,000,000

X

- Definition
Current Assets and Liabilities, Net
+ References
No definition available.
+ Details

Name: mdxg_CurrentAssetsandLiabilitiesNet

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdxg_CreditAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R40.htm IDEA: XBRL DOCUMENT v3.3.1.900

Cash Equivalents and Short Term Investments (Details) - USD ($)
$ in Thousands

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Cash and Cash Equivalents [Line Items]

Cash and cash equivalents $ 28,486 $ 46,582 $ 44,078 $ 6,754

Short term investments 3,000 5,750

Certificates of Deposit

Cash and Cash Equivalents [Line Items]

Cash and cash equivalents 1,250

Short term investments $ 3,000 $ 5,750

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Subparagraph g
-Article 7
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R41.htm IDEA: XBRL DOCUMENT v3.3.1.900

Inventories (Details) - USD ($)
$ in Thousands

Dec. 31, 2015

Dec. 31, 2014

Inventory Disclosure [Abstract]

Raw materials $ 602 $ 255

Work in process 3,850 3,419

Finished goods 3,405 1,986

Inventory, gross 7,857 5,660

Reserve for obsolescence (397) (527)

Inventory, net $ 7,460 $ 5,133

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 56 R42.htm IDEA: XBRL DOCUMENT v3.3.1.900

Investments (Details) - USD ($)

Dec. 31, 2015

Dec. 31, 2014

Investment [Line Items]

Investments $ 0 $ 3,250,000

Certificates of Deposit

Investment [Line Items]

Investments $ 0 $ 3,250,000

X

- References
No definition available.
+ Details

Name: invest_InvestmentLineItems

Namespace Prefix: invest_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.1(h))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Investments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R43.htm IDEA: XBRL DOCUMENT v3.3.1.900

Property and Equipment (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Property and equipment [Line Items]

Property and equipment, gross $ 14,454 $ 8,946

Less accumulated depreciation (4,979) (3,499)

Property and equipment, net 9,475 5,447

Other liabilities 1,148 1,526

Depreciation expense 1,799 1,197 $ 637

Leasehold improvements

Property and equipment [Line Items]

Property and equipment, gross 2,684 2,559

Lab and clean room equipment

Property and equipment [Line Items]

Property and equipment, gross 4,564 3,040

Furniture and equipment

Property and equipment [Line Items]

Property and equipment, gross 4,577 2,398

Construction in Progress

Property and equipment [Line Items]

Property and equipment, gross 2,629 $ 949

Capital leases

Property and equipment [Line Items]

Property and equipment, net 427

Other liabilities 133

Leasehold improvements paid for by landlord

Property and equipment [Line Items]

Property and equipment, net $ 1,000

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 8
-Article 7
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdxg_LeaseholdImprovementsPaidbyOthersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R44.htm IDEA: XBRL DOCUMENT v3.3.1.900

Intangible Assets and Royalty Agreement Intangible Asssets Activity Summary (Details) - USD ($)
12 Months Ended

Jan. 29, 2007

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Jan. 05, 2011

Finite-Lived Intangible Assets [Line Items]

Intangible assets, gross carrying value $ 15,627,000 $ 14,776,000

Less Accumulated amortization (4,864,000) (3,931,000)

Intangible Assets, Net 10,763,000 10,845,000

Net book value 9,755,000

Amortization of intangible assets 933,000 928,000 $ 1,054,000

Tradenames & Trademarks

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived 1,008,000 1,008,000

Tradenames & Trademarks | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived $ 1,008,000

In Process Research & Development

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived 25,000 25,000

In Process Research & Development | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived 25,000

Patents in Process

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived $ 1,823,000 1,082,000

Licenses

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives ^[1],[2],[3] 10 years

Gross carrying value ^[1],[2],[3] $ 1,009,000 1,009,000

Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.

Finite-Lived Intangible Assets [Line Items]

Acquisition price $ 996,000

Maximum time of approval 30 days

Contingent payments to licensor $ 200,000

Contingent royalty to be paid to licensor 3.00%

Annual royalty payment $ 50,000

Net book value $ 110,000

Licenses | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value ^[1],[2],[3] 13,000

Patents & Know How

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives 17 years

Gross carrying value $ 8,001,000 7,891,000

Patents & Know How | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value 7,690,000

Finite-lived intangible assets, costs $ 110,000

Customer & Supplier Relationships

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives 14 years

Gross carrying value $ 3,761,000 $ 3,761,000

Customer & Supplier Relationships | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value $ 3,761,000

[1] Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

[2] On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000.

[3] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.

X

- Definition
Royalty payment percentage on all commercial sales revenue from the licensed products.
+ References
No definition available.
+ Details

Name: mdxg_ContingentRoyaltyToBePaidToLicensor

Namespace Prefix: mdxg_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Total of accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance.
+ References
No definition available.
+ Details

Name: mdxg_IntangibleAssetsAccumulatedAmortization

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The maximum amount of time the entity has to obtain approval by the FDA to allow the sale of the product.
+ References
No definition available.
+ Details

Name: mdxg_PeriodOfApprovalMaximum

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275
+ Details

Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from a business combination.
+ References
No definition available.
+ Details

Name: us-gaap_FinitelivedIntangibleAssetsAcquired1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated amortization of intangible assets, excluding goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=mdxg_SurgicalBiologicsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mdxg_PatentsinProcessMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=mdxg_ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R45.htm IDEA: XBRL DOCUMENT v3.3.1.900

Intangible Assets and Royalty Agreement Expected Future Amortization of Intangible Assets (Details)
$ in Thousands

Dec. 31, 2015

USD ($)

Goodwill and Intangible Assets Disclosure [Abstract]

2016 $ 936

2017 846

2018 836

2019 836

2020 836

Thereafter 5,465

Net book value $ 9,755

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R46.htm IDEA: XBRL DOCUMENT v3.3.1.900

Long-Term Debt (Details) - USD ($)
2 Months Ended 12 Months Ended

Oct. 12, 2015

Dec. 31, 2011

Feb. 28, 2013

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Debt Instrument [Line Items]

Placement fee, warrants issued (in shares) 16,493 15,958

Amortization of debt discount $ 0 $ 0 $ 1,328,000

5% Convertible Senior Secured Promissory Note

Debt Instrument [Line Items]

Annual interest rate 5.00% 5.00%

Proceeds from issuance of debt $ 5,000,000

Principal of notes convertible (in shares) 5,000,000

Accrued but unpaid interest (in dollars per share) $ 1.00

Placement fee $ 32,800

Placement fee, warrants issued (in shares) 42,400

Warrant exercise price (in dollars per share) $ 1.09

Fair value of placement fee warrants $ 15,000

Direct costs of sale of notes 47,800

5% Convertible Senior Secured Promissory Note | Chairman and CEO

Debt Instrument [Line Items]

Proceeds from issuance of debt $ 500,000

Loan Agreement

Debt Instrument [Line Items]

Total amount of debt plus accrued interest $ 5,272,000

Convertible secured promissory note to common stock (in shares) 5,272,000

Amortization of debt discount $ 1,328,000

Loan Agreement | Chief Executive Officer

Debt Instrument [Line Items]

Convertible secured promissory note to common stock (in shares) 532,260

Credit Agreement | Revolving Credit Facility

Debt Instrument [Line Items]

Direct costs of sale of notes $ 500,000

Maximum borrowing capacity 50,000,000

Uncommitted incremental facility $ 35,000,000

Debt term 3 years

Credit Agreement | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum

Debt Instrument [Line Items]

Basis spread on variable rate 1.50%

Credit Agreement | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum

Debt Instrument [Line Items]

Basis spread on variable rate 2.25%

X

- Definition
The number of common stock that the holder of the debt instrument would receive if the debt was converted to equity.
+ References
No definition available.
+ Details

Name: mdxg_DebtInstrumentConvertibleNumberOfShares

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line of Credit Facility, Uncommitted Incremental Facility
+ References
No definition available.
+ Details

Name: mdxg_LineofCreditFacilityUncommittedIncrementalFacility

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of placement fees incurred in conjunction with the sale of the convertible senior secured promissory notes.
+ References
No definition available.
+ Details

Name: mdxg_PlacementFee

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Unpaid interest to be considered for conversion in to shares of common stock upon the election of the holder of the note.
+ References
No definition available.
+ Details

Name: mdxg_UnpaidInterestToBeConsideredForConversionInToSharesOfCommonStock

Namespace Prefix: mdxg_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The price of one share of common stock for each warrant.
+ References
No definition available.
+ Details

Name: mdxg_WarrantExercisePrice

Namespace Prefix: mdxg_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).
+ References
No definition available.
+ Details

Name: us-gaap_DebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromIssuanceOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of warrants not settleable in cash classified as equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsNotSettleableInCashFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdxg_FivePercentConvertibleSeniorSecuredPromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdxg_LoanAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdxg_CreditAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R47.htm IDEA: XBRL DOCUMENT v3.3.1.900

Net Income (loss) Per Share Computation of Basic and Dilutive Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Earnings Per Share [Abstract]

Net income (loss) $ 13,378 $ 6,551 $ 5,430 $ 4,087 $ 3,832 $ 3,700 $ (390) $ (922) $ (1,427) $ (307) $ (757) $ (1,620) $ 29,446 $ 6,220 $ (4,112)

Denominator for basic earnings per share - weighted average shares (in shares) 105,929,205 105,793,008 96,285,504

Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (in shares) 7,699,277 7,502,496 0

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) 113,628,482 113,295,504 96,285,504

Income (loss) per common share - basic (in dollars per share) $ 0.13 $ 0.06 $ 0.05 $ 0.04 $ 0.04 $ 0.03 $ 0.00 $ (0.01) $ (0.01) $ 0.00 $ (0.01) $ (0.02) $ 0.28 $ 0.06 $ (0.04)

Income (loss) per common share - diluted (in dollars per share) $ 0.11 $ 0.06 $ 0.05 $ 0.04 $ 0.03 $ 0.03 $ 0.00 $ (0.01) $ (0.01) $ 0.00 $ (0.01) $ (0.02) $ 0.26 $ 0.05 $ (0.04)

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 62 R48.htm IDEA: XBRL DOCUMENT v3.3.1.900

Net Income (loss) Per Share Summary of Antidilutive Securities (Details) - shares
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 7,699,277 7,502,496

Stock Options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 7,121,774 7,035,728

Warrants

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 33,676 226,926

Restricted Stock Awards

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 543,827 239,842

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R49.htm IDEA: XBRL DOCUMENT v3.3.1.900

Common Stock Placements (Details) - Common Stock
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended

Dec. 31, 2013

USD ($)

$ / shares

shares

Dec. 31, 2013

$ / shares

shares

Sale of stocks and warrants [Line Items]

Shares issued (in shares) | shares 5,750,000 5,750,000

Share issue price (in dollars per share) | $ / shares $ 6.80 $ 6.80

Proceeds from shares issued $ 36,704

Legal fees paid for secondary offering $ 194

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: mdxg_SaleOfStocksAndWarrantsLineItems

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R50.htm IDEA: XBRL DOCUMENT v3.3.1.900

Equity Narrative (Details)
12 Months Ended

Dec. 31, 2015

USD ($)

plan

$ / shares

shares

Dec. 31, 2014

USD ($)

$ / shares

shares

Dec. 31, 2013

USD ($)

$ / shares

Nov. 18, 2015

$ / shares

shares

May. 12, 2014

USD ($)

Class of Stock [Line Items]

Number of share-based compensation plans | plan 3

Outstanding assumed options (in shares) | shares 70,000

Number of shares available to be issued (in shares) | shares 26,500,000

Intrinsic value of options exercised $ 17,181,000 $ 10,566,000 $ 8,864,000

Intrinsic value of options vested 10,044,000 $ 6,615,000 $ 3,351,000

Total unrecognized compensation expense $ 6,241,000

Weighted-average grant date fair value for options granted during the period (in dollars per share) | $ / shares $ 5.15 $ 4.18 $ 3.08

Shares issued for services performed (in shares) | shares 16,493 15,958

Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively $ 164,000 $ 117,000 $ 0

Warrants, term 5 years

Authorized share amount for repurchase $ 60,000,000 $ 20,000,000 $ 10,000,000

Stock repurchase (in shares) | shares 4,610,000

Shares repurchased, value $ 40,143,000

Commissions 136,000

Remaining authorizations under the repurchase program, amount $ 14,274,000

Common Stock

Class of Stock [Line Items]

Shares issued for services performed (in shares) | shares 11,321 15,958

Consultant | Common Stock

Class of Stock [Line Items]

Shares issued for services performed (in shares) | shares 5,172

Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively $ 57,000

Restricted Stock

Class of Stock [Line Items]

Total unrecognized stock-based compensation related to time-based, nonvested restricted stock $ 16,606,000

Expenses expected to be recognized over a weighted-average period 2 years 1 month 6 days

Minimum | Restricted Stock

Class of Stock [Line Items]

Vesting period 1 year

Maximum | Restricted Stock

Class of Stock [Line Items]

Vesting period 3 years

Warrants

Class of Stock [Line Items]

Warrants outstanding (in shares) | shares 42,400

Warrants outstanding (in dollars per share) | $ / shares $ 1.09

X

- Definition
The number of share-based compensation the company maintains.
+ References
No definition available.
+ Details

Name: mdxg_NumberOfShareBasedCompensationPlans

Namespace Prefix: mdxg_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of outstanding options assumed by the company.
+ References
No definition available.
+ Details

Name: mdxg_OutstandingAssumedOptions

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Payments of Stock Repurchase Costs
+ References
No definition available.
+ Details

Name: mdxg_PaymentsofStockRepurchaseCosts

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Term of warrants.
+ References
No definition available.
+ Details

Name: mdxg_WarrantsTerm

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount remaining of a stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=mdxg_ConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R51.htm IDEA: XBRL DOCUMENT v3.3.1.900

Equity Activity of Stock Options (Details)
12 Months Ended

Dec. 31, 2015

USD ($)

$ / shares

shares

Number of Shares

Outstanding, beginning of period (in shares) | shares 16,474,227

Granted (in shares) | shares 75,100

Exercised (in shares) | shares (2,220,881)

Unvested options forfeited (in shares) | shares (239,322)

Vested options expired (in shares) | shares (69,495)

Outstanding, end of period (in shares) | shares 14,019,629

Vested at end of period (in shares) | shares 10,951,694

Exercisable options, vested and expected to vest (in shares) | shares 13,917,122 ^[1]

Weighted- Average Exercise Price

Outstanding, weighted average exercise price, beginning of period (in dollars per share) | $ / shares $ 3.43

Granted, weighted average exercise price (in dollars per share) | $ / shares 9.66

Exercised, weighted average exercise price (in dollars per share) | $ / shares 2.08

Unvested options forfeited weighted-average exercise price (in dollars per share) | $ / shares 6.66

Vested options expired weighted-average exercise price (in dollars per share) | $ / shares 2.61

Outstanding, weighted average exercise price, end of period (in dollars per share) | $ / shares 3.62

Vested at end of period weighted average exercise price (in dollars per share) | $ / shares 2.80

Vested and expected to vest, weighted average exercise price (in dollars per share) | $ / shares $ 3.60 ^[1]

Stock options, additional disclosures

Outstanding options, weighted average remaining contractual term 6 years 6 months

Vested at end of period weighted average remaining contractual term 6 years 2 months 12 days

Vested and expected to vest, weighted average remaining contractual term 6 years 6 months ^[1]

Outstanding intrinsic value | $ $ 80,740,577

Vested at end of period aggregate intrinsic value | $ 71,955,234

Vested and expected to vest, aggregate intrinsic value | $ $ 80,496,150 ^[1]

[1] Includes forfeiture adjusted unvested shares.

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28,29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30
-Article 5
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 66 R52.htm IDEA: XBRL DOCUMENT v3.3.1.900

Equity Exercise Price Ranges (Details)
12 Months Ended

Dec. 31, 2015

$ / shares

shares

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of outstanding options (in shares) | shares 14,019,629

Outstanding options, weighted average remaining contractual term 6 years 6 months

Outstanding options, weighted average exercise price (in dollars per share) $ 3.62

Number of exercisable options (in shares) | shares 10,951,694

Exercisable options, weighted average exercise price (in dollars per share) $ 2.80

$0.50 - $0.76

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 0.50

Exercise price range, upper range limit (in dollars per share) $ 0.76

Number of outstanding options (in shares) | shares 441,429

Outstanding options, weighted average remaining contractual term 3 years 4 months 24 days

Outstanding options, weighted average exercise price (in dollars per share) $ 0.72

Number of exercisable options (in shares) | shares 441,429

Exercisable options, weighted average exercise price (in dollars per share) $ 0.72

$0.87 - $1.35

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 0.87

Exercise price range, upper range limit (in dollars per share) $ 1.35

Number of outstanding options (in shares) | shares 4,783,304

Outstanding options, weighted average remaining contractual term 5 years 8 months 12 days

Outstanding options, weighted average exercise price (in dollars per share) $ 1.19

Number of exercisable options (in shares) | shares 4,783,304

Exercisable options, weighted average exercise price (in dollars per share) $ 1.19

$1.40 - $2.45

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 1.40

Exercise price range, upper range limit (in dollars per share) $ 2.45

Number of outstanding options (in shares) | shares 1,641,928

Outstanding options, weighted average remaining contractual term 5 years 1 month 6 days

Outstanding options, weighted average exercise price (in dollars per share) $ 1.93

Number of exercisable options (in shares) | shares 1,641,928

Exercisable options, weighted average exercise price (in dollars per share) $ 1.93

$2.66 - $3.99

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 2.66

Exercise price range, upper range limit (in dollars per share) $ 3.99

Number of outstanding options (in shares) | shares 957,454

Outstanding options, weighted average remaining contractual term 6 years 9 months 18 days

Outstanding options, weighted average exercise price (in dollars per share) $ 3.05

Number of exercisable options (in shares) | shares 907,452

Exercisable options, weighted average exercise price (in dollars per share) $ 3.00

$4.19 - $6.38

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 4.19

Exercise price range, upper range limit (in dollars per share) $ 6.38

Number of outstanding options (in shares) | shares 3,552,323

Outstanding options, weighted average remaining contractual term 7 years 4 months 24 days

Outstanding options, weighted average exercise price (in dollars per share) $ 5.35

Number of exercisable options (in shares) | shares 2,229,386

Exercisable options, weighted average exercise price (in dollars per share) $ 5.32

$6.45- $9.78

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 6.45

Exercise price range, upper range limit (in dollars per share) $ 9.78

Number of outstanding options (in shares) | shares 2,527,525

Outstanding options, weighted average remaining contractual term 8 years 1 month 6 days

Outstanding options, weighted average exercise price (in dollars per share) $ 7.29

Number of exercisable options (in shares) | shares 914,703

Exercisable options, weighted average exercise price (in dollars per share) $ 7.18

$9.90 - $10.99

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 9.90

Exercise price range, upper range limit (in dollars per share) $ 10.99

Number of outstanding options (in shares) | shares 115,666

Outstanding options, weighted average remaining contractual term 8 years 10 months 24 days

Outstanding options, weighted average exercise price (in dollars per share) $ 10.43

Number of exercisable options (in shares) | shares 33,492

Exercisable options, weighted average exercise price (in dollars per share) $ 10.50

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange5Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange6Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange7Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 67 R53.htm IDEA: XBRL DOCUMENT v3.3.1.900

Equity Summary of Unvested Stock Options (Details) - $ / shares
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Number of Shares

Unvested, beginning of period (in shares) 7,193,577

Granted (in shares) 75,100

Cancelled (in shares) (239,322)

Vested (in shares) (3,961,420)

Unvested, end of period (in shares) 3,067,935 7,193,577

Weighted- Average Grant Date Fair Value

Unvested, beginning of period (in dollars per share) $ 3.08

Granted (in dollars per share) 5.15 $ 4.18 $ 3.08

Cancelled (in dollars per share) 3.79

Vested (in dollars per share) 2.53

Unvested, end of period (in dollars per share) $ 3.81 $ 3.08

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of non-vested options forfeited.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of non-vested options forfeited.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 68 R54.htm IDEA: XBRL DOCUMENT v3.3.1.900

Equity Assumptions (Details)
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Fair value options valuation assumptions [Abstract]

Expected life (in years) 6 years 6 years 6 years

Expected dividend yield, percent 0.00% 0.00% 0.00%

Risk-free interest rate, minimum 1.51% 1.64% 0.85%

Risk-free interest rate, maximum 1.68% 1.96% 1.88%

Minimum

Fair value options valuation assumptions [Abstract]

Expected volatility, percent 54.35% 58.14% 61.41%

Maximum

Fair value options valuation assumptions [Abstract]

Expected volatility, percent 58.14% 64.50% 64.77%

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14
-Section D
-Subsection 2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 69 R55.htm IDEA: XBRL DOCUMENT v3.3.1.900

Equity Summary of Restricted Stock Awards (Details) - Restricted Stock
12 Months Ended

Dec. 31, 2015

$ / shares

shares

Number of Shares

Unvested, beginning of period | shares 1,228,898

Granted | shares 1,974,259

Vested | shares (517,883)

Forfeited | shares (72,007)

Unvested, end of period | shares 2,613,267

Weighted- Average Grant Date Fair Value

Unvested, beginning of period (in dollars per share) | $ / shares $ 7.16

Granted (in dollars per share) | $ / shares 9.80

Vested (in dollars per share) | $ / shares 6.90

Forfeited (in dollars per share) | $ / shares 9.77

Unvested, end of period (in dollars per share) | $ / shares $ 9.14

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 70 R56.htm IDEA: XBRL DOCUMENT v3.3.1.900

Equity Recognized Stock-Based Compensation (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Share-based Compensation [Abstract]

Stock-based compensation expense $ 16,896 $ 11,453 $ 6,010

Cost of sales

Share-based Compensation [Abstract]

Stock-based compensation expense 352 322 279

Research and development

Share-based Compensation [Abstract]

Stock-based compensation expense 790 660 417

Selling, general and administrative

Share-based Compensation [Abstract]

Stock-based compensation expense $ 15,754 $ 10,471 $ 5,314

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14
-Section F
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R57.htm IDEA: XBRL DOCUMENT v3.3.1.900

Income Taxes Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands

Dec. 31, 2015

Dec. 31, 2014

Deferred tax assets and liabilities [Abstract]

Accruals and prepaids $ 4,606 $ 3,563

Intangible assets 146 619

Property and equipment (1,396) (770)

R&D and other tax credits 3,293 2,086

Stock compensation 7,063 4,163

Charitable contributions 0 1

Federal and state basis difference 145 114

Net operating loss 1,763 6,382

Net deferred tax assets 15,620 16,158

Valuation allowance (782) (16,158)

Deferred tax assets and liabilities, net of valuation allowance $ 14,838 $ 0

X

- Definition
Deferred Tax Assets, Federal and State Basis Difference
+ References
No definition available.
+ Details

Name: mdxg_DeferredTaxAssetsFederalandStateBasisDifference

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51675352&loc=d3e28680-109314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, before jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=51675352&loc=d3e28680-109314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=51675352&loc=d3e28680-109314

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=51675352&loc=d3e28680-109314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51675352&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 72 R58.htm IDEA: XBRL DOCUMENT v3.3.1.900

Income Taxes Reconciliation of the Federal Statutory Income Tax (Details)
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Federal statutory rate 34.00% 34.00%

State taxes, net of federal benefit 3.33% 9.58%

Non deductible compensation 0.63% 5.59%

Meals & entertainment 2.27% 5.55%

Stock based compensation - ISO 6.39% 21.73%

Other (4.58%) (5.92%)

Valuation allowance (63.33%) (58.73%)

Effective income tax rate (21.29%) 11.80%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.
+ References
No definition available.
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 73 R59.htm IDEA: XBRL DOCUMENT v3.3.1.900

Income Taxes Schedule of current and deferred income tax expense (benefit) (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Current:

Federal $ 8,452 $ 0

State 1,218 832

Total current 9,670 832

Deferred:

Federal (13,070) 0

State (1,768) 0

Total deferred (14,838) 0

Total expense $ (5,168) $ 832 $ 100

X

- Definition
Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Paragraph Question 1-7
+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7
+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7
+ Details

Name: us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 74 R60.htm IDEA: XBRL DOCUMENT v3.3.1.900

Income Taxes Reconciliation of unrecognized tax benefits (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Unrecognized tax benefits, beginning of period $ 0 $ 0

Gross increases - tax positions in current period 170 0

Unrecognized tax benefits, end of period $ 170 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Unrecognized Tax Benefit
-URI http://asc.fasb.org/extlink&oid=6527854
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 75 R61.htm IDEA: XBRL DOCUMENT v3.3.1.900

Income Taxes Narrative (Details) - USD ($)
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Operating Loss Carryforwards [Line Items]

Federal statutory rate 34.00% 34.00%

Valuation allowance $ 782,000 $ 16,158,000

Net valuation allowance release (15,376,000)

Operating loss carry forwards 579,000 27,552,000

Net deferred tax assets 15,620,000 16,158,000

Tax benefit resulted in increase in equity 7,757,000

Stock compensation 1,661,000

Unrecognized tax benefits that would affect effective tax rate 170,000 0

Adjustments to tax accounts 170,000 $ 0

Federal

Operating Loss Carryforwards [Line Items]

Net valuation allowance release (197,000)

Net deferred tax assets 197,000

State

Operating Loss Carryforwards [Line Items]

Valuation allowance 585,000

Net deferred tax assets 1,566,000

Additional Paid-in

Operating Loss Carryforwards [Line Items]

Tax benefit resulted in increase in equity $ 7,757,000

X

- Definition
Deferred Tax Assets that Would Impact Equity, Share-based Compensation
+ References
No definition available.
+ Details

Name: mdxg_DeferredTaxAssetsthatWouldImpactEquitySharebasedCompensation

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Unrecognized Tax Benefits that Would Impact Other Tax Accounts
+ References
No definition available.
+ Details

Name: mdxg_UnrecognizedTaxBenefitsthatWouldImpactOtherTaxAccounts

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, before jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLossCarryforwardsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32123-109318
+ Details

Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 76 R62.htm IDEA: XBRL DOCUMENT v3.3.1.900

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Cash and Cash Equivalents [Line Items]

Cash paid for interest $ 86 $ 48 $ 36

Income taxes paid 2,293 384 61

Purchases of equipment financed through capital leases 0 0 355

Retirement of fixed assets 319 0 0

Deferred financing costs 504 0 27

APIC related tax adjustments 7,757 0 0

Stock issuance in connection with Earn-Out Liability of 1,174,915 shares 0 0 $ 5,792

Stock issued for earn-out liability (in shares) 1,174,915

Stock issuance in exchange for convertible debt of 5,272,004 shares 0 0 $ 5,272

Stock issued for convertible debt (in shares) 5,272,004

Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively $ 164 $ 117 $ 0

Shares issued for services performed (in shares) 16,493 15,958

Tenant improvement incentive $ 0 $ 0 997

Legal fees paid for public offering 0 0 102

Accounts Payable

Cash and Cash Equivalents [Line Items]

Legal fees paid for public offering 0 0 30

Accrued Expenses

Cash and Cash Equivalents [Line Items]

Legal fees paid for public offering $ 0 $ 0 $ 62

X

- Definition
Retirement of Fixed Assets
+ References
No definition available.
+ Details

Name: mdxg_RetirementofFixedAssets

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued during the period for earn-out liability.
+ References
No definition available.
+ Details

Name: mdxg_StockIssuedDuringPeriodSharesForEarnOutLiability

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of shares issued during the period for earn-out liability.
+ References
No definition available.
+ Details

Name: mdxg_StockIssuedDuringPeriodValueForEarnOutLiability

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 8
-Article 9
+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase during the period in capital lease obligations due to entering into new capital leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalLeaseObligationsIncurred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details

Name: us-gaap_IncomeTaxCreditsAndAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.
+ References
No definition available.
+ Details

Name: us-gaap_PaymentsForTenantImprovements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 77 R63.htm IDEA: XBRL DOCUMENT v3.3.1.900

401k Plan (Details)
12 Months Ended

Dec. 31, 2015

USD ($)

Compensation and Retirement Disclosure [Abstract]

Minimum age require to qualify for pension plan 21 years

Minimum service period require to qualify for pension plan 3 months

Maximum wages deferred, percent 100.00%

Maximum eligible wages deferred by participants per year $ 18,000

Minimum age for additional contribution beyond normal plan 50 years

Defined benefit plan, contributions by plan participants $ 6,000

Employer matching contribution, percent 6.00%

X

- Definition
The amount of maximum pre tax contributions made by plan participants. This item represents a periodic increase to the plan obligation and an increase to plan assets.
+ References
No definition available.
+ Details

Name: mdxg_DefinedBenefitPlanMaximumPreTaxContributionsByPlanParticipants

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Maximum percentage of employee eligible wages, deferred by participants under contribution plan.
+ References
No definition available.
+ Details

Name: mdxg_DefinedContributionPlanMaximumPercentageOfEligibleWagesDeferredByParticipants

Namespace Prefix: mdxg_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum eligible wages deferred by participants per year under contribution plan.
+ References
No definition available.
+ Details

Name: mdxg_MaximumEligibleWagesDeferredByParticipantsPerYear

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Minimum age required for additional pre-tax contributions by employee beyond normal plan.
+ References
No definition available.
+ Details

Name: mdxg_MinimumAgeForAdditionalContributionBeyondNormalPlan

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Minimum age required to qualify for pension under the plan.
+ References
No definition available.
+ Details

Name: mdxg_MinimumAgeRequireToQualifyForPensionPlan

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
This line item represents the minimum service period served by the employee require to qualify for pension plan.
+ References
No definition available.
+ Details

Name: mdxg_MinimumServicePeriodRequireToQualifyForPensionPlan

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 78 R64.htm IDEA: XBRL DOCUMENT v3.3.1.900

Commitments and Contingencies Estimated Annual Lease, Royalty, and Employment Agreement Expenses (Details)
$ in Thousands

Dec. 31, 2015

USD ($)

Commitments and Contingencies Disclosure [Abstract]

2016 $ 2,818

2017 2,340

2018 1,766

2019 1,763

2020 352

Total Contractual commitments $ 9,039

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueAfterFifthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueInFourthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueInSecondYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueInThirdYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 79 R65.htm IDEA: XBRL DOCUMENT v3.3.1.900

Commitments and Contingencies Narrative (Details)
$ in Thousands
1 Months Ended 12 Months Ended

Mar. 31, 2015

Dec. 31, 2015

USD ($)

claim

Dec. 31, 2014

USD ($)

Dec. 31, 2013

USD ($)

Dec. 30, 2015

term

Dec. 22, 2015

term

Oct. 02, 2015

term

Aug. 18, 2015

claim

Jul. 10, 2015

claim

Jun. 29, 2015

claim

Loss Contingencies [Line Items]

Lessee expiration period (years) 5 years

Rent and operating leases expense | $ $ 1,317 $ 1,130 $ 1,000

Period for plaintiff to proceed with case (days) 120 days

Product Concentration Risk | Sales Revenue, Net

Loss Contingencies [Line Items]

Percentage of revenue (percent) 12.00%

Letters of Credit

Loss Contingencies [Line Items]

Standby letters of credit | $ $ 235

Pending Litigation [Member]

Loss Contingencies [Line Items]

Number of pending claims 3

Liventa Action [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Number of dispute claim terms at issue | term 1 30

Liventa Action, 701 Patent [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Number of pending claims 6

Liventa Action, 437 Patent [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Number of pending claims 7

Opinion allowing a review of patent, number 1

Bone Bank Action [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Number of pending claims 5 7

Number of dispute claim terms at issue | term 1

Opinion allowing a review of patent, number 2

X

- Definition
Loss Contingency Pending Claims Number Allowed for Review
+ References
No definition available.
+ Details

Name: mdxg_LossContingencyPendingClaimsAllowedforReviewNumber

Namespace Prefix: mdxg_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Loss Contingency, Pending Disputed Claim Terms, Number
+ References
No definition available.
+ Details

Name: mdxg_LossContingencyPendingDisputedClaimTermsNumber

Namespace Prefix: mdxg_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Loss Contingency, Period for Plaintiff to Proceed
+ References
No definition available.
+ Details

Name: mdxg_LossContingencyPeriodforPlaintifftoProceed

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.
+ References
No definition available.
+ Details

Name: us-gaap_LettersOfCreditOutstandingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of pending claims pertaining to a loss contingency.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349
+ Details

Name: us-gaap_LossContingencyPendingClaimsNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_StandbyLettersOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=mdxg_LiventaActionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=mdxg_LiventaAction701PatentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=mdxg_LiventaAction437PatentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=mdxg_BoneBankActionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 80 R66.htm IDEA: XBRL DOCUMENT v3.3.1.900

Quarterly Financial Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

NET SALES $ 51,835 $ 49,015 $ 45,679 $ 40,767 $ 39,573 $ 33,518 $ 25,573 $ 19,559 $ 17,994 $ 16,116 $ 13,515 $ 11,556 $ 187,296 $ 118,223 $ 59,181

GROSS MARGIN 46,849 44,036 40,590 35,619 35,973 30,170 22,833 16,582 14,883 14,002 11,316 9,651 167,094 105,558 49,853

NET INCOME (LOSS) $ 13,378 $ 6,551 $ 5,430 $ 4,087 $ 3,832 $ 3,700 $ (390) $ (922) $ (1,427) $ (307) $ (757) $ (1,620) $ 29,446 $ 6,220 $ (4,112)

Net income (loss) per common share - basic (in dollars per share) $ 0.13 $ 0.06 $ 0.05 $ 0.04 $ 0.04 $ 0.03 $ 0.00 $ (0.01) $ (0.01) $ 0.00 $ (0.01) $ (0.02) $ 0.28 $ 0.06 $ (0.04)

Net income (loss) per common share - diluted (in dollars per share) $ 0.11 $ 0.06 $ 0.05 $ 0.04 $ 0.03 $ 0.03 $ 0.00 $ (0.01) $ (0.01) $ 0.00 $ (0.01) $ (0.02) $ 0.26 $ 0.05 $ (0.04)

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 81 R67.htm IDEA: XBRL DOCUMENT v3.3.1.900

Subsequent Events (Details) - Stability Biologics, LLC [Member] - Subsequent Event
$ in Thousands

Jan. 13, 2016

USD ($)

Subsequent Event [Line Items]

Consideration transferred for business acquired $ 10,000

Payments to acquire businesses paid in cash (percent) 60.00%

Payments to acquire businesses paid in shares of common stock (percent) 40.00%

Debt assumed $ 800

Amount of receivable eliminated $ 2,400

Contingent consideration earn out arrangement term (in years) 2 years

Earn out to be paid in cash (percent) 60.00%

Earn out to be paid in shares of common stock (percent) 40.00%

X

- Definition
Business Combination, Consideration Transferred, Paid in Cash, Percent
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationConsiderationTransferredPaidinCashPercent

Namespace Prefix: mdxg_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Business Combination, Consideration Transferred, Paid in Common Stock, Percent
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationConsiderationTransferredPaidinCommonStockPercent

Namespace Prefix: mdxg_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Business Combination, Consideration Transferred, Receivable Write-offs
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationConsiderationTransferredReceivableWriteoffs

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Business Combination, Contingent Consideration Arrangements, Term
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationContingentConsiderationArrangementsTerm

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Business Combination, Contingent Consideration Arrangements to Be Settled In Cash, Percent
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationContingentConsiderationArrangementstoBeSettledInCashPercent

Namespace Prefix: mdxg_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Business Combination, Contingent Consideration Arrangements to Be Settled In Shares Of Common Stock, Percent
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationContingentConsiderationArrangementstoBeSettledInSharesOfCommonStockPercent

Namespace Prefix: mdxg_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdxg_StabilityBiologicsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 82 R68.htm IDEA: XBRL DOCUMENT v3.3.1.900

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Allowance for doubtful accounts

Movement in Valuation Allowances and Reserves [Roll Forward]

Balance at Beginning of Year $ 1,750 $ 407 $ 49

Additions charged to Expense or Revenue 1,698 1,357 391

Deductions and write-offs (178) (14) (33)

Balance at End of Year 3,270 1,750 407

Allowance for product returns

Movement in Valuation Allowances and Reserves [Roll Forward]

Balance at Beginning of Year 841 215 89

Additions charged to Expense or Revenue 3,257 2,215 917

Deductions and write-offs (2,836) (1,589) (791)

Balance at End of Year 1,262 841 215

Allowance for obsolescence

Movement in Valuation Allowances and Reserves [Roll Forward]

Balance at Beginning of Year 527 322 159

Additions charged to Expense or Revenue 540 405 213

Deductions and write-offs (670) (200) (50)

Balance at End of Year $ 397 $ 527 $ 322

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_MovementInValuationAllowancesAndReservesRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
+ Details

Name: us-gaap_ValuationAllowancesAndReservesBalance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, charged to costs and expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
+ Details

Name: us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12
+ Details

Name: us-gaap_ValuationAllowancesAndReservesDeductions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForDoubtfulAccountsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForSalesReturnsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=mdxg_AllowanceforObsolescenceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 83 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 191 361 1 true 65 0 false 9 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://mimedx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://mimedx.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mimedx.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://mimedx.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://mimedx.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1003501 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://mimedx.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mimedx.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - Nature of Business Sheet http://mimedx.com/role/NatureOfBusiness Nature of Business Notes 8 false false R9.htm 2102100 - Disclosure - Significant Accounting Policies Sheet http://mimedx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 2103100 - Disclosure - Liquidity and Capital Resources Sheet http://mimedx.com/role/LiquidityAndCapitalResources Liquidity and Capital Resources Notes 10 false false R11.htm 2104100 - Disclosure - Cash Equivalents and Short Term Investments Sheet http://mimedx.com/role/CashEquivalentsAndShortTermInvestments Cash Equivalents and Short Term Investments Notes 11 false false R12.htm 2105100 - Disclosure - Inventories Sheet http://mimedx.com/role/Inventories Inventories Notes 12 false false R13.htm 2106100 - Disclosure - Investments Sheet http://mimedx.com/role/Investments Investments Notes 13 false false R14.htm 2107100 - Disclosure - Property and Equipment Sheet http://mimedx.com/role/PropertyAndEquipment Property and Equipment Notes 14 false false R15.htm 2108100 - Disclosure - Intangible Assets and Royalty Agreement Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreement Intangible Assets and Royalty Agreement Notes 15 false false R16.htm 2109100 - Disclosure - Long-Term Debt Sheet http://mimedx.com/role/LongTermDebt Long-Term Debt Notes 16 false false R17.htm 2110100 - Disclosure - Net Income (loss) Per Share Sheet http://mimedx.com/role/NetIncomeLossPerShare Net Income (loss) Per Share Notes 17 false false R18.htm 2155100 - Disclosure - Common Stock Placements Sheet http://mimedx.com/role/CommonStockPlacements Common Stock Placements Notes 18 false false R19.htm 2160100 - Disclosure - Equity Sheet http://mimedx.com/role/Equity Equity Notes 19 false false R20.htm 2165100 - Disclosure - Income Taxes Sheet http://mimedx.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2170100 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities Notes 21 false false R22.htm 2185100 - Disclosure - 401k Plan Sheet http://mimedx.com/role/A401KPlan 401k Plan Notes 22 false false R23.htm 2186100 - Disclosure - Commitments and Contingencies Sheet http://mimedx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 23 false false R24.htm 2187100 - Disclosure - Quarterly Financial Data (Unaudited) Sheet http://mimedx.com/role/QuarterlyFinancialDataUnaudited Quarterly Financial Data (Unaudited) Notes 24 false false R25.htm 2188100 - Disclosure - Subsequent Events Sheet http://mimedx.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 2189100 - Schedule - Schedule II - Valuation and Qualifying Accounts Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II - Valuation and Qualifying Accounts Uncategorized 26 false false R27.htm 2202201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mimedx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Uncategorized 27 false false R28.htm 2305301 - Disclosure - Inventories (Tables) Sheet http://mimedx.com/role/InventoriesTables Inventories (Tables) Uncategorized 28 false false R29.htm 2307301 - Disclosure - Property and Equipment (Tables) Sheet http://mimedx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Uncategorized 29 false false R30.htm 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementTables Intangible Assets and Royalty Agreement (Tables) Uncategorized 30 false false R31.htm 2310301 - Disclosure - Net Income (loss) Per Share (Tables) Sheet http://mimedx.com/role/NetIncomeLossPerShareTables Net Income (loss) Per Share (Tables) Uncategorized 31 false false R32.htm 2360301 - Disclosure - Equity (Tables) Sheet http://mimedx.com/role/EquityTables Equity (Tables) Uncategorized 32 false false R33.htm 2365301 - Disclosure - Income Taxes (Tables) Sheet http://mimedx.com/role/IncomeTaxesTables Income Taxes (Tables) Uncategorized 33 false false R34.htm 2370301 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables) Uncategorized 34 false false R35.htm 2386301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://mimedx.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Uncategorized 35 false false R36.htm 2387301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) Sheet http://mimedx.com/role/QuarterlyFinancialDataUnauditedTables Quarterly Financial Data (Unaudited) (Tables) Uncategorized 36 false false R37.htm 2401401 - Disclosure - Nature of Business (Details) Sheet http://mimedx.com/role/NatureOfBusinessDetails Nature of Business (Details) Uncategorized 37 false false R38.htm 2402402 - Disclosure - Significant Accounting Policies (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Uncategorized 38 false false R39.htm 2403401 - Disclosure - Liquidity and Capital Resources (Details) Sheet http://mimedx.com/role/LiquidityAndCapitalResourcesDetails Liquidity and Capital Resources (Details) Uncategorized 39 false false R40.htm 2404401 - Disclosure - Cash Equivalents and Short Term Investments (Details) Sheet http://mimedx.com/role/CashEquivalentsAndShortTermInvestmentsDetails Cash Equivalents and Short Term Investments (Details) Uncategorized 40 false false R41.htm 2405402 - Disclosure - Inventories (Details) Sheet http://mimedx.com/role/InventoriesDetails Inventories (Details) Uncategorized 41 false false R42.htm 2406401 - Disclosure - Investments (Details) Sheet http://mimedx.com/role/InvestmentsDetails Investments (Details) Uncategorized 42 false false R43.htm 2407402 - Disclosure - Property and Equipment (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Uncategorized 43 false false R44.htm 2408402 - Disclosure - Intangible Assets and Royalty Agreement Intangible Asssets Activity Summary (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementIntangibleAsssetsActivitySummaryDetails Intangible Assets and Royalty Agreement Intangible Asssets Activity Summary (Details) Uncategorized 44 false false R45.htm 2408403 - Disclosure - Intangible Assets and Royalty Agreement Expected Future Amortization of Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementExpectedFutureAmortizationOfIntangibleAssetsDetails Intangible Assets and Royalty Agreement Expected Future Amortization of Intangible Assets (Details) Uncategorized 45 false false R46.htm 2409401 - Disclosure - Long-Term Debt (Details) Sheet http://mimedx.com/role/LongTermDebtDetails Long-Term Debt (Details) Uncategorized 46 false false R47.htm 2410402 - Disclosure - Net Income (loss) Per Share Computation of Basic and Dilutive Net Loss per Share (Details) Sheet http://mimedx.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutiveNetLossPerShareDetails Net Income (loss) Per Share Computation of Basic and Dilutive Net Loss per Share (Details) Uncategorized 47 false false R48.htm 2410403 - Disclosure - Net Income (loss) Per Share Summary of Antidilutive Securities (Details) Sheet http://mimedx.com/role/NetIncomeLossPerShareSummaryOfAntidilutiveSecuritiesDetails Net Income (loss) Per Share Summary of Antidilutive Securities (Details) Uncategorized 48 false false R49.htm 2455401 - Disclosure - Common Stock Placements (Details) Sheet http://mimedx.com/role/CommonStockPlacementsDetails Common Stock Placements (Details) Uncategorized 49 false false R50.htm 2460402 - Disclosure - Equity Narrative (Details) Sheet http://mimedx.com/role/EquityNarrativeDetails Equity Narrative (Details) Uncategorized 50 false false R51.htm 2460403 - Disclosure - Equity Activity of Stock Options (Details) Sheet http://mimedx.com/role/EquityActivityOfStockOptionsDetails Equity Activity of Stock Options (Details) Uncategorized 51 false false R52.htm 2460404 - Disclosure - Equity Exercise Price Ranges (Details) Sheet http://mimedx.com/role/EquityExercisePriceRangesDetails Equity Exercise Price Ranges (Details) Uncategorized 52 false false R53.htm 2460405 - Disclosure - Equity Summary of Unvested Stock Options (Details) Sheet http://mimedx.com/role/EquitySummaryOfUnvestedStockOptionsDetails Equity Summary of Unvested Stock Options (Details) Uncategorized 53 false false R54.htm 2460406 - Disclosure - Equity Assumptions (Details) Sheet http://mimedx.com/role/EquityAssumptionsDetails Equity Assumptions (Details) Uncategorized 54 false false R55.htm 2460407 - Disclosure - Equity Summary of Restricted Stock Awards (Details) Sheet http://mimedx.com/role/EquitySummaryOfRestrictedStockAwardsDetails Equity Summary of Restricted Stock Awards (Details) Uncategorized 55 false false R56.htm 2460408 - Disclosure - Equity Recognized Stock-Based Compensation (Details) Sheet http://mimedx.com/role/EquityRecognizedStockBasedCompensationDetails Equity Recognized Stock-Based Compensation (Details) Uncategorized 56 false false R57.htm 2465402 - Disclosure - Income Taxes Deferred Tax Assets and Liabilities (Details) Sheet http://mimedx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails Income Taxes Deferred Tax Assets and Liabilities (Details) Uncategorized 57 false false R58.htm 2465403 - Disclosure - Income Taxes Reconciliation of the Federal Statutory Income Tax (Details) Sheet http://mimedx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxDetails Income Taxes Reconciliation of the Federal Statutory Income Tax (Details) Uncategorized 58 false false R59.htm 2465404 - Disclosure - Income Taxes Schedule of current and deferred income tax expense (benefit) (Details) Sheet http://mimedx.com/role/IncomeTaxesScheduleOfCurrentAndDeferredIncomeTaxExpenseBenefitDetails Income Taxes Schedule of current and deferred income tax expense (benefit) (Details) Uncategorized 59 false false R60.htm 2465405 - Disclosure - Income Taxes Reconciliation of unrecognized tax benefits (Details) Sheet http://mimedx.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails Income Taxes Reconciliation of unrecognized tax benefits (Details) Uncategorized 60 false false R61.htm 2465406 - Disclosure - Income Taxes Narrative (Details) Sheet http://mimedx.com/role/IncomeTaxesNarrativeDetails Income Taxes Narrative (Details) Uncategorized 61 false false R62.htm 2470402 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) Uncategorized 62 false false R63.htm 2485401 - Disclosure - 401k Plan (Details) Sheet http://mimedx.com/role/A401KPlanDetails 401k Plan (Details) Uncategorized 63 false false R64.htm 2486402 - Disclosure - Commitments and Contingencies Estimated Annual Lease, Royalty, and Employment Agreement Expenses (Details) Sheet http://mimedx.com/role/CommitmentsAndContingenciesEstimatedAnnualLeaseRoyaltyAndEmploymentAgreementExpensesDetails Commitments and Contingencies Estimated Annual Lease, Royalty, and Employment Agreement Expenses (Details) Uncategorized 64 false false R65.htm 2486403 - Disclosure - Commitments and Contingencies Narrative (Details) Sheet http://mimedx.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies Narrative (Details) Uncategorized 65 false false R66.htm 2487402 - Disclosure - Quarterly Financial Data (Unaudited) (Details) Sheet http://mimedx.com/role/QuarterlyFinancialDataUnauditedDetails Quarterly Financial Data (Unaudited) (Details) Uncategorized 66 false false R67.htm 2488401 - Disclosure - Subsequent Events (Details) Sheet http://mimedx.com/role/SubsequentEventsDetails Subsequent Events (Details) Uncategorized 67 false false R68.htm 2489401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Uncategorized 68 false false All Reports Book All Reports mdxg-20151231.xml mdxg-20151231.xsd mdxg-20151231_cal.xml mdxg-20151231_def.xml mdxg-20151231_lab.xml mdxg-20151231_pre.xml true true ZIP 89 0001376339-16-000138-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-16-000138-xbrl.zip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
(%4(AYJ MS;@M!4:J8??\ 5)K6D"K+3\55N?;\C^\XW95U]4WWASOVUVYO@/K? =N>(N" M]1W[*_8+O!E!#IJ'8EW>ENS?QP8'^:[:W[$O&^YOR=\KV+>-$*J'X=UL_B]& MP8'_?MW^ZZ[:LAQPU7YJ\3V_?]@65^#FL ?LL\"VO"_Y>;5]=772!OR_&K"N M[N_9)S;[:OVG?@MNI9UQ\39EUV%B ZFK!KPP]%1)JV35.?V[(21(W MX)>M9DGL!+$' S\;#(5A[ KKI=K'6U;,OEF\BF8JTB6@FO:9DM/-YR2I**7-\F95VL^>D6 M>L=/ZN:[P2A*0AS&<4!2ZF(7X0P'@]'(D[M=4=.4;:'MT717=*37YAOHR51?6J0UQO(S5:E/.5%:>0\G>A'=E<9M^ M9Q/T/9O 7]_>ENOQMJXTB-P4D=1'68@)C!+DC!8I#>6NI]:P8UVC�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

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
Document and Entity Information - USD ($) $ in Thousands	Dec. 31, 2015	Feb. 10, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	MIMEDX GROUP, INC.
Entity Central Index Key	0001376339
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		107,810,490
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,135,614

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 28,486	$ 46,582
Short term investments	3,000	5,750
Accounts receivable, net	53,755	26,672
Inventory, net	7,460	5,133
Prepaid expenses and other current assets	3,609	1,540
Total current assets	96,310	85,677
Investments	0	3,250
Property and equipment, net of accumulated depreciation	9,475	5,447
Goodwill	4,040	4,040
Intangible assets, net of accumulated amortization	10,763	10,845
Deferred tax asset, net	14,838	0
Deferred financing costs and other assets	487	0
Total assets	135,913	109,259
Current liabilities:
Accounts payable	6,633	3,661
Accrued compensation	15,034	11,523
Accrued expenses	4,644	2,504
Other current liabilities	466	716
Total current liabilities	26,777	18,404
Other liabilities	1,148	1,526
Total liabilities	$ 27,925	$ 19,930
Commitments and contingencies
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	$ 0	$ 0
Common stock; $0.001 par value; 150,000,000 shares authorized; 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 and 108,776,247 issued and 107,789,611 outstanding at December 31, 2014	109	108
Additional paid-in capital	163,133	162,433
Treasury stock at cost: 2,105,945 shares at December 31, 2015 and 986,636 shares at December 31, 2014	(17,125)	(5,637)
Accumulated deficit	(38,129)	(67,575)
Total stockholders' equity	107,988	89,329
Total liabilities and stockholders' equity	$ 135,913	$ 109,259

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	109,467,416	108,776,247
Common stock, shares outstanding (in shares)	107,361,471	107,789,611
Treasury stock, shares (in shares)	2,105,945	986,636

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net sales	$ 187,296	$ 118,223	$ 59,181
Cost of sales	20,202	12,665	9,328
Gross margin	167,094	105,558	49,853
Operating expenses:
Research and development expenses	8,413	7,050	4,843
Selling, general and administrative expenses	133,384	90,480	46,227
Impairment of intangible assets	0	0	368
Amortization of intangible assets	933	928	1,054
Operating income (loss)	24,364	7,100	(2,639)
Other income (expense), net
Amortization of debt discount	0	0	(1,328)
Interest expense, net	(86)	(48)	(45)
Income (loss) before income tax provision	24,278	7,052	(4,012)
Income tax provision	5,168	(832)	(100)
Net income (loss)	$ 29,446	$ 6,220	$ (4,112)
Net income (loss) per common share - basic (in dollars per share)	$ 0.28	$ 0.06	$ (0.04)
Net income (loss) per common share - diluted (in dollars per share)	$ 0.26	$ 0.05	$ (0.04)
Weighted average shares outstanding - basic (in shares)	105,929,205	105,793,008	96,285,504
Weighted average shares outstanding - diluted (in shares)	113,628,482	113,295,504	96,285,504

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in	Treasury Stock	Accumulated Deficit
Balance, beginning of period at Dec. 31, 2012	$ 20,007	$ 88	$ 89,627	$ (25)	$ (69,683)
Balance, beginning of period (in shares) at Dec. 31, 2012		88,423,169		50,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,010		6,010
Exercise of stock options	1,981	$ 2	1,979
Exercise of stock options (in shares)		1,958,674
Exercise of warrants	2,108	$ 2	2,106
Exercise of warrants (in shares)		1,844,352
Common stock issued for 5% convertible note	$ 5,272	$ 5	5,267
Common stock issued for 5% convertible note (in shares)	5,272,004	5,272,004
Common stock issued for earn - out liability	$ 5,792	$ 1	5,791
Common stock issued for earn-out liability (in shares)	1,174,915	1,174,915
Issuance of restricted stock	$ 0
Issuance of restricted stock (in shares)		2,500
Public offering of common stock, net of expenses	36,510	$ 6	36,504
Public offering of common stock, net of expenses (in shares)		5,750,000
Shares issued for services performed	0
Net income (loss)	(4,112)				(4,112)
Balance, end of period at Dec. 31, 2013	73,568	$ 104	147,284	$ (25)	(73,795)
Balance, end of period (in shares) at Dec. 31, 2013		104,425,614		50,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	11,453		11,453
Exercise of stock options	2,470	$ 2	2,468
Exercise of stock options (in shares)		1,653,690
Exercise of warrants	1,113	$ 1	1,112
Exercise of warrants (in shares)		1,242,416
Common stock issued for 5% convertible note	0
Common stock issued for earn - out liability	0
Issuance of restricted stock	0	$ 1	(1)
Issuance of restricted stock (in shares)		1,438,569
Shares issued for services performed	$ 117		117
Shares issued for services performed (in shares)	15,958	15,958
Stock repurchase	$ (5,612)			$ (5,612)
Stock repurchase (in shares)				936,636
Net income (loss)	6,220				6,220
Balance, end of period at Dec. 31, 2014	89,329	$ 108	162,433	$ (5,637)	(67,575)
Balance, end of period (in shares) at Dec. 31, 2014		108,776,247		986,636
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	16,896		16,896
Tax benefit of share-based compensation expense	7,757		7,757
Exercise of stock options	$ 4,629	$ 1	(9,792)	$ 14,420
Exercise of stock options (in shares)	2,220,881	647,656		(1,573,225)
Exercise of warrants	$ 46		(379)	$ 425
Exercise of warrants (in shares)				(42,400)
Common stock issued for 5% convertible note	0
Common stock issued for earn - out liability	0
Issuance of restricted stock	0		(14,547)	$ 14,547
Issuance of restricted stock (in shares)		34,250		(1,940,009)
Restricted stock shares canceled/forfeited	$ 0		652	$ (652)
Restricted stock shares canceled/forfeited (in shares)	69,949	(2,058)
Shares issued for services performed	$ 164		113	$ 51
Shares issued for services performed (in shares)	16,493	11,321		(5,172)
Stock repurchase	$ (40,279)			$ (40,279)
Stock repurchase (in shares)	4,610,000			4,610,166
Net income (loss)	$ 29,446				29,446
Balance, end of period at Dec. 31, 2015	$ 107,988	$ 109	$ 163,133	$ (17,125)	$ (38,129)
Balance, end of period (in shares) at Dec. 31, 2015		109,467,416		2,105,945

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)	Dec. 31, 2013	Dec. 31, 2011
5% Convertible Senior Secured Promissory Note
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Convertible note	5.00%	5.00%

Nature of Business	12 Months Ended
Nature of Business	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	Nature of Business MiMedx Group, Inc. (“MiMedx,” "the Company,” “we,” or “us”) operates in one business segment, Regenerative Biomaterials, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix and EpiFix, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology CollaFix,which the Company has yet to commercialize. The Company is focused primarily on the United States but is actively exploring international expansion opportunities. The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.

Liquidity and Capital Resources	12 Months Ended
Liquidity and Capital Resources	Dec. 31, 2015
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	Liquidity and Capital Resources Net Working Capital As of December 31, 2015, the Company had approximately $28,486,000 of cash and cash equivalents. The Company reported total current assets of approximately $96,310,000 and current liabilities of approximately $26,777,000 and had net working capital of approximately $69,533,000. Overall Liquidity and Capital Resources The Company's largest cash requirement for the twelve months ended December 31, 2015 was cash for general working capital needs. In addition, the Company's other cash requirements included capital expenditures, and repurchases of the Company's common stock. The Company funded its cash requirements through its existing cash reserves, and its operating activities which generated approximately $18,807,000 during the period. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents as well as its investments in FDIC insured certificates of deposit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year. In addition, on October 12, 2015, the Company entered into a new three-year $50 million senior secured revolving credit facility, which provides additional liquidity.

Cash Equivalents and Short Term Investments	12 Months Ended
Cash Equivalents and Short Term Investments	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash Equivalent and Short Term Investments	Cash Equivalents and Short Term Investments Included in Cash and cash equivalents as of December 31, 2014, were approximately $1,250,000 of FDIC insured certificates of deposit held with various U.S. financial institutions. Short term investments at December 31, 2015 and 2014 consist of approximately $3,000,000 and $5,750,000, respectively, of FDIC insured certificates of deposits held with various financial institutions. The cost of these instruments approximates their fair market value.

Investments	12 Months Ended
Investments	Dec. 31, 2015
Investments, All Other Investments [Abstract]
Investments	Investments Investments consisted of FDIC insured certificates of deposit with various U.S. financial institutions. The balance as of December 31, 2015 was zero and the balance as of December 31, 2014 was approximately $3,250,000 and the cost approximated fair market value. Maturities of these instruments range to May of 2016.

Long-Term Debt	12 Months Ended
Long-Term Debt	Dec. 31, 2015
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Senior Secured Promissory Notes From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000. The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO. In total, the principal of the Notes were convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) plus accrued but unpaid interest at $1.00 per share at any time upon the election of the holder of the note. In conjunction with the sale of the Notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share. These warrants were exercised in November 2015. The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique. The total direct costs of approximately $47,800 were recorded as deferred financing costs and were amortized over the term of the Notes using the effective interest method. Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP. During the months of January and February 2013, all holders of the Notes converted their interest in this obligation to shares of MiMedx common stock. The total amount of debt plus accrued interest that was exchanged was approximately $5,272,000. In conjunction with this exchange, approximately 5,272,000 shares of the Company’s common stock were issued in full satisfaction of this obligation. Included in this total are 532,260 shares representing the CEO’s conversion of his Note. This also resulted in the acceleration of amortization of debt discount and total interest expense of approximately $1,328,000 during the year ended December 31, 2013. Credit Facility On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%. Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary representations, warranties, covenants, and events of default. As of December 31, 2015, there were no outstanding revolving loans under the credit facility.

Common Stock Placements	12 Months Ended
Common Stock Placements	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Common Stock Placements	Common Stock Placements Public Offering of Common Stock In December of 2013, the Company completed a public offering (the "Offering”) of 5,750,000 shares of its common stock at $6.80 per share. Proceeds from the Offering, net of underwriting expenses were $36,704,000. In addition, the Company incurred approximately $194,000 in various legal fees for services related to the Offering. Proceeds from the Offering were used for general corporate purposes, including, but not limited to, research, development and further commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures, working capital and future acquisitions of complementary businesses, technology or products.

401k Plan	12 Months Ended
401k Plan	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
401k Plan	401k Plan The Company has a 401(k) plan (the “Plan”) covering employees who have attained 21 years of age and have completed three months of service. Under the Plan, participants may defer up to 100% of their eligible wages to a maximum of $18,000 per year (annual limit for 2015). Employees age 50 or over in 2015 may make additional pre-tax contributions up to $6,000 above and beyond normal plan and legal limits. Annually, the Company may elect to match employee contributions up to 6% of the employee’s compensation. Additionally, the Company may elect to make a discretionary contribution to the Plan. The Company did not provide matching contributions for the years ended December 31, 2015, 2014 and 2013.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. The acquisition of Stability was effected by the merger of Stability Inc. into a newly created wholly owned subsidiary of the Company. The new subsidiary was the surviving company in the merger and was subsequently renamed Stability Biologics, LLC ("Stability"). The Company paid $10 million at the closing, comprised of 60% cash and 40% in shares of common stock of MiMedx Group, Inc., assumed approximately $800,000 in debt, and eliminated a $2.4 million receivable related to Company products sold to Stability prior to the acquisition . The Company will also pay future contingent consideration through a two-year earn out arrangement based on the 2016 and 2017 performance of Stability's business. The Company expects the earn out will be the larger portion of the overall consideration for the transaction. The earn out will also be paid in the form of 60% cash and 40% in shares of stock of MiMedx Group, Inc.

Nature of Business (Details)	12 Months Ended
Nature of Business (Details)	Dec. 31, 2015 Business_Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments	1

Significant Accounting Policies (Details)	3 Months Ended	12 Months Ended
Significant Accounting Policies (Details)	Dec. 31, 2013 USD ($)	Dec. 31, 2015 USD ($) Business_Segment distributor	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Jul. 31, 2010 USD ($)
Market Concentrations and Credit Risk [Line Items]
Number of business segments \| Business_Segment		1
FDIC insured amount						$ 250,000
Cash and cash equivalents uninsured amount		$ 27,700,000	$ 44,600,000
Number of major customers \| distributor		1
Impairment of intangible assets				$ 368,000	$ 1,800,000
Impairment of Long-lived Assets [Abstract]
Impairment loss	$ 30,000
Grant Income [Abstract]
Proceeds from grant				250,000
Patents
Impairment of Long-lived Assets [Abstract]
Intangible assets, net of accumulated amortization		$ 851,000	$ 594,000	$ 689,000
Minimum
Property and Equipment [Abstract]
Property and equipment estimated useful life		3 years
Maximum
Property and Equipment [Abstract]
Property and equipment estimated useful life		7 years
Revenue \| AvKare
Market Concentrations and Credit Risk [Line Items]
Concentration of risk (percent)		24.00%	34.00%	56.00%
Accounts Receivable \| AvKare
Market Concentrations and Credit Risk [Line Items]
Concentration of risk (percent)		26.00%	33.00%

Liquidity and Capital Resources (Details) - USD ($)		12 Months Ended
Liquidity and Capital Resources (Details) - USD ($)	Oct. 12, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Cash and cash equivalents		$ 28,486,000	$ 46,582,000	$ 44,078,000	$ 6,754,000
Total current assets		96,310,000	85,677,000
Total current liabilities		26,777,000	18,404,000
Net working capital		69,533,000
Net cash flows from operating activities		$ 18,807,000	$ 16,802,000	$ (284,000)
Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Debt term	3 years
Senior secured revolving credit facility	$ 50,000,000

Cash Equivalents and Short Term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 28,486	$ 46,582	$ 44,078	$ 6,754
Short term investments	3,000	5,750
Certificates of Deposit
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents		1,250
Short term investments	$ 3,000	$ 5,750

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 602	$ 255
Work in process	3,850	3,419
Finished goods	3,405	1,986
Inventory, gross	7,857	5,660
Reserve for obsolescence	(397)	(527)
Inventory, net	$ 7,460	$ 5,133

Investments (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Investment [Line Items]
Investments	$ 0	$ 3,250,000
Certificates of Deposit
Investment [Line Items]
Investments	$ 0	$ 3,250,000

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property and equipment [Line Items]
Property and equipment, gross	$ 14,454	$ 8,946
Less accumulated depreciation	(4,979)	(3,499)
Property and equipment, net	9,475	5,447
Other liabilities	1,148	1,526
Depreciation expense	1,799	1,197	$ 637
Leasehold improvements
Property and equipment [Line Items]
Property and equipment, gross	2,684	2,559
Lab and clean room equipment
Property and equipment [Line Items]
Property and equipment, gross	4,564	3,040
Furniture and equipment
Property and equipment [Line Items]
Property and equipment, gross	4,577	2,398
Construction in Progress
Property and equipment [Line Items]
Property and equipment, gross	2,629	$ 949
Capital leases
Property and equipment [Line Items]
Property and equipment, net	427
Other liabilities	133
Leasehold improvements paid for by landlord
Property and equipment [Line Items]
Property and equipment, net	$ 1,000

Intangible Assets and Royalty Agreement Expected Future Amortization of Intangible Assets (Details) $ in Thousands	Dec. 31, 2015 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2016	$ 936
2017	846
2018	836
2019	836
2020	836
Thereafter	5,465
Net book value	$ 9,755

Long-Term Debt (Details) - USD ($)			2 Months Ended	12 Months Ended
Long-Term Debt (Details) - USD ($)	Oct. 12, 2015	Dec. 31, 2011	Feb. 28, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Placement fee, warrants issued (in shares)				16,493	15,958
Amortization of debt discount				$ 0	$ 0	$ 1,328,000
5% Convertible Senior Secured Promissory Note
Debt Instrument [Line Items]
Annual interest rate		5.00%				5.00%
Proceeds from issuance of debt		$ 5,000,000
Principal of notes convertible (in shares)		5,000,000
Accrued but unpaid interest (in dollars per share)		$ 1.00
Placement fee		$ 32,800
Placement fee, warrants issued (in shares)		42,400
Warrant exercise price (in dollars per share)		$ 1.09
Fair value of placement fee warrants		$ 15,000
Direct costs of sale of notes		47,800
5% Convertible Senior Secured Promissory Note \| Chairman and CEO
Debt Instrument [Line Items]
Proceeds from issuance of debt		$ 500,000
Loan Agreement
Debt Instrument [Line Items]
Total amount of debt plus accrued interest			$ 5,272,000
Convertible secured promissory note to common stock (in shares)			5,272,000
Amortization of debt discount						$ 1,328,000
Loan Agreement \| Chief Executive Officer
Debt Instrument [Line Items]
Convertible secured promissory note to common stock (in shares)			532,260
Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Direct costs of sale of notes	$ 500,000
Maximum borrowing capacity	50,000,000
Uncommitted incremental facility	$ 35,000,000
Debt term	3 years
Credit Agreement \| Revolving Credit Facility \| London Interbank Offered Rate (LIBOR) \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
Credit Agreement \| Revolving Credit Facility \| London Interbank Offered Rate (LIBOR) \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%

Net Income (loss) Per Share Computation of Basic and Dilutive Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Net income (loss)	$ 13,378	$ 6,551	$ 5,430	$ 4,087	$ 3,832	$ 3,700	$ (390)	$ (922)	$ (1,427)	$ (307)	$ (757)	$ (1,620)	$ 29,446	$ 6,220	$ (4,112)
Denominator for basic earnings per share - weighted average shares (in shares)													105,929,205	105,793,008	96,285,504
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (in shares)													7,699,277	7,502,496	0
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares)													113,628,482	113,295,504	96,285,504
Income (loss) per common share - basic (in dollars per share)	$ 0.13	$ 0.06	$ 0.05	$ 0.04	$ 0.04	$ 0.03	$ 0.00	$ (0.01)	$ (0.01)	$ 0.00	$ (0.01)	$ (0.02)	$ 0.28	$ 0.06	$ (0.04)
Income (loss) per common share - diluted (in dollars per share)	$ 0.11	$ 0.06	$ 0.05	$ 0.04	$ 0.03	$ 0.03	$ 0.00	$ (0.01)	$ (0.01)	$ 0.00	$ (0.01)	$ (0.02)	$ 0.26	$ 0.05	$ (0.04)

Net Income (loss) Per Share Summary of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,699,277	7,502,496
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,121,774	7,035,728
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	33,676	226,926
Restricted Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	543,827	239,842

Common Stock Placements (Details) - Common Stock $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2013 $ / shares shares
Sale of stocks and warrants [Line Items]
Shares issued (in shares) \| shares	5,750,000	5,750,000
Share issue price (in dollars per share) \| $ / shares	$ 6.80	$ 6.80
Proceeds from shares issued	$ 36,704
Legal fees paid for secondary offering	$ 194

Equity Narrative (Details)	12 Months Ended
Equity Narrative (Details)	Dec. 31, 2015 USD ($) plan $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) $ / shares	Nov. 18, 2015 $ / shares shares	May. 12, 2014 USD ($)
Class of Stock [Line Items]
Number of share-based compensation plans \| plan	3
Outstanding assumed options (in shares) \| shares	70,000
Number of shares available to be issued (in shares) \| shares	26,500,000
Intrinsic value of options exercised	$ 17,181,000	$ 10,566,000	$ 8,864,000
Intrinsic value of options vested	10,044,000	$ 6,615,000	$ 3,351,000
Total unrecognized compensation expense	$ 6,241,000
Weighted-average grant date fair value for options granted during the period (in dollars per share) \| $ / shares	$ 5.15	$ 4.18	$ 3.08
Shares issued for services performed (in shares) \| shares	16,493	15,958
Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively	$ 164,000	$ 117,000	$ 0
Warrants, term	5 years
Authorized share amount for repurchase	$ 60,000,000	$ 20,000,000			$ 10,000,000
Stock repurchase (in shares) \| shares	4,610,000
Shares repurchased, value	$ 40,143,000
Commissions	136,000
Remaining authorizations under the repurchase program, amount	$ 14,274,000
Common Stock
Class of Stock [Line Items]
Shares issued for services performed (in shares) \| shares	11,321	15,958
Consultant \| Common Stock
Class of Stock [Line Items]
Shares issued for services performed (in shares) \| shares	5,172
Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively	$ 57,000
Restricted Stock
Class of Stock [Line Items]
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock	$ 16,606,000
Expenses expected to be recognized over a weighted-average period	2 years 1 month 6 days
Minimum \| Restricted Stock
Class of Stock [Line Items]
Vesting period	1 year
Maximum \| Restricted Stock
Class of Stock [Line Items]
Vesting period	3 years
Warrants
Class of Stock [Line Items]
Warrants outstanding (in shares) \| shares				42,400
Warrants outstanding (in dollars per share) \| $ / shares				$ 1.09

Equity Exercise Price Ranges (Details)	12 Months Ended
Equity Exercise Price Ranges (Details)	Dec. 31, 2015 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of outstanding options (in shares) \| shares	14,019,629
Outstanding options, weighted average remaining contractual term	6 years 6 months
Outstanding options, weighted average exercise price (in dollars per share)	$ 3.62
Number of exercisable options (in shares) \| shares	10,951,694
Exercisable options, weighted average exercise price (in dollars per share)	$ 2.80
$0.50 - $0.76
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	0.50
Exercise price range, upper range limit (in dollars per share)	$ 0.76
Number of outstanding options (in shares) \| shares	441,429
Outstanding options, weighted average remaining contractual term	3 years 4 months 24 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 0.72
Number of exercisable options (in shares) \| shares	441,429
Exercisable options, weighted average exercise price (in dollars per share)	$ 0.72
$0.87 - $1.35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	0.87
Exercise price range, upper range limit (in dollars per share)	$ 1.35
Number of outstanding options (in shares) \| shares	4,783,304
Outstanding options, weighted average remaining contractual term	5 years 8 months 12 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 1.19
Number of exercisable options (in shares) \| shares	4,783,304
Exercisable options, weighted average exercise price (in dollars per share)	$ 1.19
$1.40 - $2.45
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	1.40
Exercise price range, upper range limit (in dollars per share)	$ 2.45
Number of outstanding options (in shares) \| shares	1,641,928
Outstanding options, weighted average remaining contractual term	5 years 1 month 6 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 1.93
Number of exercisable options (in shares) \| shares	1,641,928
Exercisable options, weighted average exercise price (in dollars per share)	$ 1.93
$2.66 - $3.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	2.66
Exercise price range, upper range limit (in dollars per share)	$ 3.99
Number of outstanding options (in shares) \| shares	957,454
Outstanding options, weighted average remaining contractual term	6 years 9 months 18 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 3.05
Number of exercisable options (in shares) \| shares	907,452
Exercisable options, weighted average exercise price (in dollars per share)	$ 3.00
$4.19 - $6.38
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	4.19
Exercise price range, upper range limit (in dollars per share)	$ 6.38
Number of outstanding options (in shares) \| shares	3,552,323
Outstanding options, weighted average remaining contractual term	7 years 4 months 24 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 5.35
Number of exercisable options (in shares) \| shares	2,229,386
Exercisable options, weighted average exercise price (in dollars per share)	$ 5.32
$6.45- $9.78
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	6.45
Exercise price range, upper range limit (in dollars per share)	$ 9.78
Number of outstanding options (in shares) \| shares	2,527,525
Outstanding options, weighted average remaining contractual term	8 years 1 month 6 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 7.29
Number of exercisable options (in shares) \| shares	914,703
Exercisable options, weighted average exercise price (in dollars per share)	$ 7.18
$9.90 - $10.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	9.90
Exercise price range, upper range limit (in dollars per share)	$ 10.99
Number of outstanding options (in shares) \| shares	115,666
Outstanding options, weighted average remaining contractual term	8 years 10 months 24 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 10.43
Number of exercisable options (in shares) \| shares	33,492
Exercisable options, weighted average exercise price (in dollars per share)	$ 10.50

Equity Assumptions (Details)	12 Months Ended
Equity Assumptions (Details)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair value options valuation assumptions [Abstract]
Expected life (in years)	6 years	6 years	6 years
Expected dividend yield, percent	0.00%	0.00%	0.00%
Risk-free interest rate, minimum	1.51%	1.64%	0.85%
Risk-free interest rate, maximum	1.68%	1.96%	1.88%
Minimum
Fair value options valuation assumptions [Abstract]
Expected volatility, percent	54.35%	58.14%	61.41%
Maximum
Fair value options valuation assumptions [Abstract]
Expected volatility, percent	58.14%	64.50%	64.77%

Equity Summary of Restricted Stock Awards (Details) - Restricted Stock	12 Months Ended
	Dec. 31, 2015 $ / shares shares
Number of Shares
Unvested, beginning of period \| shares	1,228,898
Granted \| shares	1,974,259
Vested \| shares	(517,883)
Forfeited \| shares	(72,007)
Unvested, end of period \| shares	2,613,267
Weighted- Average Grant Date Fair Value
Unvested, beginning of period (in dollars per share) \| $ / shares	$ 7.16
Granted (in dollars per share) \| $ / shares	9.80
Vested (in dollars per share) \| $ / shares	6.90
Forfeited (in dollars per share) \| $ / shares	9.77
Unvested, end of period (in dollars per share) \| $ / shares	$ 9.14